<!DOCTYPE html><html lang="en" class="scroll-smooth"><head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>059 Pharmacology Ini-Cet 2024 - Brain And Scalpel</title>
    <link rel="preload" href="assets/background.jpg" as="image">
    <script src="https://cdn.tailwindcss.com"></script>
    <!-- HLS.js for M3U8 support -->
    <script src="https://cdn.jsdelivr.net/npm/hls.js@latest"></script>
    <style>
        
/* Liquid Glass Morphism Universal Theme - Enhanced & Mobile-First */
:root {
  --glass-bg: rgba(0, 0, 0, 0.6);
  --glass-bg-light: rgba(255, 255, 255, 0.1);
  --glass-bg-medium: rgba(255, 255, 255, 0.15);
  --glass-bg-heavy: rgba(255, 255, 255, 0.2);
  --glass-border: rgba(255, 255, 255, 0.2);
  --glass-border-light: rgba(255, 255, 255, 0.1);
  --text-primary: rgba(255, 255, 255, 0.95);
  --text-secondary: rgba(255, 255, 255, 0.7);
  --text-tertiary: rgba(255, 255, 255, 0.5);
  --accent-blue: #60a5fa;
  --accent-purple: #a855f7;
  --accent-green: #34d399;
  --accent-orange: #fb923c;
  --accent-red: #f87171;
  --accent-yellow: #fbbf24;
}

* {
  margin: 0;
  padding: 0;
  box-sizing: border-box;
}

html {
  scroll-behavior: smooth;
}

body {
  margin: 0;
  min-height: 100vh;
  font-family: system-ui, -apple-system, BlinkMacSystemFont, 'Segoe UI', sans-serif;
  position: relative;
  overflow-x: hidden;
  color: var(--text-primary);
  background-color: #000;
}

/* iOS Background Fix */
body::before {
  content: '';
  position: fixed;
  top: 0;
  left: 0;
  height: 100vh;
  width: 100vw;
  z-index: -2;
  background: url("assets/background.jpg") center center / cover no-repeat;
}

body::after {
  content: "";
  position: fixed;
  inset: 0;
  background: rgba(0, 0, 0, 0.4);
  backdrop-filter: blur(10px);
  -webkit-backdrop-filter: blur(10px);
  z-index: -1;
}

/* Glass morphism components */
.glass {
  background: var(--glass-bg);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid var(--glass-border);
  border-radius: 16px;
}

.glass-light {
  background: var(--glass-bg-light);
  backdrop-filter: blur(15px);
  -webkit-backdrop-filter: blur(15px);
  border: 1px solid var(--glass-border-light);
  border-radius: 12px;
}

.glass-medium {
  background: var(--glass-bg-medium);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid var(--glass-border);
  border-radius: 16px;
}

.glass-heavy {
  background: var(--glass-bg-heavy);
  backdrop-filter: blur(25px);
  -webkit-backdrop-filter: blur(25px);
  border: 1px solid var(--glass-border);
  border-radius: 20px;
}

.glass-card {
  background: rgba(255, 255, 255, 0.08);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid rgba(255, 255, 255, 0.15);
  border-radius: 20px;
  transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
  box-shadow: 0 8px 32px rgba(0, 0, 0, 0.3);
}

.glass-card:hover {
  transform: translateY(-8px);
  background: rgba(255, 255, 255, 0.12);
  border-color: rgba(255, 255, 255, 0.25);
  box-shadow: 0 20px 60px rgba(0, 0, 0, 0.4);
}

.glass-button {
  background: linear-gradient(135deg, rgba(96, 165, 250, 0.8), rgba(168, 85, 247, 0.8));
  backdrop-filter: blur(15px);
  -webkit-backdrop-filter: blur(15px);
  border: 1px solid rgba(255, 255, 255, 0.2);
  border-radius: 12px;
  color: white;
  font-weight: 600;
  transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
  box-shadow: 0 4px 20px rgba(96, 165, 250, 0.3);
  cursor: pointer;
  border: none;
}

.glass-button:hover {
  transform: translateY(-2px);
  box-shadow: 0 8px 30px rgba(96, 165, 250, 0.4);
  background: linear-gradient(135deg, rgba(96, 165, 250, 0.9), rgba(168, 85, 247, 0.9));
}

.glass-button:disabled {
  opacity: 0.5;
  cursor: not-allowed;
  transform: none;
}

.glass-input {
  background: rgba(255, 255, 255, 0.08);
  backdrop-filter: blur(15px);
  -webkit-backdrop-filter: blur(15px);
  border: 1px solid rgba(255, 255, 255, 0.2);
  border-radius: 12px;
  color: var(--text-primary);
  transition: all 0.3s ease;
}

.glass-input:focus {
  outline: none;
  border-color: var(--accent-blue);
  background: rgba(255, 255, 255, 0.12);
  box-shadow: 0 0 20px rgba(96, 165, 250, 0.3);
}

.glass-input::placeholder {
  color: var(--text-tertiary);
}

/* Performance analysis styles */
.performance-card {
  background: rgba(255, 255, 255, 0.08);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid rgba(255, 255, 255, 0.15);
  border-radius: 20px;
  box-shadow: 0 8px 32px rgba(0, 0, 0, 0.3);
}

.score-circle {
  position: relative;
  width: 150px;
  height: 150px;
  margin: 0 auto;
}

.score-circle svg {
  transform: rotate(-90deg);
}

.score-circle .circle-bg {
  fill: none;
  stroke: rgba(255, 255, 255, 0.1);
  stroke-width: 8;
}

.score-circle .circle-progress {
  fill: none;
  stroke-width: 8;
  stroke-linecap: round;
  transition: stroke-dasharray 2s cubic-bezier(0.4, 0, 0.2, 1);
}

.score-text {
  position: absolute;
  top: 50%;
  left: 50%;
  transform: translate(-50%, -50%);
  text-align: center;
}

/* Review question styles */
.review-question {
  background: rgba(255, 255, 255, 0.05);
  border: 1px solid rgba(255, 255, 255, 0.1);
  border-radius: 16px;
  padding: 20px;
  margin-bottom: 20px;
}

.review-question.correct {
  border-left: 4px solid #22c55e;
}

.review-question.incorrect {
  border-left: 4px solid #ef4444;
}

.review-question.not-attempted {
  border-left: 4px solid #6b7280;
}

/* Gradient backgrounds for accents */
.gradient-blue {
  background: linear-gradient(135deg, var(--accent-blue), #3b82f6);
}

.gradient-purple {
  background: linear-gradient(135deg, var(--accent-purple), #8b5cf6);
}

.gradient-green {
  background: linear-gradient(135deg, var(--accent-green), #10b981);
}

.gradient-orange {
  background: linear-gradient(135deg, var(--accent-orange), #f97316);
}

.gradient-red {
  background: linear-gradient(135deg, var(--accent-red), #ef4444);
}

.gradient-yellow {
  background: linear-gradient(135deg, var(--accent-yellow), #f59e0b);
}

/* Navigation button styles */
.nav-btn-not-attempted {
  background: rgba(255, 255, 255, 0.1);
  border: 1px solid rgba(255, 255, 255, 0.2);
  color: rgba(255, 255, 255, 0.7);
}

.nav-btn-current {
  background: linear-gradient(135deg, var(--accent-blue), #3b82f6);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
  box-shadow: 0 0 20px rgba(96, 165, 250, 0.4);
}

.nav-btn-correct {
  background: linear-gradient(135deg, var(--accent-green), #10b981);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-incorrect {
  background: linear-gradient(135deg, var(--accent-red), #ef4444);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-bookmarked {
  background: linear-gradient(135deg, var(--accent-yellow), #f59e0b);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-marked-review {
  background: linear-gradient(135deg, var(--accent-purple), #8b5cf6);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-answered {
  background: linear-gradient(135deg, #6b7280, #4b5563);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

/* Option button styles - REVISED FOR INLINE FEEDBACK */
.option-button {
  background: rgba(255, 255, 255, 0.05);
  border: 1px solid rgba(255, 255, 255, 0.15);
  transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
  position: relative;
  overflow: hidden;
  width: 100%;
  text-align: left;
  padding: 1rem;
  border-radius: 12px;
  color: var(--text-primary);
  cursor: pointer;
  display: flex;
  align-items: center;
  gap: 1rem;
  font-size: 1rem;
}

.option-button:hover {
  background: rgba(255, 255, 255, 0.1);
  border-color: rgba(96, 165, 250, 0.5);
  transform: translateX(8px);
}

.option-button.selected {
  background: linear-gradient(135deg, rgba(96, 165, 250, 0.3), rgba(59, 130, 246, 0.3));
  border-color: var(--accent-blue);
  transform: translateX(8px);
}

#optionsContainer.answered .option-button:hover {
    transform: translateX(0); /* Disable hover effect after answering */
}

#optionsContainer.answered .option-button {
    cursor: not-allowed;
    pointer-events: none;
}

#optionsContainer.answered .option-button:not(.correct):not(.incorrect) {
    opacity: 0.5;
}

.option-button.correct {
    background: linear-gradient(135deg, #22c55e, #16a34a);
    border-color: #22c55e;
    color: white;
    transform: translateX(0);
}

.option-button.incorrect {
    background: linear-gradient(135deg, #ef4444, #dc2626);
    border-color: #ef4444;
    color: white;
    transform: translateX(0);
}

.option-letter {
  background: rgba(255, 255, 255, 0.1);
  border: 1px solid rgba(255, 255, 255, 0.2);
  transition: all 0.3s ease;
  width: 2.5rem;
  height: 2.5rem;
  border-radius: 50%;
  display: flex;
  align-items: center;
  justify-content: center;
  font-weight: bold;
  color: var(--text-primary);
  flex-shrink: 0;
}

.option-button.selected .option-letter {
  background: var(--accent-blue);
  border-color: var(--accent-blue);
  color: white;
}

.option-button.correct .option-letter, .option-button.incorrect .option-letter {
    background: rgba(255, 255, 255, 0.2);
    border-color: rgba(255, 255, 255, 0.3);
}

.option-text {
  flex: 1;
  font-size: 1rem;
  line-height: 1.5;
}

/* Stats bar responsive grid */
.stats-grid {
  display: grid;
  grid-template-columns: repeat(5, 1fr);
  gap: 1rem;
  align-items: center;
  justify-items: center;
}

@media (max-width: 768px) {
  .stats-grid {
    grid-template-columns: repeat(3, 1fr);
    gap: 0.5rem;
  }
  
  .stats-grid > div:nth-child(4),
  .stats-grid > div:nth-child(5) {
    grid-column: span 1;
  }
}

@media (max-width: 480px) {
  .stats-grid {
    grid-template-columns: repeat(2, 1fr);
  }
  
  .stats-grid > div:last-child {
    grid-column: span 2;
    justify-self: center;
  }
}

/* Animations */
@keyframes float {
  0%, 100% { transform: translateY(0px); }
  50% { transform: translateY(-20px); }
}

@keyframes pulse-glow {
  0%, 100% { box-shadow: 0 0 20px rgba(96, 165, 250, 0.3); }
  50% { box-shadow: 0 0 40px rgba(96, 165, 250, 0.6); }
}

@keyframes checkmark {
  0% { transform: scale(0) rotate(0deg); }
  50% { transform: scale(0.8) rotate(180deg); }
  100% { transform: scale(1) rotate(360deg); }
}

@keyframes cross {
  0% { transform: scale(0) rotate(0deg); }
  50% { transform: scale(0.8) rotate(90deg); }
  100% { transform: scale(1) rotate(180deg); }
}

.animate-float {
  animation: float 6s ease-in-out infinite;
}

.animate-pulse-glow {
  animation: pulse-glow 2s ease-in-out infinite;
}

.animate-checkmark {
  animation: checkmark 0.6s cubic-bezier(0.4, 0, 0.2, 1);
}

.animate-cross {
  animation: cross 0.6s cubic-bezier(0.4, 0, 0.2, 1);
}

/* Custom scrollbar */
::-webkit-scrollbar {
  width: 8px;
}

::-webkit-scrollbar-track {
  background: rgba(255, 255, 255, 0.05);
  border-radius: 4px;
}

::-webkit-scrollbar-thumb {
  background: rgba(255, 255, 255, 0.2);
  border-radius: 4px;
}

::-webkit-scrollbar-thumb:hover {
  background: rgba(255, 255, 255, 0.3);
}

/* --- MOBILE RESPONSIVE STYLES --- */
.quiz-container {
    display: flex;
    flex-direction: column;
    gap: 1.5rem;
}

#mobile-nav-toggle {
    display: none; /* Hidden on desktop */
}

@media (min-width: 1024px) {
    .quiz-container {
        flex-direction: row;
        gap: 2rem;
    }
}

@media (max-width: 1023px) {
    .quiz-sidebar {
        position: fixed;
        top: 0;
        left: 0;
        width: 300px;
        height: 100%;
        z-index: 100;
        transform: translateX(-100%);
        transition: transform 0.3s ease-in-out;
        box-shadow: 10px 0px 30px rgba(0,0,0,0.5);
    }
    .quiz-sidebar.open {
        transform: translateX(0);
    }
    #mobile-nav-toggle {
        display: flex;
        position: fixed;
        bottom: 20px;
        left: 20px;
        z-index: 50;
    }
    .quiz-main-content {
        width: 100%;
    }
}

@media (max-width: 768px) {
    .glass-card, .glass {
        border-radius: 16px;
    }
    h1 { font-size: 2.5rem; }
    #questionText { font-size: 1.125rem; }
    .controls-container {
        flex-direction: column;
        gap: 1rem;
    }
    .controls-container button {
        width: 100%;
    }
}

    </style>
</head>
<body>
    <!-- Mode Selection Modal -->
    <div id="modeModal" class="fixed inset-0 bg-black bg-opacity-70 flex items-center justify-center z-50 backdrop-blur-sm">
        <div class="glass-heavy p-8 max-w-md w-full mx-4 shadow-2xl">
            <h2 class="text-2xl font-bold text-white mb-6 text-center">Choose Study Mode</h2>
            
            <div class="space-y-4">
                <button onclick="selectMode('study')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Study Mode</h3>
                            <p class="text-sm text-white text-opacity-70">Interactive learning with immediate feedback</p>
                        </div>
                        <div class="gradient-blue w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path d="M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z"></path>
                            </svg>
                        </div>
                    </div>
                </button>
                
                <button onclick="selectMode('test')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Test Mode</h3>
                            <p class="text-sm text-white text-opacity-70">Practice test with performance analysis at end</p>
                        </div>
                        <div class="gradient-purple w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path d="M9 2a1 1 0 000 2h2a1 1 0 100-2H9z"></path>
                                <path fill-rule="evenodd" d="M4 5a2 2 0 012-2v1a1 1 0 001 1h6a1 1 0 001-1V3a2 2 0 012 2v6a2 2 0 01-2 2H6a2 2 0 01-2-2V5zm3 4a1 1 0 000 2h.01a1 1 0 100-2H7zm3 0a1 1 0 000 2h3a1 1 0 100-2h-3z" clip-rule="evenodd"></path>
                            </svg>
                        </div>
                    </div>
                </button>
                
                <button onclick="selectMode('timed_study')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Timed Study</h3>
                            <p class="text-sm text-white text-opacity-70">Study with time pressure and immediate feedback</p>
                        </div>
                        <div class="gradient-green w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path fill-rule="evenodd" d="M10 18a8 8 0 100-16 8 8 0 000 16zm1-12a1 1 0 10-2 0v4a1 1 0 00.293.707l2.828 2.829a1 1 0 101.415-1.415L11 9.586V6z" clip-rule="evenodd"></path>
                            </svg>
                        </div>
                    </div>
                </button>
                
                <button onclick="selectMode('timed_exam')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Timed Exam</h3>
                            <p class="text-sm text-white text-opacity-70">Real exam simulation with strict timing</p>
                        </div>
                        <div class="gradient-red w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path fill-rule="evenodd" d="M12.395 2.553a1 1 0 00-1.45-.385c-.345.23-.614.558-.822.88-.214.33-.403.713-.57 1.116-.334.804-.614 1.768-.84 2.734a31.365 31.365 0 00-.613 3.58 2.64 2.64 0 01-.945-1.067c-.328-.68-.398-1.534-.398-2.654A1 1 0 005.05 6.05 6.981 6.981 0 003 11a7 7 0 1011.95-4.95c-.592-.591-.98-.985-1.348-1.467-.363-.476-.724-1.063-1.207-2.03z" clip-rule="evenodd"></path>
                            </svg>
                        </div>
                    </div>
                </button>
            </div>
        </div>
    </div>

    <!-- Performance Analysis Modal -->
    <div id="performanceModal" class="hidden fixed inset-0 bg-black bg-opacity-80 flex items-center justify-center z-50 backdrop-blur-sm">
        <div class="glass-heavy p-8 max-w-4xl w-full mx-4 shadow-2xl max-h-[90vh] overflow-y-auto">
            <div class="flex items-center justify-between mb-8">
                <h2 class="text-3xl font-bold text-white">Performance Analysis</h2>
                <button onclick="closePerformanceModal()" class="glass-light p-2 rounded-lg text-white hover:bg-white hover:bg-opacity-20">
                    <svg class="w-6 h-6" fill="currentColor" viewBox="0 0 20 20">
                        <path fill-rule="evenodd" d="M4.293 4.293a1 1 0 011.414 0L10 8.586l4.293-4.293a1 1 0 111.414 1.414L11.414 10l4.293 4.293a1 1 0 01-1.414 1.414L10 11.414l-4.293 4.293a1 1 0 01-1.414-1.414L8.586 10 4.293 5.707a1 1 0 010-1.414z" clip-rule="evenodd"></path>
                    </svg>
                </button>
            </div>
            
            <!-- Score Overview -->
            <div class="grid grid-cols-1 md:grid-cols-3 gap-6 mb-8">
                <div class="performance-card p-6 text-center">
                    <div class="score-circle mb-4">
                        <svg width="150" height="150" class="mx-auto">
                            <circle class="circle-bg" cx="75" cy="75" r="65"></circle>
                            <circle id="scoreCircle" class="circle-progress" cx="75" cy="75" r="65" stroke="#22c55e" stroke-dasharray="0 408"></circle>
                        </svg>
                        <div class="score-text">
                            <div class="text-3xl font-bold text-white" id="accuracyScore">0%</div>
                            <div class="text-sm text-white text-opacity-70">Accuracy</div>
                        </div>
                    </div>
                </div>
                
                <div class="performance-card p-6">
                    <h3 class="text-lg font-bold text-white mb-4 text-center">Results Summary</h3>
                    <div class="space-y-3">
                        <div class="flex justify-between items-center">
                            <span class="text-white text-opacity-70">Total Questions:</span>
                            <span class="text-white font-semibold" id="totalQuestionsResult">0</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-green-400">Correct:</span>
                            <span class="text-green-400 font-semibold" id="correctResult">0</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-red-400">Incorrect:</span>
                            <span class="text-red-400 font-semibold" id="incorrectResult">0</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-gray-400">Not Attempted:</span>
                            <span class="text-gray-400 font-semibold" id="notAttemptedResult">0</span>
                        </div>
                    </div>
                </div>
                
                <div class="performance-card p-6">
                    <h3 class="text-lg font-bold text-white mb-4 text-center">Time Analysis</h3>
                    <div class="space-y-3">
                        <div class="flex justify-between items-center">
                            <span class="text-white text-opacity-70">Total Time:</span>
                            <span class="text-white font-semibold" id="totalTimeResult">0:00</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-white text-opacity-70">Avg per Question:</span>
                            <span class="text-white font-semibold" id="avgTimeResult">0:00</span>
                        </div>
                    </div>
                </div>
            </div>
            
            <!-- Action Buttons -->
            <div class="flex justify-center space-x-4 mb-8">
                <button onclick="reviewQuestions()" class="glass-button px-8 py-3 text-lg">
                    Review All Questions
                </button>
                <button onclick="retakeQuiz()" class="glass-light px-8 py-3 text-lg text-white hover:bg-white hover:bg-opacity-20">
                    Retake Quiz
                </button>
            </div>
            
            <!-- Question Review Section -->
            <div id="questionReviewSection" class="hidden">
                <h3 class="text-2xl font-bold text-white mb-6">Question Review</h3>
                <div id="reviewQuestionsContainer">
                    <!-- Review questions will be populated here -->
                </div>
            </div>
        </div>
    </div>

    <!-- Header -->
    <header class="glass sticky top-0 z-40 mb-6">
        <div class="container mx-auto px-6 py-4">
            <div class="flex items-center justify-between">
                <div class="flex items-center space-x-4">
                    <button onclick="goBack()" class="glass-light px-4 py-2 text-white hover:bg-white hover:bg-opacity-20 transition-all duration-300 flex items-center">
                        <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                            <path fill-rule="evenodd" d="M9.707 16.707a1 1 0 01-1.414 0l-6-6a1 1 0 010-1.414l6-6a1 1 0 011.414 1.414L5.414 9H17a1 1 0 110 2H5.414l4.293 4.293a1 1 0 010 1.414z" clip-rule="evenodd"></path>
                        </svg>
                        Back
                    </button>
                    <div id="quizHierarchy" class="text-sm text-white text-opacity-60">
                        Marrow / PYQ / Pharmacology
                    </div>
                </div>
                
                <div class="flex items-center space-x-4">
                    <div class="glass-light px-3 py-1 text-sm text-white">
                        Question <span id="currentQuestion">1</span> of <span id="totalQuestions">24</span>
                    </div>
                    
                    <!-- Timer -->
                    <div id="timerContainer" class="hidden gradient-red px-3 py-1 text-sm text-white font-bold animate-pulse-glow">
                        <span id="timeDisplay">2:00</span>
                    </div>
                </div>
            </div>
        </div>
    </header>

    <!-- Progress Bar -->
    <div class="w-full h-1 bg-black bg-opacity-30 mb-6">
        <div id="progressBar" class="h-1 gradient-blue transition-all duration-500 ease-out" style="width: 0%"></div>
    </div>

    <!-- Stats Bar - Show only in study modes -->
    <div id="statsBar" class="glass-light mb-8">
        <div class="container mx-auto px-6 py-4">
            <div class="stats-grid">
                <div class="text-center">
                    <div class="text-lg font-bold text-green-400" id="correctCount">0</div>
                    <div class="text-xs text-white text-opacity-60">Correct</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-red-400" id="incorrectCount">0</div>
                    <div class="text-xs text-white text-opacity-60">Incorrect</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-blue-400" id="totalAttempted">0</div>
                    <div class="text-xs text-white text-opacity-60">Attempted</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-purple-400" id="accuracy">0%</div>
                    <div class="text-xs text-white text-opacity-60">Accuracy</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-orange-400" id="timeSpent">0:00</div>
                    <div class="text-xs text-white text-opacity-60">Time</div>
                </div>
            </div>
        </div>
    </div>

    <div class="quiz-container container mx-auto px-6">
        <!-- Question Navigation Sidebar -->
        <div id="quizSidebar" class="quiz-sidebar glass p-6 h-fit lg:sticky top-24">
            <h3 class="text-lg font-bold text-white mb-4">Question Navigator</h3>
            <div id="questionNav" class="grid grid-cols-5 gap-2 mb-6">
                <!-- Question numbers will be populated here -->
            </div>
            
            <div class="space-y-3 text-xs">
                <h4 class="text-sm font-medium text-white text-opacity-80 mb-3">Legend</h4>
                <div class="flex items-center">
                    <div class="w-6 h-6 nav-btn-not-attempted rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Not Attempted</span>
                </div>
                <div class="flex items-center">
                    <div class="w-6 h-6 nav-btn-current rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Current</span>
                </div>
                <div id="studyModeLegend" class="space-y-2">
                    <div class="flex items-center">
                        <div class="w-6 h-6 nav-btn-correct rounded mr-2"></div>
                        <span class="text-white text-opacity-60">Correct</span>
                    </div>
                    <div class="flex items-center">
                        <div class="w-6 h-6 nav-btn-incorrect rounded mr-2"></div>
                        <span class="text-white text-opacity-60">Incorrect</span>
                    </div>
                </div>
                <div id="testModeLegend" class="hidden space-y-2">
                    <div class="flex items-center">
                        <div class="w-6 h-6 nav-btn-answered rounded mr-2"></div>
                        <span class="text-white text-opacity-60">Answered</span>
                    </div>
                </div>
                <div class="flex items-center">
                    <div class="w-6 h-6 nav-btn-bookmarked rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Bookmarked</span>
                </div>
                <div id="testModeReviewLegend" class="hidden items-center">
                    <div class="w-6 h-6 nav-btn-marked-review rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Marked for Review</span>
                </div>
            </div>
            
            <!-- Submit Quiz Button for test modes -->
            <div id="submitSection" class="hidden mt-6">
                <button onclick="submitQuiz()" class="glass-button w-full py-3 text-lg font-bold">
                    Submit Quiz
                </button>
            </div>
        </div>

        <!-- Main Quiz Interface -->
        <div class="quiz-main-content flex-1 max-w-4xl">
            <div class="glass-card p-4 md:p-8 lg:p-12 mb-8 relative">
                <!-- Question Text -->
                <div id="questionText" class="text-xl lg:text-2xl leading-relaxed text-white mb-8">
                    Loading question...
                </div>

                <!-- Question Media -->
                <div id="questionMedia" class="mb-8"></div>

                <!-- Options -->
                <div id="optionsContainer" class="space-y-3 mb-8">
                    <!-- Options will be inserted here -->
                </div>

                <!-- Solution Display (only for study modes) -->
                <div id="solutionContainer" class="hidden glass-light p-6 border-l-4 border-green-400">
                    <h3 class="text-lg font-bold text-green-400 mb-3 flex items-center">
                        <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                            <path fill-rule="evenodd" d="M18 10a8 8 0 11-16 0 8 8 0 0116 0zm-7-4a1 1 0 11-2 0 1 1 0 012 0zM9 9a1 1 0 000 2v3a1 1 0 001 1h1a1 1 0 100-2v-3a1 1 0 00-1-1H9z" clip-rule="evenodd"></path>
                        </svg>
                        Explanation
                    </h3>
                    <div id="solutionText" class="text-white text-opacity-90 leading-relaxed mb-4"></div>
                    <div id="solutionAudio" class="space-y-2 mt-4"></div>
                    <div id="solutionImages" class="space-y-4 mt-4"></div>
                    <div id="solutionVideo" class="hidden mt-4">
                        <video id="explanationVideoPlayer" class="w-full rounded-lg" controls="">
                            Your browser does not support the video tag.
                        </video>
                    </div>
                </div>
            </div>

            <!-- Controls -->
            <div class="controls-container flex justify-between items-center mb-8">
                <button onclick="previousQuestion()" id="prevBtn" class="glass-button px-6 py-3 flex items-center justify-center disabled:opacity-50 disabled:cursor-not-allowed">
                    <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                        <path fill-rule="evenodd" d="M12.707 5.293a1 1 0 010 1.414L9.414 10l3.293 3.293a1 1 0 01-1.414 1.414l-4-4a1 1 0 010-1.414l4-4a1 1 0 011.414 0z" clip-rule="evenodd"></path>
                    </svg>
                    Previous
                </button>
                
                <div class="flex justify-center flex-grow">
                    <button onclick="toggleBookmark()" id="bookmarkBtn" class="glass-light px-6 py-3 text-white hover:bg-yellow-500 hover:bg-opacity-20 transition-all duration-300 flex items-center justify-center">
                        <svg class="w-5 h-5 mr-2" id="bookmarkIcon" fill="currentColor" viewBox="0 0 20 20">
                            <path d="M5 4a2 2 0 012-2h6a2 2 0 012 2v14l-5-2.5L5 18V4z"></path>
                        </svg>
                        <span id="bookmarkText">Bookmark</span>
                    </button>
                    
                    <button onclick="toggleMarkForReview()" id="markReviewBtn" class="hidden glass-light px-6 py-3 text-white hover:bg-purple-500 hover:bg-opacity-20 transition-all duration-300 flex items-center justify-center">
                        <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                           <path fill-rule="evenodd" d="M5 2a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V4a2 2 0 00-2-2H5zm0 2h10v12H5V4z" clip-rule="evenodd"></path>
                           <path d="M12.586 6.586a2 2 0 10-2.828 2.828l-3 3a2 2 0 102.828-2.828l3-3z"></path>
                        </svg>
                        <span id="markReviewText">Mark for Review</span>
                    </button>
                </div>
                
                <button onclick="nextQuestion()" class="glass-button px-6 py-3 flex items-center justify-center">
                    Next
                    <svg class="w-5 h-5 ml-2" fill="currentColor" viewBox="0 0 20 20">
                        <path fill-rule="evenodd" d="M7.293 14.707a1 1 0 010-1.414L10.586 10 7.293 6.707a1 1 0 011.414-1.414l4 4a1 1 0 010 1.414l-4 4a1 1 0 01-1.414 0z" clip-rule="evenodd"></path>
                    </svg>
                </button>
            </div>
        </div>
    </div>

     <!-- Mobile Nav Toggle -->
    <button id="mobile-nav-toggle" onclick="toggleSidebar()" class="glass-button w-14 h-14 rounded-full items-center justify-center">
        <svg class="w-6 h-6 text-white" fill="none" stroke="currentColor" viewBox="0 0 24 24"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M4 6h16M4 12h16M4 18h16"></path></svg>
    </button>


    <script>const _0xa90e1a=_0x2977;(function(_0x545714,_0x3c86ee){const _0x5a8431=_0x2977,_0x36d7a8=_0x545714();while(!![]){try{const _0xf0e629=parseInt(_0x5a8431(0x3c7))/0x1+-parseInt(_0x5a8431(0x238))/0x2+-parseInt(_0x5a8431(0x3a7))/0x3+parseInt(_0x5a8431(0x254))/0x4*(-parseInt(_0x5a8431(0x3f8))/0x5)+parseInt(_0x5a8431(0x29a))/0x6+-parseInt(_0x5a8431(0x348))/0x7*(-parseInt(_0x5a8431(0x1f2))/0x8)+parseInt(_0x5a8431(0x1a9))/0x9;if(_0xf0e629===_0x3c86ee)break;else _0x36d7a8['push'](_0x36d7a8['shift']());}catch(_0x2c478c){_0x36d7a8['push'](_0x36d7a8['shift']());}}}(_0x1ffe,0xe1354));const _0x251951=(function(){const _0x84b5ce=_0x2977,_0xf61fbd={'PbzyS':function(_0x523cef,_0x5243cf){return _0x523cef===_0x5243cf;},'uBFJu':_0x84b5ce(0x2da),'CuWAc':'border-red-500','DXxzS':function(_0x2a263e,_0x481b79){return _0x2a263e!==_0x481b79;},'QMOAN':_0x84b5ce(0x426),'bIQLF':_0x84b5ce(0x222)};let _0x34921a=!![];return function(_0x461688,_0x127085){const _0x1b9838=_0x84b5ce;if(_0xf61fbd['DXxzS'](_0xf61fbd['QMOAN'],_0xf61fbd[_0x1b9838(0x28d)])){const _0x250fcc=_0x34921a?function(){const _0x7aee61=_0x1b9838;if(_0x127085){const _0x2f5ef8=_0x127085[_0x7aee61(0x1ac)](_0x461688,arguments);return _0x127085=null,_0x2f5ef8;}}:function(){};return _0x34921a=![],_0x250fcc;}else{const _0x4ef0fa=_0xf61fbd[_0x1b9838(0x40e)](_0x401d8d[_0x1b9838(0x32c)],_0x4bfaef),_0x20fe90=_0xf61fbd['PbzyS'](_0x104eff['id'],_0x68e09a);let _0x52fcac=_0x1b9838(0x344);if(_0x20fe90)_0x52fcac=_0xf61fbd[_0x1b9838(0x2ce)];else{if(_0x4ef0fa)_0x52fcac=_0xf61fbd[_0x1b9838(0x3f2)];}return _0x1b9838(0x239)+_0x52fcac+_0x1b9838(0x262)+_0x104408['fromCharCode'](0x41+_0x3ea3ac)+'</span><span>'+_0x5271b4[_0x1b9838(0x30f)]+_0x1b9838(0x247);}};}()),_0x28919d=_0x251951(this,function(){const _0x4c3e9e=_0x2977,_0xbee744={'paGIe':'(((.+)+)+)+$'};return _0x28919d[_0x4c3e9e(0x25b)]()['search'](_0xbee744[_0x4c3e9e(0x36b)])[_0x4c3e9e(0x25b)]()[_0x4c3e9e(0x42e)](_0x28919d)[_0x4c3e9e(0x389)](_0xbee744['paGIe']);});_0x28919d();const _0x19c3dc=(function(){const _0x82850b=_0x2977,_0x2205f7={'EjJzS':function(_0x1b4ed4){return _0x1b4ed4();},'OQHpP':function(_0x323295,_0x1b795e){return _0x323295!==_0x1b795e;},'hBOpK':'yMeFL','WKPyc':_0x82850b(0x232)};let _0x145e5e=!![];return function(_0x32fade,_0x17034c){const _0x18d9e8=_0x145e5e?function(){const _0x20b202=_0x2977,_0x1ab924={'LTUZO':function(_0xa19290){const _0x926a7b=_0x2977;return _0x2205f7[_0x926a7b(0x318)](_0xa19290);}};if(_0x17034c){if(_0x2205f7[_0x20b202(0x360)](_0x2205f7[_0x20b202(0x320)],_0x2205f7[_0x20b202(0x220)])){const _0xfa900c=_0x17034c[_0x20b202(0x1ac)](_0x32fade,arguments);return _0x17034c=null,_0xfa900c;}else{const _0x401f4e=!_0x55a575[_0x4ddfd5]['bookmarked'];_0x562412[_0xb896ab][_0x20b202(0x3b7)]=_0x401f4e;let _0x2290d9=_0x3f2dd2[_0x20b202(0x36c)](_0x41ce83['getItem'](_0x20b202(0x201)))||[];if(_0x401f4e){const _0x1c3eb4={'quizName':_0x395b95,'quizFile':_0x440a4b['location'][_0x20b202(0x2ed)][_0x20b202(0x432)]('/')[_0x20b202(0x213)](),'questionIndex':_0x31693d,'question':_0x191ba0[_0x23c569],'hierarchy':_0x4d6283,'timestamp':_0x1130bb[_0x20b202(0x1c8)]()};_0x2290d9[_0x20b202(0x1f9)](_0x1c3eb4);}else _0x2290d9=_0x2290d9[_0x20b202(0x3c0)](_0x50fb3b=>!(_0x50fb3b['quizFile'][_0x20b202(0x3fc)](_0x3a9217[_0x20b202(0x1ba)]()['replace'](/ /g,'-'))&&_0x50fb3b[_0x20b202(0x335)]===_0x32fac6));_0xd4436f[_0x20b202(0x1d3)](_0x20b202(0x201),_0x35eb35[_0x20b202(0x317)](_0x2290d9)),_0x1ab924[_0x20b202(0x459)](_0x2b24ae),_0x1753fb();}}}:function(){};return _0x145e5e=![],_0x18d9e8;};}()),_0x5dfc06=_0x19c3dc(this,function(){const _0xd57667=_0x2977,_0x9dfe20={'riiTV':_0xd57667(0x2fa),'rlcga':function(_0x576cd5,_0x43fdf1){return _0x576cd5===_0x43fdf1;},'JFQwj':_0xd57667(0x3e4),'wIOfz':_0xd57667(0x1db),'hoggN':function(_0x3be914,_0x44d8da){return _0x3be914!==_0x44d8da;},'nbwSN':_0xd57667(0x230),'kpOIU':function(_0x59112d,_0x3ef732){return _0x59112d!==_0x3ef732;},'GuhHw':_0xd57667(0x31c),'cnmBU':'optionsContainer','cSGuI':_0xd57667(0x1a4),'OTTBI':function(_0x443640){return _0x443640();},'xTZtM':_0xd57667(0x298),'lJBAp':function(_0x5b37f5,_0x11556b){return _0x5b37f5===_0x11556b;},'PuSDW':_0xd57667(0x314),'WwCrT':_0xd57667(0x2fe),'RDdwq':'ppOgT','jWApt':function(_0x428fd3,_0x300c91){return _0x428fd3+_0x300c91;},'bPxRp':_0xd57667(0x3fa),'SMGry':'{}.constructor(\x22return\x20this\x22)(\x20)','ZQVFB':_0xd57667(0x453),'DvEhq':_0xd57667(0x25c),'NoVWj':_0xd57667(0x2a4),'yLHiK':_0xd57667(0x1f8),'zgAQb':_0xd57667(0x369),'sfHjE':_0xd57667(0x30e)},_0x425231=function(){const _0x5f16bb=_0xd57667,_0x55527a={'wnQUV':'correct','QAESX':_0x9dfe20[_0x5f16bb(0x399)]};if(_0x9dfe20[_0x5f16bb(0x1c4)](_0x9dfe20['PuSDW'],_0x9dfe20[_0x5f16bb(0x422)]))_0x275e28=_0x55527a['wnQUV'],_0x376457=_0x55527a[_0x5f16bb(0x402)];else{let _0x5e4a28;try{if(_0x9dfe20[_0x5f16bb(0x1c4)](_0x9dfe20[_0x5f16bb(0x21e)],_0x9dfe20[_0x5f16bb(0x21e)]))_0x5e4a28=Function(_0x9dfe20[_0x5f16bb(0x1ef)](_0x9dfe20[_0x5f16bb(0x1ef)](_0x9dfe20[_0x5f16bb(0x205)],_0x9dfe20[_0x5f16bb(0x3d8)]),');'))();else{const _0x4e27df={'MiPED':_0x9dfe20[_0x5f16bb(0x2d2)],'BhmKu':function(_0x522592,_0x387207){const _0x4bb598=_0x5f16bb;return _0x9dfe20[_0x4bb598(0x255)](_0x522592,_0x387207);},'HPEWZ':_0x9dfe20['JFQwj'],'Xzjhi':_0x9dfe20[_0x5f16bb(0x2a3)]};if(_0x9dfe20[_0x5f16bb(0x28e)](_0x2e7b7d,_0x9dfe20[_0x5f16bb(0x2d5)])&&_0x9dfe20['kpOIU'](_0x72778d,_0x9dfe20['GuhHw']))return;const _0x5e0547=_0x405f1a[_0x5f16bb(0x1a7)](_0x9dfe20[_0x5f16bb(0x234)]),_0x1489f8=_0x5e0547[_0x5f16bb(0x29c)](_0x5f16bb(0x1d8)),_0x17d9e5=_0x3b1a54[_0x325bbc],_0x1f7e14=_0x17d9e5[_0x5f16bb(0x27a)];let _0x48ccd2=_0x17d9e5[_0x5f16bb(0x420)][_0x5f16bb(0x439)](_0x4726e9=>_0x4726e9['id']===_0x1f7e14);_0x5e0547[_0x5f16bb(0x2f3)][_0x5f16bb(0x253)](_0x9dfe20[_0x5f16bb(0x3cf)]),_0x1489f8[_0x5f16bb(0x43d)]((_0x421b74,_0x2511ac)=>{const _0xa595c7=_0x5f16bb;_0x421b74[_0xa595c7(0x2f3)][_0xa595c7(0x367)](_0x4e27df[_0xa595c7(0x3f3)]);if(_0x4e27df['BhmKu'](_0x2511ac,_0x48ccd2))_0x421b74[_0xa595c7(0x2f3)][_0xa595c7(0x253)](_0x4e27df[_0xa595c7(0x39c)]);else{if(_0x2511ac===_0x39f048&&!_0x2e7d5a)_0x421b74[_0xa595c7(0x2f3)][_0xa595c7(0x253)](_0x4e27df[_0xa595c7(0x2f5)]);}}),_0x9dfe20['OTTBI'](_0x78a120);}}catch(_0x4252e0){_0x5e4a28=window;}return _0x5e4a28;}},_0x3c2c61=_0x9dfe20[_0xd57667(0x1f0)](_0x425231),_0x31ab23=_0x3c2c61[_0xd57667(0x3c5)]=_0x3c2c61[_0xd57667(0x3c5)]||{},_0xa473d3=[_0x9dfe20[_0xd57667(0x3c8)],_0xd57667(0x2c5),_0x9dfe20['DvEhq'],_0x9dfe20[_0xd57667(0x387)],_0x9dfe20[_0xd57667(0x3a5)],_0x9dfe20['zgAQb'],_0x9dfe20[_0xd57667(0x41b)]];for(let _0xf589d2=0x0;_0xf589d2<_0xa473d3[_0xd57667(0x33e)];_0xf589d2++){const _0x41cd1b=_0x19c3dc[_0xd57667(0x42e)]['prototype']['bind'](_0x19c3dc),_0x49e773=_0xa473d3[_0xf589d2],_0x123eb5=_0x31ab23[_0x49e773]||_0x41cd1b;_0x41cd1b[_0xd57667(0x231)]=_0x19c3dc[_0xd57667(0x41d)](_0x19c3dc),_0x41cd1b[_0xd57667(0x25b)]=_0x123eb5['toString'][_0xd57667(0x41d)](_0x123eb5),_0x31ab23[_0x49e773]=_0x41cd1b;}});_0x5dfc06();let questionsData=[{'text':_0xa90e1a(0x36a),'choices':[{'id':0x1,'text':_0xa90e1a(0x357)},{'id':0x2,'text':_0xa90e1a(0x3a6)},{'id':0x3,'text':'Pioglitazone'},{'id':0x4,'text':'Glimeperide'}],'correct_choice_id':0x1,'solution':_0xa90e1a(0x455),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0xa90e1a(0x1bf),'choices':[{'id':0x1,'text':_0xa90e1a(0x3d5)},{'id':0x2,'text':_0xa90e1a(0x200)},{'id':0x3,'text':_0xa90e1a(0x334)},{'id':0x4,'text':_0xa90e1a(0x277)}],'correct_choice_id':0x3,'solution':_0xa90e1a(0x1b5),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':'A\x20patient\x20is\x20set\x20to\x20receive\x20intermittent\x20treatment\x20with\x20teriparatide.\x20Which\x20of\x20the\x20following\x20complications\x20does\x20this\x20drug\x20predispose\x20him\x20to?','choices':[{'id':0x1,'text':'Osteonecrosis\x20of\x20the\x20jaw\x20bone'},{'id':0x2,'text':_0xa90e1a(0x22f)},{'id':0x3,'text':'Net\x20loss\x20of\x20bone\x20mass'},{'id':0x4,'text':'Osteosarcoma'}],'correct_choice_id':0x4,'solution':_0xa90e1a(0x2f7),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':'Which\x20of\x20the\x20following\x20monoclonal\x20antibodies\x20is\x20not\x20a\x20HER\x20-\x201\x20inhibitor?','choices':[{'id':0x1,'text':_0xa90e1a(0x31a)},{'id':0x2,'text':_0xa90e1a(0x2c4)},{'id':0x3,'text':_0xa90e1a(0x292)},{'id':0x4,'text':_0xa90e1a(0x351)}],'correct_choice_id':0x1,'solution':'<p><strong>Pertuzumab</strong>\x20is\x20a\x20humanized\x20IgG1\x20monoclonal\x20antibody\x20directed\x20against\x20<strong>HER2</strong>.\u00a0</p>\x0a<p>Pertuzumab\x20is\x20approved\x20for\x20the\x20treatment\x20of\x20patients\x20with\x20HER2-positive,\x20locally\x20advanced,\x20inflammatory,\x20or\x20early-stage\x20<strong>breast\x20cancer</strong>\x20in\x20combination\x20with\x20trastuzumab\x20and\x20docetaxel.\x20Its\x20adverse\x20effect\x20includes\x20<strong>cardiotoxicity</strong>.</p>\x0a<p>The\x20other\x20three\x20antibodies\x20act\x20against\x20<strong>epidermal\x20growth\x20factor\x20receptor</strong>\x20(EGFR)/\x20<strong>HER-1</strong>.\u00a0</p>\x0a<p>Option\x20B\x20-\x20Cetuximab\x20is\x20used\x20to\x20treat\x20patients\x20with\x20metastatic\x20colon\x20cancers\x20and\x20head\x20and\x20neck\x20squamous\x20cell\x20carcinoma\x20(HNSCC).</p>\x0a<p>Option\x20C\x20-\x20Panitumumab\x20is\x20approved\x20for\x20the\x20treatment\x20of\x20EGFR-expressing\x20metastatic\x20colorectal\x20cancer.</p>\x0a<p>Option\x20D\x20-\x20Necitumumab\x20is\x20approved\x20for\x20first-line\x20treatment\x20of\x20patients\x20with\x20metastatic,\x20squamous\x20non-small\x20cell\x20lung\x20cancer\x20in\x20combination\x20with\x20gemcitabine\x20and\x20cisplatin.</p>','explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0xa90e1a(0x23c),'choices':[{'id':0x1,'text':'Cabergoline'},{'id':0x2,'text':_0xa90e1a(0x2f6)},{'id':0x3,'text':_0xa90e1a(0x1b3)},{'id':0x4,'text':_0xa90e1a(0x3b4)}],'correct_choice_id':0x1,'solution':_0xa90e1a(0x2af),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0xa90e1a(0x454),'choices':[{'id':0x1,'text':'Lepirudin'},{'id':0x2,'text':_0xa90e1a(0x2a5)},{'id':0x3,'text':_0xa90e1a(0x327)},{'id':0x4,'text':_0xa90e1a(0x1f4)}],'correct_choice_id':0x1,'solution':_0xa90e1a(0x1cf),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0xa90e1a(0x283),'choices':[{'id':0x1,'text':_0xa90e1a(0x2b6)},{'id':0x2,'text':_0xa90e1a(0x42a)},{'id':0x3,'text':'Angiotensin\x20receptor\x20blockers'},{'id':0x4,'text':_0xa90e1a(0x353)}],'correct_choice_id':0x2,'solution':_0xa90e1a(0x3fe),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0xa90e1a(0x24b),'choices':[{'id':0x1,'text':'Calcitriol'},{'id':0x2,'text':'Risedronate'},{'id':0x3,'text':_0xa90e1a(0x1d9)},{'id':0x4,'text':_0xa90e1a(0x378)}],'correct_choice_id':0x1,'solution':_0xa90e1a(0x343),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0xa90e1a(0x1d2),'choices':[{'id':0x1,'text':'1,2'},{'id':0x2,'text':'3,4'},{'id':0x3,'text':_0xa90e1a(0x27e)},{'id':0x4,'text':_0xa90e1a(0x1d6)}],'correct_choice_id':0x2,'solution':'<p><strong>Ritonavir</strong>\x20and\x20<strong>benzbromarone</strong>\x20are\x20both\x20<strong>suicide\x20inhibitors.</strong>\u00a0</p>\x0a<p><strong>Suicide\x20inhibition</strong>\x20is\x20when\x20an\x20<strong>inhibitor</strong>\x20binds\x20to\x20an\x20<strong>enzyme</strong>\x20and\x20then\x20<strong>undergoes</strong>\x20a\x20reaction\x20to\x20form\x20an\x20<strong>irreversible\x20complex</strong>\x20with\x20the\x20<strong>enzyme,</strong>\x20inactivating\x20it\x20permanently.\x20Ritonavir\x20is\x20a\x20protease\x20inhibitor\x20used\x20in\x20HIV\x20treatment\x20and\x20benzbromarone\x20is\x20a\x20uricosuric\x20agent\x20used\x20to\x20treat\x20gout\x20by\x20increasing\x20uric\x20acid\x20excretion.\x20It\x20also\x20inhibits\x20CYP2C9\x20via\x20mechanism-based\x20(suicide)\x20inhibition.</p>\x0a<p>Other\x20options:\u00a0</p>\x0a<p>Ethinyl\x20<strong>estradiol</strong>\x20is\x20a\x20synthetic\x20estrogen\x20used\x20in\x20oral\x20contraceptives\x20and\x20hormone\x20replacement\x20therapy.\x20It\x20acts\x20through\x20<strong>receptor-mediated</strong>\x20mechanisms,\x20not\x20through\x20suicide\x20inhibition.</p>\x0a<p><strong>Spironolactone</strong>\x20is\x20a\x20potassium-sparing\x20diuretic\x20and\x20aldosterone\x20antagonist.\x20It\x20works\x20by\x20competitively\x20<strong>inhibiting\x20aldosterone\x20receptors</strong>\x20in\x20the\x20distal\x20tubules\x20of\x20the\x20kidney,\x20not\x20through\x20suicide\x20inhibition.</p>','explanation_video':'','question_images':[],'explanation_images':[]},{'text':'Which\x20of\x20the\x20following\x20diuretics\x20is\x20matched\x20correctly\x20with\x20its\x20location\x20of\x20action?','choices':[{'id':0x1,'text':_0xa90e1a(0x42b)},{'id':0x2,'text':_0xa90e1a(0x1c0)},{'id':0x3,'text':'2,\x204'},{'id':0x4,'text':'1,2'}],'correct_choice_id':0x2,'solution':_0xa90e1a(0x284),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0xa90e1a(0x2fd),'choices':[{'id':0x1,'text':_0xa90e1a(0x302)},{'id':0x2,'text':_0xa90e1a(0x35c)},{'id':0x3,'text':_0xa90e1a(0x2b2)},{'id':0x4,'text':_0xa90e1a(0x219)}],'correct_choice_id':0x4,'solution':'<p><strong>Evolocumab</strong>\x20is\x20a\x20monoclonal\x20antibody\x20that\x20acts\x20by\x20<strong>inhibiting\x20PCSK9</strong>.</p>\x0a<p><strong>PCSK9</strong>\x20(proprotein\x20convertase\x20subtilisin/kexin\x20type)\x20is\x20a\x20serine\x20protease\x20that\x20causes\x20lysosomal\x20<strong>degradation</strong>\x20of\x20the\x20low-density\x20lipoprotein\x20(<strong>LDL</strong>)\x20<strong>receptors</strong>\x20present\x20on\x20hepatocytes.\x20Monoclonal\x20antibodies\x20against\x20PCSK9\x20such\x20as\x20<strong>alirocumab</strong>\x20and\x20<strong>evolocumab</strong>\x20counter\x20this\x20and\x20cause\x20persistence\x20of\x20LDL\x20receptors\x20on\x20hepatocytes.\x20This\x20leads\x20to<strong>\x20more\x20LDL\x20uptake</strong>\x20from\x20the\x20circulation,\x20bringing\x20down\x20the\x20LDL-cholesterol\x20levels.</p>\x0a<p>Evolocumab\x20is\x20administered\x20as\x20a\x20140-mg\x20injection\x20every\x202\x20weeks\x20or\x20as\x20a\x20420-mg\x20injection\x20once\x20a\x20month.\x20PCKS9\x20inhibitors\x20should\x20not\x20be\x20used\x20in\x20pregnancy\x20because\x20transmission\x20across\x20the\x20placenta\x20is\x20expected.</p>\x0a<p>PCSK9\x20inhibitors\x20are\x20indicated\x20only\x20as\x20<strong>adjunctive\x20therapy</strong>\x20in\x20patients\x20with\x20<strong>familial\x20hypercholesterolemia</strong>(FH)\x20or\x20established\x20<strong>atherosclerotic\x20cardiovascular\x20disease</strong>(ASCVD)\x20who\x20have\x20elevated\x20LDL-cholesterol\x20levels\x20despite\x20being\x20on\x20maximum\x20statin\x20therapy.</p>\x0a<p>Other\x20options\x20:</p>\x0a<p>Option\x20A\x20-\u00a0<strong>Bempedoic\x20acid\x20</strong>acts\x20by\x20inhibiting\x20<strong>de\x20novo</strong>\x20hepatocyte\x20<strong>cholesterol\x20biosynthesis</strong>,\x20by\x20blocking\x20the\x20enzyme\x20<strong>adenosine</strong>\x20<strong>triphosphate\x20citrate\x20lyase</strong>.\x20The\x20drug\x20is\x20approved\x20as\x20an\x20adjunct\x20to\x20diet\x20and\x20maximally\x20tolerated\x20statin\x20therapy\x20to\x20further\x20lower\x20LDL-C\x20in\x20patients\x20with\x20FH\x20or\x20established\x20ASCVD.</p>\x0a<p>Option\x20B\x20-\u00a0<strong>Lomitapide</strong>\x20acts\x20by\x20inhibiting\x20<strong>microsomal\x20triglyceride\x20transfer\x20protein</strong>\x20(MTP),\x20which\x20is\x20essential\x20for\x20the\x20intracellular\x20transfer\x20of\x20triglycerides\x20into\x20triglyceride-rich\x20lipoproteins,\x20thus\x20inhibiting\x20the\x20formation\x20of\x20<strong>VLDLs</strong>\x20in\x20hepatocytes\x20and\x20<strong>chylomicrons</strong>\x20in\x20intestinal\x20epithelial\x20cells.\u00a0It\x20is\x20approved\x20as\x20an\x20adjunct\x20to\x20diet\x20for\x20lowering\x20LDL-C\x20levels,\x20total\x20cholesterol,\x20apo\x20B,\x20and\x20non–HDL\x20lipoproteins\x20in\x20patients\x20with\x20FH.</p>\x0a<p>Option\x20C\x20-\u00a0<strong>Ezetimibe</strong>\x20inhibits\x20luminal\x20cholesterol\x20uptake\x20by\x20jejunal\x20enterocytes,\x20by\x20inhibiting\x20<strong>Niemann-Pick\x20C1–like\x201\x20transport</strong>\x20protein.\x20The\x20role\x20of\x20ezetimibe\x20as\x20monotherapy\x20for\x20patients\x20with\x20elevated\x20LDL-C\x20levels\x20is\x20generally\x20limited\x20to\x20a\x20small\x20group\x20of\x20statin-intolerant\x20patients.</p>','explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0xa90e1a(0x1ce),'choices':[{'id':0x1,'text':_0xa90e1a(0x22e)},{'id':0x2,'text':'Unstable\x20angina'},{'id':0x3,'text':_0xa90e1a(0x37b)},{'id':0x4,'text':'Erectile\x20dysfunction'}],'correct_choice_id':0x1,'solution':'<p>Inhaled\x20nitric\x20oxide(iNO)\x20is\x20used\x20for\x20<strong>persistent\x20pulmonary\x20hypertension\x20in\x20newborns</strong>.\x20(Option\x20A)</p>\x0a<p><strong>Inhaled\x20NO</strong>\x20selectively\x20<strong>dilates</strong>\x20the\x20<strong>pulmonary\x20vasculature</strong>,\x20hence\x20used\x20in\x20diseases\x20associated\x20with\x20increased\x20pulmonary\x20vascular<strong>\x20</strong>resistance.\x20Inhaled\x20NO\x20is\x20an\x20FDA-approved\x20drug\x20for\x20persistent\x20pulmonary\x20hypertension\x20in\x20the\x20newborn.\u00a0</p>\x0a<p>Inhaled\x20NO\x20can\x20also\x20be\x20used\x20during\x20<strong>cardiac\x20catheterization</strong>\x20to\x20evaluate\x20the\x20<strong>pulmonary\x20vasodilating\x20capacity</strong>\x20of\x20patients\x20with\x20<strong>heart\x20failure</strong>\x20and\x20infants\x20with\x20<strong>congenital\x20heart\x20disease</strong>.\x20Another\x20use\x20of\x20inhaled\x20NO\x20is\x20to\x20determine\x20the\x20<strong>diffusion\x20capacity\x20(DL)</strong>\x20across\x20the\x20alveolar-capillary\x20membrane.\x20It\x20is\x20more\x20effective\x20than\x20CO2\x20because\x20of\x20its\x20greater\x20affinity\x20for\x20hemoglobin\x20and\x20its\x20higher\x20water\x20solubility\x20at\x20body\x20temperature.</p>\x0a<p>NO\x20is\x20produced\x20from\x20the\x20nasal\x20passages\x20and\x20the\x20lungs\x20of\x20normal\x20human\x20subjects\x20and\x20can\x20be\x20detected\x20in\x20exhaled\x20gas.\x20The\x20measurement\x20of\x20fractional\x20<strong>exhaled\x20NO</strong>\x20is\x20a\x20<strong>noninvasive\x20marker</strong>\x20for\x20<strong>airway\x20inflammation</strong>\x20in\x20the\x20assessment\x20of\x20respiratory\x20tract\x20diseases,\x20including\x20<strong>asthma</strong>,\x20<strong>respiratory\x20tract\x20infection</strong>,\x20and\x20<strong>chronic\x20lung\x20disease</strong>.</p>\x0a<p>Inhaled\x20NO\x20is\x20administered\x20at\x20<strong>low\x20concentrations</strong>\x20(<strong>0.1–50\x20ppm</strong>)\x20since\x20high\x20concentrations\x20of\x2050\x20to\x20100\x20ppm\x20can\x20cause\x20significant\x20<strong>methemoglobinemia\x20</strong>that\x20can\x20cause\x20death.</p>\x0a<p>Other\x20options:</p>\x0a<p>Option\x20B:\x20<strong>Unstable\x20angina</strong>\x20is\x20treated\x20by\x20<strong>anti-platelet\x20drugs</strong>\x20such\x20as<strong>\x20</strong>aspirin\x20and\x20clopidogrel,\x20and\x20anticoagulants\x20such\x20as<strong>\x20heparin</strong>.</p>\x0a<p>Option\x20C:\x20<strong>Obstructive\x20sleep\x20apnoea</strong>\x20is\x20mainly\x20treated\x20by\x20using\x20a\x20<strong>BiPAP\x20machine</strong>\x20during\x20sleep\x20and\x20<strong>CNS\x20stimulants</strong>\x20such\x20as\x20<strong>armodafinil</strong>\x20for\x20<strong>daytime\x20sleepiness</strong>\x20associated\x20with\x20the\x20condition.\u00a0</p>\x0a<p>Option\x20D:\x20<strong>Erectile\x20dysfunction</strong>\x20is\x20treated\x20by\x20<strong>PDE5\x20inhibitors</strong>\x20such\x20as\x20<strong>sildenafil</strong>,\x20tadalafil,\x20etc.</p>','explanation_video':'','question_images':[],'explanation_images':[]},{'text':'A\x20patient\x20presents\x20with\x20complaints\x20of\x20a\x20cough\x20producing\x20tenacious\x20white\x20sputum.\x20Which\x20of\x20the\x20following\x20statements\x20is\x20true\x20about\x20the\x20drug\x20that\x20could\x20be\x20prescribed\x20for\x20this\x20condition?','choices':[{'id':0x1,'text':_0xa90e1a(0x312)},{'id':0x2,'text':_0xa90e1a(0x2ca)},{'id':0x3,'text':_0xa90e1a(0x27c)},{'id':0x4,'text':_0xa90e1a(0x22b)}],'correct_choice_id':0x4,'solution':'<p><strong>Bromhexine</strong>\x20should\x20be\x20prescribed\x20for\x20a\x20patient\x20with\x20a\x20<strong>productive\x20cough</strong>,\x20as\x20it\x20<strong>liquifies</strong>\x20the\x20sputum.</p>\x0a<p>Bromhexine\x20belongs\x20to\x20a\x20class\x20of\x20drugs\x20called\x20<strong>mucolytics</strong>,\x20capable\x20of\x20inducing\x20thin\x20copious\x20bronchial\x20secretion.\x20It\x20<strong>depolymerizes</strong>\x20mucopolysaccharides\x20directly\x20as\x20well\x20as\x20by\x20liberating\x20lysosomal\x20enzymes-\x20the\x20network\x20of\x20fibers\x20in\x20tenacious\x20sputum\x20is\x20broken.\x20It\x20is\x20particularly\x20useful\x20if\x20mucus\x20plugs\x20are\x20present.</p>\x0a<p>Other\x20examples\x20of\x20mucolytics\x20are\x20ambroxol,\x20carbocisteine,\x20and\x20N-acetyl\x20cysteine.</p>\x0a<p>Other\x20options\x20:</p>\x0a<p><strong>Codeine</strong>\x20and\x20<strong>dextromethorphan</strong>\x20belong\x20to\x20the\x20class\x20of\x20drugs\x20called\x20<strong>antitussives</strong>.\x20These\x20are\x20drugs\x20that\x20act\x20in\x20the\x20CNS\x20to\x20raise\x20the\x20threshold\x20of\x20the\x20cough\x20center\x20or\x20act\x20peripherally\x20in\x20the\x20respiratory\x20tract\x20to\x20reduce\x20tussal\x20impulses,\x20or\x20both\x20these\x20actions.\x20Because\x20they\x20aim\x20to\x20control\x20rather\x20than\x20eliminate\x20cough,\x20antitussive\x20drugs\x20should\x20be\x20used\x20only\x20for\x20<strong>dry\x20nonproductive</strong>\x20cough\x20or\x20if\x20it\x20is\x20unduly\x20tiring,\x20disturbs\x20sleep,\x20or\x20is\x20hazardous\x20(hernia,\x20piles,\x20cardiac\x20disease,\x20ocular\x20surgery).\u00a0</p>\x0a<p>Cough\x20is\x20a\x20defensive\x20reflex\x20and\x20its\x20suppression\x20may\x20be\x20inappropriate\x20in\x20bacterial\x20lung\x20infection.\x20Hence,\x20before\x20treatment\x20with\x20antitussives,\x20it\x20is\x20important\x20to\x20identify\x20underlying\x20causal\x20mechanisms\x20that\x20may\x20require\x20therapy.</p>','explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0xa90e1a(0x392),'choices':[{'id':0x1,'text':_0xa90e1a(0x3a6)},{'id':0x2,'text':_0xa90e1a(0x391)},{'id':0x3,'text':_0xa90e1a(0x3f4)},{'id':0x4,'text':_0xa90e1a(0x1f6)}],'correct_choice_id':0x2,'solution':'<p><strong>Metformin</strong>\x20is\x20known\x20to\x20cause\x20<strong>unexplained\x20diarrhoea</strong>\x20as\x20its\x20adverse\x20effect.</p>\x0a<p><strong>Metformin</strong>\x20is\x20a\x20member\x20of\x20the\x20<strong>biguanide</strong>\x20class\x20of\x20oral\x20hypoglycemic\x20drugs.\x20It\x20acts\x20by\x20primarily\x20by\x20inhibiting\x20<strong>hepatic\x20gluconeogenesis</strong>.\x20<span\x20style=\x22font-family:\x20-apple-system,\x20BlinkMacSystemFont,\x20\x27Segoe\x20UI\x27,\x20Roboto,\x20Oxygen,\x20Ubuntu,\x20Cantarell,\x20\x27Open\x20Sans\x27,\x20\x27Helvetica\x20Neue\x27,\x20sans-serif;\x22>It\x20activates\x20<strong>AMP-dependent\x20protein\x20kinase</strong>,\x20</span>leading\x20to\x20stimulation\x20of\x20hepatic\x20fatty\x20acid\x20oxidation,\x20glucose\x20uptake,\x20and\x20nonoxidative\x20glucose\x20metabolism\x20and\x20reduction\x20of\x20lipogenesis\x20and\x20gluconeogenesis.\x20It\x20also\x20appears\x20to\x20act\x20in\x20the\x20gut.</p>\x0a<p>Metformin\x20is\x20accepted\x20as\x20the\x20first-line\x20treatment\x20of\x20<strong>type\x202\x20diabetes</strong>\x20and\x20is\x20the\x20most\x20commonly\x20used\x20oral\x20agent\x20for\x20this\x20condition.\u00a0It\x20has\x20been\x20used\x20as\x20a\x20treatment\x20of\x20infertility\x20in\x20women\x20with\x20<strong>polycystic\x20ovarian\x20syndrome</strong>.</p>\x0a<p>The\x20most\x20common\x20<strong>side\x20effects</strong>\x20of\x20metformin\x20are\x20<strong>gastrointestinal</strong>:\x20nausea,\x20indigestion,\x20<strong>abdominal\x20cramps,\x20</strong>bloating,\x20and\x20<strong>diarrhea</strong>.\x20The\x20use\x20of\x20metformin\x20is\x20also\x20associated\x20with<strong>\u00a0lower\x20blood\x20levels\x20of\x20vitamin\x20B12.</strong></p>\x0a<p>Most\x20adverse\x20GI\x20effects\x20of\x20metformin\x20abate\x20over\x20time\u00a0and\x20can\x20be\x20minimized\x20by\x20<strong>starting\x20at\x20a\x20low\x20dose</strong>\x20and\x20gradually\x20titrating\x20to\x20a\x20target\x20dose\x20over\x20several\x20weeks,\x20as\x20well\x20as\x20by\x20having\x20patients\x20take\x20the\x20drug\x20<strong>with\x20meals</strong>.\x20<strong>Extended-release</strong>\x20metformin\x20has\x20decreased\x20GI\x20side\x20effects\x20and\x20can\x20be\x20substituted\x20for\x20immediate-release\x20metformin.\x20<strong>Lactic\x20acidosis</strong>\x20has\x20been\x20linked\x20with\x20the\x20use\x20of\x20metformin.</p>\x0a<p>Other\x20options:</p>\x0a<p>Option\x20A\x20-\x20<strong>Sitagliptin</strong>\x20is\x20a\x20dipeptidyl\x20peptidase-4\x20inhibitor.\x20Its\x20use\x20is\x20associated\x20with\x20an\x20increased\x20risk\x20of\x20<strong>heart\x20failure</strong>.</p>\x0a<p>Option\x20C\x20-\x20<strong>Glimepiride\x20</strong>belongs\x20to\x20the\x20class\x20of\x20sulfonylureas.\x20It\x20stimulates\x20insulin\x20release\x20by\x20inhibiting\x20the\x20activity\x20of\x20the\x20β\x20cell\x20KATP\x20channel\x20complex.\x20Its\x20side\x20effects\x20include\x20<strong>hypoglycemia</strong>,\x20and\x20<strong>weight\x20gain.</strong></p>\x0a<p>Option\x20D\x20-\x20<strong>Pioglitazone</strong>\x20is\x20an\x20activator\x20of\x20the\x20peroxisome\x20proliferator-activated\x20receptor\x20γ\x20(PPARγ),\x20which<span\x20style=\x22font-family:\x20-apple-system,\x20BlinkMacSystemFont,\x20\x27Segoe\x20UI\x27,\x20Roboto,\x20Oxygen,\x20Ubuntu,\x20Cantarell,\x20\x27Open\x20Sans\x27,\x20\x27Helvetica\x20Neue\x27,\x20sans-serif;\x22>\x20is\x20involved\x20in\x20the\x20regulation\x20of\x20genes\x20related\x20to\x20glucose\x20and\u00a0</span>lipid\x20metabolism.\x20Its\x20adverse\x20effects\x20include\x20increased\x20incidence\x20of\x20<strong>heart\x20failure</strong>,\x20<strong>peripheral\x20edema</strong>,\x20weight\x20gain,\x20<strong>macular\x20edema</strong>,\x20and\x20<strong>osteoporosis</strong>.</p>','explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0xa90e1a(0x2c1),'choices':[{'id':0x1,'text':'4h'},{'id':0x2,'text':_0xa90e1a(0x1f3)},{'id':0x3,'text':'42h'},{'id':0x4,'text':'0.9h'}],'correct_choice_id':0x3,'solution':'<p>Therefore,\u00a0</p>\x0a<p>t1/2\x20~\x200.7\x20x\x2046x6/4.6\x20=\x200.7\x20x\x2060</p>\x0a<p>t1/2\x20~\x20<strong>42\x20hours</strong></p>\x0a<p>Where,</p>\x0a<p>t1/2\x20-\x20Plasma\x20half-life<br\x20/>Vd\x20-\x20Volume\x20of\x20distribution\u00a0<br\x20/>CL\x20-\x20Clearance\u00a0</p>','explanation_video':'','question_images':[],'explanation_images':[_0xa90e1a(0x449)]},{'text':'Choose\x20the\x20correct\x20option\x20regarding\x20phenytoin.','choices':[{'id':0x1,'text':_0xa90e1a(0x26f)},{'id':0x2,'text':_0xa90e1a(0x227)},{'id':0x3,'text':'These\x20complications\x20can\x20be\x20minimized\x20by\x20administering\x20fosphenytoin\x20at\x20a\x20rate\x20of\x20less\x20than\x20250\x20mg\x20of\x20phenytoin\x20sodium\x20equivalents\x20per\x20minute'},{'id':0x4,'text':_0xa90e1a(0x40c)}],'correct_choice_id':0x1,'solution':_0xa90e1a(0x37c),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0xa90e1a(0x293),'choices':[{'id':0x1,'text':'Iron\x20requirement\x20can\x20be\x20fulfilled\x20in\x20single\x20dose'},{'id':0x2,'text':_0xa90e1a(0x3e3)},{'id':0x3,'text':_0xa90e1a(0x3dc)},{'id':0x4,'text':_0xa90e1a(0x2cb)}],'correct_choice_id':0x1,'solution':_0xa90e1a(0x352),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0xa90e1a(0x29d),'choices':[{'id':0x1,'text':'Maraviroc'},{'id':0x2,'text':_0xa90e1a(0x1e6)},{'id':0x3,'text':_0xa90e1a(0x23a)},{'id':0x4,'text':_0xa90e1a(0x390)}],'correct_choice_id':0x2,'solution':_0xa90e1a(0x225),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0xa90e1a(0x1ca),'choices':[{'id':0x1,'text':_0xa90e1a(0x45a)},{'id':0x2,'text':_0xa90e1a(0x3ff)},{'id':0x3,'text':'Regorafenib'},{'id':0x4,'text':_0xa90e1a(0x244)}],'correct_choice_id':0x2,'solution':_0xa90e1a(0x435),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0xa90e1a(0x1bc),'choices':[{'id':0x1,'text':_0xa90e1a(0x421)},{'id':0x2,'text':'Only\x201\x20and\x202'},{'id':0x3,'text':_0xa90e1a(0x44d)},{'id':0x4,'text':'Only\x201\x20and\x203'}],'correct_choice_id':0x1,'solution':_0xa90e1a(0x236),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0xa90e1a(0x440),'choices':[{'id':0x1,'text':_0xa90e1a(0x2db)},{'id':0x2,'text':_0xa90e1a(0x301)},{'id':0x3,'text':_0xa90e1a(0x3be)},{'id':0x4,'text':_0xa90e1a(0x427)}],'correct_choice_id':0x2,'solution':_0xa90e1a(0x2d7),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':'Which\x20of\x20the\x20following\x20drugs\x20act\x20on\x20sodium\x20channels\x20and\x20potentiate\x20slow\x20sodium\x20inactivation?','choices':[{'id':0x1,'text':_0xa90e1a(0x290)},{'id':0x2,'text':'Lamotrigine'},{'id':0x3,'text':'Lacosamide'},{'id':0x4,'text':_0xa90e1a(0x3d4)}],'correct_choice_id':0x3,'solution':_0xa90e1a(0x1e2),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0xa90e1a(0x2ac),'choices':[{'id':0x1,'text':_0xa90e1a(0x2bc)},{'id':0x2,'text':_0xa90e1a(0x2b8)},{'id':0x3,'text':_0xa90e1a(0x3e7)},{'id':0x4,'text':_0xa90e1a(0x32e)}],'correct_choice_id':0x1,'solution':_0xa90e1a(0x1bb),'explanation_video':'','question_images':['https://cdn1.dailyrounds.org/uploads/921730699eae46c3843301d7d92a1f02.JPEG'],'explanation_images':['https://dhmbxeygs57ff.cloudfront.net/uploads/a989056e57504c4fbaed4b616bf3068cx1280x1618.JPEG']},{'text':_0xa90e1a(0x1dc),'choices':[{'id':0x1,'text':_0xa90e1a(0x375)},{'id':0x2,'text':_0xa90e1a(0x379)},{'id':0x3,'text':_0xa90e1a(0x2c7)},{'id':0x4,'text':_0xa90e1a(0x3a4)}],'correct_choice_id':0x2,'solution':_0xa90e1a(0x1d5),'explanation_video':'','question_images':[],'explanation_images':[]}],quizName=_0xa90e1a(0x37d);const quizFilename=_0xa90e1a(0x2f1);let hierarchy=[_0xa90e1a(0x308),'PYQ',_0xa90e1a(0x2e2)];if(window[_0xa90e1a(0x2eb)][_0xa90e1a(0x2ed)][_0xa90e1a(0x337)](_0xa90e1a(0x388))){const customData=JSON['parse'](localStorage[_0xa90e1a(0x38d)]('customQuizData'));if(customData){const UWhjMK=_0xa90e1a(0x266)['split']('|');let IdxllH=0x0;while(!![]){switch(UWhjMK[IdxllH++]){case'0':hierarchy=customData[_0xa90e1a(0x34c)];continue;case'1':quizName=customData[_0xa90e1a(0x2f2)];continue;case'2':document[_0xa90e1a(0x3b0)]=quizName+_0xa90e1a(0x1e5);continue;case'3':questionsData=customData[_0xa90e1a(0x207)];continue;case'4':document[_0xa90e1a(0x1a7)](_0xa90e1a(0x25f))[_0xa90e1a(0x1cd)]=questionsData[_0xa90e1a(0x33e)];continue;case'5':document[_0xa90e1a(0x1a7)](_0xa90e1a(0x1fd))[_0xa90e1a(0x1cd)]=hierarchy[_0xa90e1a(0x355)](_0xa90e1a(0x26a));continue;}break;}}}let currentQuestionIndex=0x0,selectedOption=null,currentMode=_0xa90e1a(0x230),timer=null,timeRemaining=0x0,questionStartTime=Date[_0xa90e1a(0x1c8)](),quizStartTime=Date[_0xa90e1a(0x1c8)](),isQuizCompleted=![],questionStates=new Array(questionsData[_0xa90e1a(0x33e)])[_0xa90e1a(0x291)](null)['map'](()=>({'status':_0xa90e1a(0x446),'bookmarked':![],'markedForReview':![],'selectedAnswer':null,'timeSpent':0x0})),stats={'correctAnswers':0x0,'incorrectAnswers':0x0,'totalAttempted':0x0,'totalTime':0x0,'notAttempted':questionsData[_0xa90e1a(0x33e)]};function saveProgress(){const _0x39636f=_0xa90e1a,_0x40bae4={'lWkYi':_0x39636f(0x1be),'DuDVP':_0x39636f(0x24e)};if(isQuizCompleted)return;const _0x12f7f6=JSON[_0x39636f(0x36c)](localStorage['getItem'](_0x40bae4[_0x39636f(0x3bb)]))||{};_0x12f7f6[quizFilename]={'questionStates':questionStates,'stats':stats,'currentQuestionIndex':currentQuestionIndex,'currentMode':currentMode,'status':_0x40bae4[_0x39636f(0x1f5)],'lastSeen':new Date()['toISOString']()},localStorage[_0x39636f(0x1d3)](_0x40bae4['lWkYi'],JSON[_0x39636f(0x317)](_0x12f7f6));}function loadProgress(){const _0x169a5d=_0xa90e1a,_0x4644a2={'tjukd':_0x169a5d(0x1be),'ZMLBw':_0x169a5d(0x2be),'EVJIx':'5|0|1|3|2|4','CpgNa':'Progress\x20loaded.'},_0x5389da=JSON[_0x169a5d(0x36c)](localStorage[_0x169a5d(0x38d)](_0x4644a2[_0x169a5d(0x209)]))||{},_0x26250a=_0x5389da[quizFilename];if(_0x26250a){if(_0x4644a2[_0x169a5d(0x2d8)]!==_0x4644a2[_0x169a5d(0x2d8)]){if(_0x1b8b59){const _0x2db937=_0x20489e[_0x169a5d(0x1ac)](_0x4b62ef,arguments);return _0x3314c0=null,_0x2db937;}}else{const _0x227878=_0x4644a2[_0x169a5d(0x286)][_0x169a5d(0x432)]('|');let _0x50f58d=0x0;while(!![]){switch(_0x227878[_0x50f58d++]){case'0':stats=_0x26250a[_0x169a5d(0x30b)];continue;case'1':currentQuestionIndex=_0x26250a[_0x169a5d(0x21d)];continue;case'2':console['log'](_0x4644a2[_0x169a5d(0x418)]);continue;case'3':currentMode=_0x26250a[_0x169a5d(0x3df)];continue;case'4':return!![];case'5':questionStates=_0x26250a[_0x169a5d(0x2f4)];continue;}break;}}}return![];}function clearProgress(){const _0x4cd16c=_0xa90e1a,_0x428447={'EcOvq':function(_0x15b764){return _0x15b764();},'HINNj':_0x4cd16c(0x1be),'uIDkn':_0x4cd16c(0x2f0),'RbCBZ':_0x4cd16c(0x31d)},_0x4373a3=JSON[_0x4cd16c(0x36c)](localStorage[_0x4cd16c(0x38d)](_0x428447[_0x4cd16c(0x394)]))||{};_0x4373a3[quizFilename]&&(_0x4cd16c(0x2f0)===_0x428447[_0x4cd16c(0x1a8)]?(delete _0x4373a3[quizFilename],localStorage[_0x4cd16c(0x1d3)](_0x428447['HINNj'],JSON['stringify'](_0x4373a3)),console[_0x4cd16c(0x453)](_0x428447[_0x4cd16c(0x257)])):_0x428447[_0x4cd16c(0x3cd)](_0x105b76));}function _0x2977(_0x335537,_0x3a7a15){const _0xd43c1a=_0x1ffe();return _0x2977=function(_0x5dfc06,_0x19c3dc){_0x5dfc06=_0x5dfc06-0x1a2;let _0x5ac2fd=_0xd43c1a[_0x5dfc06];return _0x5ac2fd;},_0x2977(_0x335537,_0x3a7a15);}function markQuizAsCompleted(){const _0x29d393=_0xa90e1a,_0x1c3a21={'CWkgw':_0x29d393(0x242)},_0x4838d4=JSON[_0x29d393(0x36c)](localStorage[_0x29d393(0x38d)](_0x29d393(0x1be)))||{},_0x524d00=questionsData[_0x29d393(0x33e)],_0x52a7c3=stats[_0x29d393(0x250)]||0x0;_0x4838d4[quizFilename]={'score':_0x52a7c3,'total':_0x524d00,'status':_0x1c3a21[_0x29d393(0x1df)],'completedOn':new Date()[_0x29d393(0x1e7)]()},localStorage['setItem'](_0x29d393(0x1be),JSON['stringify'](_0x4838d4));}const urlParams=new URLSearchParams(window[_0xa90e1a(0x2eb)][_0xa90e1a(0x389)]),startAt=parseInt(urlParams[_0xa90e1a(0x26d)]('startAt')),resume=urlParams['get'](_0xa90e1a(0x368))==='true';function goBack(){const _0x6f6499=_0xa90e1a,_0x5d91f6={'cZIWW':function(_0x92e459){return _0x92e459();},'aENFN':'index.html'};if(!isQuizCompleted)_0x5d91f6['cZIWW'](saveProgress);window[_0x6f6499(0x2eb)][_0x6f6499(0x26b)]=document[_0x6f6499(0x2dd)]||_0x5d91f6[_0x6f6499(0x385)];}function selectMode(_0x473e67){const _0x2a90a3=_0xa90e1a,_0x2efc85={'Mkvgy':_0x2a90a3(0x256),'FDPwu':'none','ZbJXb':function(_0x2ca43b){return _0x2ca43b();}};currentMode=_0x473e67,document[_0x2a90a3(0x1a7)](_0x2efc85[_0x2a90a3(0x415)])['style'][_0x2a90a3(0x3de)]=_0x2efc85[_0x2a90a3(0x407)],_0x2efc85['ZbJXb'](initializeQuiz);}function initializeQuiz(){const _0x2e99ae=_0xa90e1a,_0x376812={'wPOVq':_0x2e99ae(0x256),'UDEQk':_0x2e99ae(0x1dd),'uEiLK':function(_0x1ca322){return _0x1ca322();},'gzpSy':_0x2e99ae(0x2fb),'EElks':function(_0x3a0c63,_0x593389){return _0x3a0c63===_0x593389;},'UnncD':function(_0x47c6c1,_0x2fcd8a){return _0x47c6c1===_0x2fcd8a;},'DOjGg':_0x2e99ae(0x43f),'luWHH':_0x2e99ae(0x405),'FXzzb':_0x2e99ae(0x21f),'RXdbU':_0x2e99ae(0x1ad),'YJWOp':_0x2e99ae(0x2a8),'VCUID':function(_0x49dbda,_0x5d3ab8){return _0x49dbda===_0x5d3ab8;},'djhwi':_0x2e99ae(0x31c),'WJTAT':_0x2e99ae(0x2b9),'mjizW':_0x2e99ae(0x1c9),'qORbG':function(_0x334177,_0x5cc9ac){return _0x334177<_0x5cc9ac;},'GKQdT':function(_0x25d636,_0x4c5979){return _0x25d636!==_0x4c5979;},'xWxYc':_0x2e99ae(0x1ab),'kpvaa':function(_0x932c8e){return _0x932c8e();},'EYLMV':function(_0x4e6874){return _0x4e6874();}};quizStartTime=Date[_0x2e99ae(0x1c8)]();const _0x58b42d=document[_0x2e99ae(0x1a7)](_0x2e99ae(0x2c2)),_0x10f5e1=document[_0x2e99ae(0x1a7)](_0x2e99ae(0x404)),_0x5b6196=document[_0x2e99ae(0x1a7)](_0x376812[_0x2e99ae(0x233)]),_0x3dd41b=_0x376812[_0x2e99ae(0x44a)](currentMode,_0x2e99ae(0x38a))||_0x376812[_0x2e99ae(0x338)](currentMode,_0x376812[_0x2e99ae(0x331)]);document[_0x2e99ae(0x1a7)](_0x2e99ae(0x34f))[_0x2e99ae(0x3e0)][_0x2e99ae(0x3de)]=_0x3dd41b?_0x376812[_0x2e99ae(0x33b)]:_0x2e99ae(0x21f),document[_0x2e99ae(0x1a7)](_0x376812[_0x2e99ae(0x295)])[_0x2e99ae(0x3e0)][_0x2e99ae(0x3de)]=_0x3dd41b?_0x376812[_0x2e99ae(0x33b)]:_0x376812['FXzzb'],document[_0x2e99ae(0x1a7)](_0x376812[_0x2e99ae(0x329)])[_0x2e99ae(0x3e0)][_0x2e99ae(0x3de)]=_0x3dd41b?'block':_0x376812[_0x2e99ae(0x33b)],document[_0x2e99ae(0x1a7)](_0x2e99ae(0x447))['style']['display']=_0x3dd41b?_0x2e99ae(0x21f):'none',_0x58b42d[_0x2e99ae(0x3e0)][_0x2e99ae(0x3de)]=_0x3dd41b?_0x376812[_0x2e99ae(0x33b)]:_0x376812[_0x2e99ae(0x228)],_0x10f5e1[_0x2e99ae(0x3e0)][_0x2e99ae(0x3de)]=_0x3dd41b?_0x2e99ae(0x2a8):_0x376812['UDEQk'],_0x5b6196[_0x2e99ae(0x3e0)][_0x2e99ae(0x3de)]=_0x3dd41b?_0x376812['YJWOp']:_0x376812['UDEQk'],(_0x376812[_0x2e99ae(0x289)](currentMode,_0x376812['djhwi'])||_0x376812[_0x2e99ae(0x338)](currentMode,_0x376812[_0x2e99ae(0x331)]))&&document[_0x2e99ae(0x1a7)](_0x376812[_0x2e99ae(0x425)])[_0x2e99ae(0x2f3)][_0x2e99ae(0x367)](_0x376812['mjizW']),!isNaN(startAt)&&startAt>=0x0&&_0x376812['qORbG'](startAt,questionsData[_0x2e99ae(0x33e)])&&(_0x376812['GKQdT'](_0x376812[_0x2e99ae(0x28f)],_0x376812[_0x2e99ae(0x28f)])?(_0x5e7b21[_0x2e99ae(0x1a7)](_0x376812[_0x2e99ae(0x235)])[_0x2e99ae(0x3e0)]['display']=_0x376812['UDEQk'],_0x376812[_0x2e99ae(0x33c)](_0x1e7d21)):currentQuestionIndex=startAt),_0x376812[_0x2e99ae(0x33c)](loadBookmarkedQuestions),_0x376812[_0x2e99ae(0x3bc)](generateQuestionNav),_0x376812[_0x2e99ae(0x458)](updateStats),_0x376812[_0x2e99ae(0x33c)](displayQuestion);}function generateQuestionNav(){const _0x44b07f=_0xa90e1a,_0x19f215={'TLGyK':'questionNav','ugClU':function(_0x54cdd2,_0x560ad2){return _0x54cdd2<_0x560ad2;},'nJQap':_0x44b07f(0x275),'MbWqX':function(_0x193ed6,_0x37e74f){return _0x193ed6+_0x37e74f;},'Bibzq':_0x44b07f(0x2df),'XHVUx':function(_0x13e15e){return _0x13e15e();}},_0x52e371=document[_0x44b07f(0x1a7)](_0x19f215[_0x44b07f(0x2e6)]);_0x52e371[_0x44b07f(0x1c2)]='';for(let _0x409bc8=0x0;_0x19f215[_0x44b07f(0x259)](_0x409bc8,questionsData[_0x44b07f(0x33e)]);_0x409bc8++){const _0x3c6e35=document[_0x44b07f(0x2f8)](_0x19f215['nJQap']);_0x3c6e35[_0x44b07f(0x1cd)]=_0x19f215[_0x44b07f(0x42f)](_0x409bc8,0x1),_0x3c6e35[_0x44b07f(0x2bf)]=_0x19f215[_0x44b07f(0x20d)],_0x3c6e35['onclick']=()=>jumpToQuestion(_0x409bc8),_0x3c6e35['id']=_0x44b07f(0x409)+_0x409bc8,_0x52e371[_0x44b07f(0x1ff)](_0x3c6e35);}_0x19f215[_0x44b07f(0x38b)](updateQuestionNav);}function updateQuestionNav(){const _0x49262e=_0xa90e1a,_0x505a12={'xeIdr':function(_0x3d0686,_0x4ba84e){return _0x3d0686(_0x4ba84e);},'btMeT':_0x49262e(0x23f),'gcThA':function(_0x144bc7){return _0x144bc7();},'JnThn':_0x49262e(0x201),'nzQVG':_0x49262e(0x1db),'REaqy':_0x49262e(0x315),'McCfS':function(_0x4d695d){return _0x4d695d();},'tlXOZ':function(_0x1ac06c,_0x1745fe){return _0x1ac06c===_0x1745fe;},'yDYRh':_0x49262e(0x1ae),'uTNxV':'ltbZP','naqCQ':function(_0x596b46,_0x537f5e){return _0x596b46===_0x537f5e;},'eybGa':_0x49262e(0x1fc),'BWpQZ':function(_0xc1c074,_0x4dc275){return _0xc1c074!==_0x4dc275;},'TvCEY':'LsMiQ','dOtcA':_0x49262e(0x3d9),'UqYYY':'nav-btn-marked-review','iYwzX':_0x49262e(0x230),'PKDUo':function(_0x304599,_0x3e6c1a){return _0x304599===_0x3e6c1a;},'AyjMK':'timed_study','mIqyI':function(_0x4bf5b6,_0x4abf5c){return _0x4bf5b6===_0x4abf5c;},'DfEkk':'kDLKL','bcUOx':function(_0x28e6b8,_0x331e31){return _0x28e6b8===_0x331e31;},'MeJfy':_0x49262e(0x3e4),'LCqsw':function(_0x18831a,_0x58f6d9){return _0x18831a===_0x58f6d9;},'HvhEd':_0x49262e(0x310),'UglWR':function(_0x479ae8,_0x2af082){return _0x479ae8!==_0x2af082;},'GQrjw':_0x49262e(0x34b)};for(let _0x4bb12d=0x0;_0x4bb12d<questionsData[_0x49262e(0x33e)];_0x4bb12d++){if(_0x505a12['tlXOZ'](_0x505a12[_0x49262e(0x1d0)],_0x505a12['uTNxV']))_0x505a12['xeIdr'](_0x901bdc,_0x505a12[_0x49262e(0x28c)])&&_0x505a12[_0x49262e(0x249)](_0x230149);else{const _0x4c9faa=document[_0x49262e(0x1a7)](_0x49262e(0x409)+_0x4bb12d),_0x2acded=questionStates[_0x4bb12d];let _0x43fffd='';if(_0x505a12[_0x49262e(0x41e)](_0x4bb12d,currentQuestionIndex))_0x43fffd=_0x505a12[_0x49262e(0x43a)];else{if(_0x2acded[_0x49262e(0x3b7)])_0x43fffd=_0x49262e(0x408);else{if(_0x2acded[_0x49262e(0x32b)]){if(_0x505a12[_0x49262e(0x35d)](_0x505a12[_0x49262e(0x359)],_0x505a12[_0x49262e(0x316)]))_0x43fffd=_0x505a12[_0x49262e(0x438)];else{const _0x195c3d=_0x2fdf22[_0x49262e(0x36c)](_0x45e490[_0x49262e(0x38d)](_0x505a12[_0x49262e(0x1b1)]))||[];_0x195c3d['forEach'](_0x376c5=>{const _0x217401=_0x49262e;_0x376c5[_0x217401(0x1cc)][_0x217401(0x3fc)](_0x59fcd3['toLowerCase']()[_0x217401(0x1e0)](/ /g,'-'))&&(_0x376c5[_0x217401(0x335)]<_0x552217[_0x217401(0x33e)]&&(_0x4121bc[_0x376c5[_0x217401(0x335)]][_0x217401(0x3b7)]=!![]));});}}else{if(currentMode===_0x505a12['iYwzX']||_0x505a12[_0x49262e(0x3f0)](currentMode,_0x505a12[_0x49262e(0x311)])){if(_0x505a12[_0x49262e(0x33a)](_0x505a12[_0x49262e(0x2e9)],_0x49262e(0x304)))_0xb5db03=_0x505a12[_0x49262e(0x210)],_0x3584fc=_0x505a12[_0x49262e(0x3b3)];else{if(_0x505a12['bcUOx'](_0x2acded[_0x49262e(0x3ac)],_0x505a12['MeJfy']))_0x43fffd='nav-btn-correct';else{if(_0x505a12[_0x49262e(0x2ea)](_0x2acded[_0x49262e(0x3ac)],_0x505a12[_0x49262e(0x210)]))_0x43fffd=_0x505a12[_0x49262e(0x226)];else _0x43fffd=_0x49262e(0x34b);}}}else{if('vFCfj'==='ciQLG')_0x505a12[_0x49262e(0x386)](_0x51e02a);else{if(_0x505a12['UglWR'](_0x2acded[_0x49262e(0x32c)],null))_0x43fffd='nav-btn-answered';else _0x43fffd=_0x505a12[_0x49262e(0x276)];}}}}}_0x4c9faa[_0x49262e(0x2bf)]=_0x49262e(0x34d)+_0x43fffd;}}}function jumpToQuestion(_0x1654f1){const _0xbab074=_0xa90e1a,_0x3629a1={'DPqMf':_0xbab074(0x1be),'faluC':'5|2|0|3|1|4','AZuRh':'Progress\x20loaded.','EpiOK':function(_0x3522e6,_0x3c37ad){return _0x3522e6>=_0x3c37ad;},'oVdOK':function(_0xa90261,_0x4ade48){return _0xa90261===_0x4ade48;},'amPPw':_0xbab074(0x1ea),'BdGlh':function(_0x308d08){return _0x308d08();}};if(_0x3629a1[_0xbab074(0x41a)](_0x1654f1,0x0)&&_0x1654f1<questionsData['length']){if(questionStartTime){if(_0x3629a1['oVdOK'](_0x3629a1[_0xbab074(0x27b)],_0xbab074(0x42d))){const _0xbfefae=_0x2b5b18[_0xbab074(0x36c)](_0x182ac4['getItem'](_0x3629a1[_0xbab074(0x251)]))||{},_0x39b912=_0xbfefae[_0x55303d];if(_0x39b912){const _0xb19d8e=_0x3629a1[_0xbab074(0x3ed)]['split']('|');let _0x58f846=0x0;while(!![]){switch(_0xb19d8e[_0x58f846++]){case'0':_0x1d26aa=_0x39b912[_0xbab074(0x21d)];continue;case'1':_0x187839[_0xbab074(0x453)](_0x3629a1['AZuRh']);continue;case'2':_0x4ec072=_0x39b912[_0xbab074(0x30b)];continue;case'3':_0x1f356d=_0x39b912['currentMode'];continue;case'4':return!![];case'5':_0x4cbc38=_0x39b912[_0xbab074(0x2f4)];continue;}break;}}return![];}else questionStates[currentQuestionIndex][_0xbab074(0x381)]+=Date[_0xbab074(0x1c8)]()-questionStartTime;}currentQuestionIndex=_0x1654f1,displayQuestion(),_0x3629a1[_0xbab074(0x380)](saveProgress);}}function updateStats(){const _0x14ef07=_0xa90e1a,_0x3e796c={'Uhdub':function(_0x5b17b7,_0x33b7e1){return _0x5b17b7===_0x33b7e1;},'DSBuR':function(_0x2c77c2,_0x3b6d6e){return _0x2c77c2===_0x3b6d6e;},'teSbK':_0x14ef07(0x230),'hlRsR':function(_0x36fec9,_0x113c1a){return _0x36fec9===_0x113c1a;},'TywGG':_0x14ef07(0x31c),'zZnRx':function(_0x3bfae3,_0x343875){return _0x3bfae3!==_0x343875;},'OMedh':'sOuLC','yNJhU':'avsSd','WuRAG':'incorrectCount','MaRjU':'totalAttempted','YFJNy':function(_0x158d76,_0x1e2e9c){return _0x158d76*_0x1e2e9c;},'uojJq':'accuracy','cQCXf':function(_0xda49fb,_0x20a88b){return _0xda49fb+_0x20a88b;},'aZogk':function(_0x4f7bed,_0x55c44b){return _0x4f7bed/_0x55c44b;},'fjppL':function(_0xc859c9,_0xcd4bd1){return _0xc859c9%_0xcd4bd1;},'oJYce':_0x14ef07(0x381),'QwbMl':function(_0x502eb2,_0x3d1573){return _0x502eb2+_0x3d1573;}};if(_0x3e796c[_0x14ef07(0x3dd)](currentMode,_0x3e796c[_0x14ef07(0x264)])||_0x3e796c[_0x14ef07(0x342)](currentMode,_0x3e796c[_0x14ef07(0x397)])){if(_0x3e796c[_0x14ef07(0x363)](_0x3e796c[_0x14ef07(0x2c6)],_0x3e796c['yNJhU'])){document['getElementById'](_0x14ef07(0x2e5))[_0x14ef07(0x1cd)]=stats['correctAnswers'],document[_0x14ef07(0x1a7)](_0x3e796c[_0x14ef07(0x1e4)])['textContent']=stats[_0x14ef07(0x1ed)],document[_0x14ef07(0x1a7)](_0x3e796c[_0x14ef07(0x3b9)])['textContent']=stats[_0x14ef07(0x3aa)];const _0x2aa739=stats[_0x14ef07(0x3aa)]>0x0?Math[_0x14ef07(0x1c7)](_0x3e796c[_0x14ef07(0x23d)](stats[_0x14ef07(0x250)]/stats[_0x14ef07(0x3aa)],0x64)):0x0;document['getElementById'](_0x3e796c[_0x14ef07(0x349)])['textContent']=_0x3e796c[_0x14ef07(0x1b7)](_0x2aa739,'%'),stats['totalTime']=questionStates['reduce']((_0x472a75,_0x165a3b)=>_0x472a75+_0x165a3b['timeSpent'],0x0);const _0x27ebb1=Math[_0x14ef07(0x3a9)](stats[_0x14ef07(0x20f)]/0x3e8),_0x267ce8=Math[_0x14ef07(0x3a9)](_0x3e796c[_0x14ef07(0x403)](_0x27ebb1,0x3c)),_0x43ec72=_0x3e796c[_0x14ef07(0x3e9)](_0x27ebb1,0x3c);document['getElementById'](_0x3e796c['oJYce'])[_0x14ef07(0x1cd)]=_0x3e796c['cQCXf'](_0x3e796c[_0x14ef07(0x38f)](_0x267ce8,':'),_0x43ec72[_0x14ef07(0x25b)]()[_0x14ef07(0x457)](0x2,'0'));}else _0x37ff2b[_0x14ef07(0x2f3)][_0x14ef07(0x1e3)](_0x14ef07(0x2fa),_0x3e796c[_0x14ef07(0x1cb)](_0x172943,_0x4d307a));}}function setupVideo(_0x5d1693,_0x356776){const _0x1fcd19=_0xa90e1a,_0x141b2c={'brhTA':_0x1fcd19(0x3ef),'fCsKZ':_0x1fcd19(0x2fc),'YKjfY':function(_0x35a1c8,_0x1a3cd2){return _0x35a1c8+_0x1a3cd2;},'ZExUo':_0x1fcd19(0x1fd),'MDaiK':'totalQuestions','gqgqb':function(_0x3de0e1,_0x5eb777){return _0x3de0e1!==_0x5eb777;},'HDGuz':_0x1fcd19(0x269)};if(Hls[_0x1fcd19(0x248)]()){const _0x5b2c80=new Hls();_0x5b2c80[_0x1fcd19(0x3d7)](_0x356776),_0x5b2c80[_0x1fcd19(0x2ef)](_0x5d1693);}else{if(_0x5d1693[_0x1fcd19(0x413)]('application/vnd.apple.mpegurl')){if(_0x141b2c[_0x1fcd19(0x24c)](_0x141b2c[_0x1fcd19(0x23b)],_0x141b2c[_0x1fcd19(0x23b)])){const _0x3371ee=_0x1b6661[_0x1fcd19(0x36c)](_0x4a120f[_0x1fcd19(0x38d)](_0x141b2c[_0x1fcd19(0x2e4)]));if(_0x3371ee){const _0x2890a9=_0x141b2c[_0x1fcd19(0x24f)][_0x1fcd19(0x432)]('|');let _0x4c7122=0x0;while(!![]){switch(_0x2890a9[_0x4c7122++]){case'0':_0x902cbf[_0x1fcd19(0x3b0)]=_0x141b2c['YKjfY'](_0x40ba91,_0x1fcd19(0x1e5));continue;case'1':_0x48bcc3=_0x3371ee[_0x1fcd19(0x34c)];continue;case'2':_0xbe59bd=_0x3371ee[_0x1fcd19(0x2f2)];continue;case'3':_0x4ddf8c['getElementById'](_0x141b2c[_0x1fcd19(0x2e0)])[_0x1fcd19(0x1cd)]=_0x3eaf8d[_0x1fcd19(0x355)](_0x1fcd19(0x26a));continue;case'4':_0x2bd5b4[_0x1fcd19(0x1a7)](_0x141b2c[_0x1fcd19(0x1e1)])[_0x1fcd19(0x1cd)]=_0x37737a['length'];continue;case'5':_0x2c3d28=_0x3371ee['questions'];continue;}break;}}}else _0x5d1693[_0x1fcd19(0x431)]=_0x356776;}}}function displayQuestion(){const _0x5052bd=_0xa90e1a,_0x16f576={'MwPzx':_0x5052bd(0x2b9),'gtSof':_0x5052bd(0x1c9),'nzZoM':_0x5052bd(0x372),'myGzS':'xdpJJ','XWcpc':function(_0x74b4c0,_0x5d1ba4){return _0x74b4c0+_0x5d1ba4;},'RAfRL':function(_0x290cfa,_0x53e22e){return _0x290cfa===_0x53e22e;},'tkCpL':'div','erudQ':'selected','kmClu':_0x5052bd(0x279),'MtWse':function(_0x1fb836,_0x30104c){return _0x1fb836+_0x30104c;},'iWtVC':_0x5052bd(0x24a),'RkGAo':_0x5052bd(0x1d8),'qpQMo':_0x5052bd(0x362),'zvnvd':function(_0x1fa619,_0x4a33b8){return _0x1fa619(_0x4a33b8);},'bGsvm':function(_0x5191a1,_0x364eb9){return _0x5191a1===_0x364eb9;},'tJbFq':_0x5052bd(0x1af),'RjEcS':_0x5052bd(0x3ea),'MMEne':function(_0x566fc8,_0x3c09f4){return _0x566fc8*_0x3c09f4;},'UWsBU':function(_0x411d3b,_0x9a1998){return _0x411d3b/_0x9a1998;},'OPrty':function(_0x157b25,_0x454c38){return _0x157b25+_0x454c38;},'KkAiG':_0x5052bd(0x37a),'eTIqT':_0x5052bd(0x31b),'GdjaJ':function(_0x5ab3b4){return _0x5ab3b4();},'UflZW':_0x5052bd(0x35f),'Wvijt':function(_0x4da2ce,_0x424d7b){return _0x4da2ce===_0x424d7b;},'dmwbm':_0x5052bd(0x229),'qHENG':'No\x20question\x20text\x20available','SqmVO':_0x5052bd(0x2a6),'LCQIv':'answered','TGTQw':_0x5052bd(0x2ad),'VuvJd':function(_0x3dd4dd,_0x4e6759){return _0x3dd4dd===_0x4e6759;},'UJAyK':'timed_study','zroEY':function(_0xec6f62,_0x25dcb7){return _0xec6f62===_0x25dcb7;},'EOOQi':_0x5052bd(0x43f)};if(!questionsData||_0x16f576[_0x5052bd(0x237)](questionsData[_0x5052bd(0x33e)],0x0)){document[_0x5052bd(0x1a7)](_0x16f576[_0x5052bd(0x1d4)])[_0x5052bd(0x1c2)]=_0x16f576[_0x5052bd(0x42c)];return;};const _0x3c964e=questionsData[currentQuestionIndex];questionStartTime=Date[_0x5052bd(0x1c8)](),selectedOption=questionStates[currentQuestionIndex][_0x5052bd(0x32c)];const _0x22b8bd=_0x16f576[_0x5052bd(0x40a)](_0x16f576['UWsBU'](_0x16f576['OPrty'](currentQuestionIndex,0x1),questionsData['length']),0x64);document[_0x5052bd(0x1a7)](_0x16f576[_0x5052bd(0x288)])[_0x5052bd(0x3e0)]['width']=_0x22b8bd+'%',document['getElementById'](_0x16f576['eTIqT'])[_0x5052bd(0x1cd)]=_0x16f576[_0x5052bd(0x3a1)](currentQuestionIndex,0x1),_0x16f576[_0x5052bd(0x1f7)](updateQuestionNav),document[_0x5052bd(0x1a7)](_0x16f576[_0x5052bd(0x2e7)])[_0x5052bd(0x3c9)]=_0x16f576[_0x5052bd(0x40f)](currentQuestionIndex,0x0),document[_0x5052bd(0x1a7)](_0x16f576['dmwbm'])[_0x5052bd(0x2f3)]['add'](_0x16f576[_0x5052bd(0x25d)]),document[_0x5052bd(0x1a7)](_0x16f576[_0x5052bd(0x1d4)])[_0x5052bd(0x1c2)]=_0x3c964e['text']||_0x16f576['qHENG'];let _0x14ea1f='';if(_0x3c964e[_0x5052bd(0x3eb)])_0x14ea1f+='<div\x20class=\x22glass-light\x20p-4\x20mb-4\x22><audio\x20src=\x22'+_0x3c964e[_0x5052bd(0x3eb)]+_0x5052bd(0x3af);if(_0x3c964e['question_video'])_0x14ea1f+=_0x5052bd(0x206)+_0x3c964e[_0x5052bd(0x44e)]+'\x22\x20controls\x20class=\x22w-full\x20rounded-lg\x22></video></div>';_0x3c964e['question_images']&&_0x3c964e['question_images'][_0x5052bd(0x43d)](_0xbe30a5=>{const _0x8541f1=_0x5052bd;if(_0x16f576[_0x8541f1(0x215)]!==_0x16f576['myGzS']){if(_0xbe30a5)_0x14ea1f+=_0x8541f1(0x1c1)+_0xbe30a5+'\x22\x20alt=\x22Question\x20Image\x22\x20class=\x22w-full\x20rounded-lg\x22></div>';}else _0x30526a[_0x8541f1(0x1a7)](_0x16f576[_0x8541f1(0x350)])[_0x8541f1(0x2f3)][_0x8541f1(0x367)](_0x16f576['gtSof']);});document[_0x5052bd(0x1a7)](_0x5052bd(0x3d3))[_0x5052bd(0x1c2)]=_0x14ea1f;const _0x39e609=document['getElementById'](_0x16f576['SqmVO']);_0x39e609['innerHTML']='',_0x39e609[_0x5052bd(0x2f3)][_0x5052bd(0x367)](_0x16f576[_0x5052bd(0x34e)]),_0x3c964e[_0x5052bd(0x420)]&&Array[_0x5052bd(0x29e)](_0x3c964e[_0x5052bd(0x420)])&&(_0x3c964e['choices'][_0x5052bd(0x43d)]((_0x12b132,_0x5cb518)=>{const _0x200a78=_0x5052bd,_0x577ec0=String[_0x200a78(0x371)](_0x16f576['XWcpc'](0x41,_0x5cb518)),_0x582b93=_0x16f576[_0x200a78(0x212)](selectedOption,_0x5cb518),_0x23eb59=document[_0x200a78(0x2f8)](_0x16f576[_0x200a78(0x39f)]);_0x23eb59[_0x200a78(0x1c2)]=_0x200a78(0x441)+(_0x582b93?_0x16f576[_0x200a78(0x36d)]:'')+_0x200a78(0x2d0)+_0x5cb518+_0x200a78(0x203)+_0x577ec0+_0x200a78(0x1d7)+(_0x12b132[_0x200a78(0x30f)]||_0x16f576[_0x200a78(0x3a1)](_0x16f576[_0x200a78(0x3f9)],_0x16f576['MtWse'](_0x5cb518,0x1)))+_0x200a78(0x3b6),_0x39e609['appendChild'](_0x23eb59);}),_0x39e609[_0x5052bd(0x3b5)](_0x16f576[_0x5052bd(0x43e)],function(_0x1b06ad){const _0x136663=_0x5052bd;if(_0x16f576[_0x136663(0x267)]!==_0x136663(0x395)){const _0x474dcf=_0x1b06ad[_0x136663(0x3fb)]['closest'](_0x16f576[_0x136663(0x2dc)]);if(_0x474dcf){const _0x41cef3=parseInt(_0x474dcf[_0x136663(0x1c5)](_0x16f576[_0x136663(0x1fb)]));_0x16f576['zvnvd'](selectOption,_0x41cef3);}}else{const _0x2895b3=_0x540651['constructor']['prototype'][_0x136663(0x41d)](_0x4d9d1d),_0x1213eb=_0x226927[_0x344e3f],_0x20b486=_0x39c4dc[_0x1213eb]||_0x2895b3;_0x2895b3[_0x136663(0x231)]=_0x55aac7['bind'](_0xd14b06),_0x2895b3[_0x136663(0x25b)]=_0x20b486[_0x136663(0x25b)][_0x136663(0x41d)](_0x20b486),_0x54315c[_0x1213eb]=_0x2895b3;}})),_0x16f576[_0x5052bd(0x1f7)](updateBookmarkButton),_0x16f576[_0x5052bd(0x1f7)](updateMarkReviewButton),(_0x16f576[_0x5052bd(0x339)](currentMode,_0x16f576[_0x5052bd(0x260)])||_0x16f576[_0x5052bd(0x38e)](currentMode,_0x16f576['EOOQi']))&&!isQuizCompleted&&startTimer();}function selectOption(_0x38e0ad){const _0x30f0af=_0xa90e1a,_0x1eceb7={'BlMbG':function(_0x3f3ca1,_0x431358){return _0x3f3ca1===_0x431358;},'Aiftu':_0x30f0af(0x3b8),'BIKmU':_0x30f0af(0x2fa),'dRkec':function(_0x24c1c3,_0x12ff7c){return _0x24c1c3-_0x12ff7c;},'TDtrV':_0x30f0af(0x2a6),'BynXh':'answered','TZjJt':_0x30f0af(0x1d8),'lDGMJ':function(_0x108365,_0xd7f603){return _0x108365===_0xd7f603;},'LKGBO':_0x30f0af(0x230),'XZCPJ':function(_0x57e556,_0x128e5a){return _0x57e556===_0x128e5a;},'mqQKx':'timed_study','dxQSi':function(_0x228805){return _0x228805();},'wXOid':'not_attempted','RhBBC':function(_0x2ccc55){return _0x2ccc55();}},_0x2718a1=document['getElementById'](_0x1eceb7['TDtrV']);if(_0x2718a1[_0x30f0af(0x2f3)][_0x30f0af(0x347)](_0x1eceb7[_0x30f0af(0x1b4)]))return;questionStartTime&&(questionStates[currentQuestionIndex][_0x30f0af(0x381)]+=_0x1eceb7[_0x30f0af(0x41c)](Date[_0x30f0af(0x1c8)](),questionStartTime),questionStartTime=Date[_0x30f0af(0x1c8)]()),selectedOption=_0x38e0ad,questionStates[currentQuestionIndex][_0x30f0af(0x32c)]=_0x38e0ad,document[_0x30f0af(0x29c)](_0x1eceb7[_0x30f0af(0x437)])['forEach']((_0x2c669a,_0x324748)=>{const _0x1a6328=_0x30f0af;_0x1eceb7[_0x1a6328(0x297)](_0x1a6328(0x3b8),_0x1eceb7[_0x1a6328(0x451)])?_0x2c669a[_0x1a6328(0x2f3)][_0x1a6328(0x1e3)](_0x1eceb7[_0x1a6328(0x273)],_0x1eceb7['BlMbG'](_0x324748,_0x38e0ad)):_0x4bfd71[_0x86fddb[_0x1a6328(0x335)]][_0x1a6328(0x3b7)]=!![];}),_0x1eceb7[_0x30f0af(0x2e1)](currentMode,_0x1eceb7[_0x30f0af(0x2b1)])||_0x1eceb7[_0x30f0af(0x1fe)](currentMode,_0x1eceb7['mqQKx'])?_0x1eceb7['lDGMJ'](_0x30f0af(0x3f5),_0x30f0af(0x3f5))?_0x1eceb7[_0x30f0af(0x373)](processAnswer):_0x23aff4[_0x39b93c][_0x30f0af(0x381)]+=_0x1eceb7[_0x30f0af(0x41c)](_0x4b47d0[_0x30f0af(0x1c8)](),_0x4e6baa):(_0x1eceb7[_0x30f0af(0x1fe)](questionStates[currentQuestionIndex][_0x30f0af(0x3ac)],_0x1eceb7[_0x30f0af(0x306)])&&(questionStates[currentQuestionIndex][_0x30f0af(0x3ac)]=_0x1eceb7[_0x30f0af(0x1b4)],stats[_0x30f0af(0x3aa)]++,stats[_0x30f0af(0x3c2)]--),updateQuestionNav()),_0x1eceb7['RhBBC'](saveProgress);}function processAnswer(){const _0x366c07=_0xa90e1a,_0x23efbf={'cwBBO':function(_0x4ea355,_0x112b88){return _0x4ea355===_0x112b88;},'jKvWN':function(_0x45eb85,_0x7527be){return _0x45eb85===_0x7527be;},'KgtNh':_0x366c07(0x446),'bMYlq':_0x366c07(0x3e4),'pLJxH':_0x366c07(0x1db),'FNXpr':function(_0x118055){return _0x118055();},'ZdjJT':function(_0x3ad75a,_0x495c97){return _0x3ad75a(_0x495c97);}},_0x3f5201=questionsData[currentQuestionIndex],_0x1888e0=_0x3f5201[_0x366c07(0x27a)];if(_0x23efbf[_0x366c07(0x3bd)](selectedOption,null))return;const _0x5e4a1d=_0x3f5201['choices'][selectedOption],_0x56beda=_0x23efbf[_0x366c07(0x35b)](_0x5e4a1d['id'],_0x1888e0);if(_0x23efbf[_0x366c07(0x3bd)](questionStates[currentQuestionIndex][_0x366c07(0x3ac)],_0x23efbf[_0x366c07(0x2b5)])){stats[_0x366c07(0x3aa)]++,stats[_0x366c07(0x3c2)]--;if(_0x56beda)stats[_0x366c07(0x250)]++;else stats[_0x366c07(0x1ed)]++;}questionStates[currentQuestionIndex][_0x366c07(0x3ac)]=_0x56beda?_0x23efbf[_0x366c07(0x1b0)]:_0x23efbf[_0x366c07(0x261)],_0x23efbf[_0x366c07(0x340)](updateStats),_0x23efbf[_0x366c07(0x448)](showInlineFeedback,_0x56beda),_0x23efbf[_0x366c07(0x340)](updateQuestionNav);}function showInlineFeedback(_0x2f9a3d){const _0x3c80cd=_0xa90e1a,_0xb0a2ff={'WGnap':_0x3c80cd(0x43c),'JeoAB':function(_0x30f01c,_0x3ad215){return _0x30f01c===_0x3ad215;},'xNeWP':'ZxDKS','Cedon':'epUES','MrRwD':_0x3c80cd(0x2fa),'NeTrN':function(_0x1f4d64,_0x599bf6){return _0x1f4d64===_0x599bf6;},'nFjkd':'correct','svtBI':function(_0x39b2df,_0x46fa1a){return _0x39b2df===_0x46fa1a;},'JsVxM':function(_0x2e8fe5,_0x5800a0){return _0x2e8fe5!==_0x5800a0;},'FIEUy':_0x3c80cd(0x31c),'Akoqg':'optionsContainer','EpWWR':_0x3c80cd(0x1d8),'bTRTg':_0x3c80cd(0x1a4),'wzgRP':function(_0x4ca622){return _0x4ca622();}};if(_0xb0a2ff['JsVxM'](currentMode,'study')&&_0xb0a2ff[_0x3c80cd(0x3cc)](currentMode,_0xb0a2ff[_0x3c80cd(0x2a7)]))return;const _0x147d8d=document[_0x3c80cd(0x1a7)](_0xb0a2ff['Akoqg']),_0x19a8cd=_0x147d8d[_0x3c80cd(0x29c)](_0xb0a2ff[_0x3c80cd(0x39b)]),_0x562afb=questionsData[currentQuestionIndex],_0x481e25=_0x562afb[_0x3c80cd(0x27a)];let _0x55381a=_0x562afb[_0x3c80cd(0x420)][_0x3c80cd(0x439)](_0x4fa48e=>_0x4fa48e['id']===_0x481e25);_0x147d8d[_0x3c80cd(0x2f3)][_0x3c80cd(0x253)](_0xb0a2ff[_0x3c80cd(0x31f)]),_0x19a8cd[_0x3c80cd(0x43d)]((_0x4b2eed,_0x4692fe)=>{const _0x55429e=_0x3c80cd;if(_0xb0a2ff[_0x55429e(0x333)](_0xb0a2ff[_0x55429e(0x3b2)],_0xb0a2ff[_0x55429e(0x2d1)]))return _0x6e1e2c['toString']()[_0x55429e(0x389)](KGwXJs['WGnap'])[_0x55429e(0x25b)]()[_0x55429e(0x42e)](_0x1f978d)['search'](KGwXJs[_0x55429e(0x3ab)]);else{_0x4b2eed[_0x55429e(0x2f3)][_0x55429e(0x367)](_0xb0a2ff[_0x55429e(0x202)]);if(_0xb0a2ff[_0x55429e(0x1d1)](_0x4692fe,_0x55381a))_0x4b2eed[_0x55429e(0x2f3)]['add'](_0xb0a2ff[_0x55429e(0x434)]);else{if(_0xb0a2ff[_0x55429e(0x25a)](_0x4692fe,selectedOption)&&!_0x2f9a3d)_0x4b2eed[_0x55429e(0x2f3)]['add'](_0x55429e(0x1db));}}}),_0xb0a2ff[_0x3c80cd(0x39a)](showSolution);}function showSolution(){const _0x970970=_0xa90e1a,_0x328167={'PGyzE':_0x970970(0x3a0),'VtLXd':function(_0x3be33e,_0x281e6b){return _0x3be33e===_0x281e6b;},'kMvmN':function(_0x3d3508,_0x4c7b00){return _0x3d3508===_0x4c7b00;},'bqHGv':'correct','BbLFs':_0x970970(0x1db),'NMYRp':function(_0x46beb5){return _0x46beb5();},'auZMk':function(_0x1695c9,_0x8f150e){return _0x1695c9(_0x8f150e);},'fYSZF':function(_0x2ac941,_0x3e48d9){return _0x2ac941!==_0x3e48d9;},'TiqVF':_0x970970(0x230),'iWYlM':_0x970970(0x31c),'FkxzH':_0x970970(0x3a2),'kbYhU':_0x970970(0x322),'CXQwo':'solutionVideo','NtCkR':_0x970970(0x430),'jErJt':function(_0x502859,_0x43ada9){return _0x502859!==_0x43ada9;},'AHEJp':_0x970970(0x280),'JxHmH':_0x970970(0x208),'tIuee':'hidden','SuRKq':_0x970970(0x2de),'rWwtg':function(_0x1ee08b,_0x4fc5c8,_0x3f5637){return _0x1ee08b(_0x4fc5c8,_0x3f5637);},'gQlhZ':_0x970970(0x428),'fphcy':_0x970970(0x216),'zxxSa':_0x970970(0x323),'BfVpX':'solutionContainer'};if(_0x328167[_0x970970(0x218)](currentMode,_0x328167['TiqVF'])&&_0x328167[_0x970970(0x218)](currentMode,_0x328167[_0x970970(0x1a5)]))return;const _0x50fe5f=questionsData[currentQuestionIndex];document[_0x970970(0x1a7)](_0x328167['FkxzH'])[_0x970970(0x1c2)]=_0x50fe5f[_0x970970(0x307)]||_0x328167[_0x970970(0x44f)];const _0x283e2a=document[_0x970970(0x1a7)](_0x328167['CXQwo']),_0x56c644=document[_0x970970(0x1a7)](_0x328167[_0x970970(0x443)]),_0x428282=_0x50fe5f[_0x970970(0x384)];if(_0x428282){if(_0x328167[_0x970970(0x411)](_0x328167[_0x970970(0x37e)],_0x328167[_0x970970(0x2b4)])){_0x283e2a[_0x970970(0x2f3)][_0x970970(0x367)](_0x328167['tIuee']);if(_0x428282['includes'](_0x328167[_0x970970(0x36f)]))_0x328167[_0x970970(0x2cd)](setupVideo,_0x56c644,_0x428282);else _0x56c644[_0x970970(0x431)]=_0x428282;}else{const _0x3ad0a0={'WkTho':function(_0x5780cc,_0x3900dd,_0x44c702){return _0x5780cc(_0x3900dd,_0x44c702);}};_0x178910[_0x970970(0x29c)](_0x328167[_0x970970(0x31e)])[_0x970970(0x43d)](_0x45a527=>{const _0x47824f=_0x970970,_0x429ca4=_0x45a527[_0x47824f(0x324)][_0x47824f(0x431)];if(_0x429ca4&&_0x429ca4[_0x47824f(0x3fc)](_0x47824f(0x2de)))_0x3ad0a0[_0x47824f(0x1bd)](_0x4a413c,_0x45a527,_0x429ca4);else _0x429ca4&&(_0x45a527[_0x47824f(0x431)]=_0x429ca4);});}}else{if(_0x970970(0x414)===_0x328167[_0x970970(0x300)]){const _0x4a2d87=_0x2ce94a[_0x59fd81],_0x906dc6=_0x4a2d87['correct_choice_id'];if(_0x328167[_0x970970(0x39d)](_0x48c002,null))return;const _0x2f5f77=_0x4a2d87[_0x970970(0x420)][_0x5724ae],_0x36b8bd=_0x328167[_0x970970(0x2b3)](_0x2f5f77['id'],_0x906dc6);if(_0x328167[_0x970970(0x39d)](_0x2b6dba[_0x216199]['status'],_0x970970(0x446))){_0x4f4d62[_0x970970(0x3aa)]++,_0x124e18[_0x970970(0x3c2)]--;if(_0x36b8bd)_0x2df8ac['correctAnswers']++;else _0x412e69['incorrectAnswers']++;}_0x14696c[_0x4459f8][_0x970970(0x3ac)]=_0x36b8bd?_0x328167[_0x970970(0x33f)]:_0x328167[_0x970970(0x1b8)],_0x328167[_0x970970(0x3c3)](_0x39a51c),_0x328167[_0x970970(0x27d)](_0x3e8096,_0x36b8bd),_0x4b1042();}else _0x283e2a[_0x970970(0x2f3)][_0x970970(0x253)](_0x328167[_0x970970(0x2e8)]);}const _0x206861=document[_0x970970(0x1a7)](_0x328167[_0x970970(0x2f9)]);_0x206861[_0x970970(0x1c2)]='';_0x50fe5f[_0x970970(0x2b7)]&&(_0x206861[_0x970970(0x1c2)]+=_0x970970(0x214)+_0x50fe5f['explanation_audio_eng']+_0x970970(0x3af));_0x50fe5f[_0x970970(0x444)]&&(_0x206861[_0x970970(0x1c2)]+=_0x970970(0x25e)+_0x50fe5f['explanation_audio_hin']+_0x970970(0x3af));const _0x3322f5=document[_0x970970(0x1a7)](_0x328167[_0x970970(0x20c)]);_0x3322f5['innerHTML']='',_0x50fe5f[_0x970970(0x2ba)]&&_0x50fe5f[_0x970970(0x2ba)]['forEach'](_0x3e0655=>{const _0x1b87c2=_0x970970;if(_0x3e0655)_0x3322f5[_0x1b87c2(0x1c2)]+=_0x1b87c2(0x30d)+_0x3e0655+_0x1b87c2(0x2d4);}),document[_0x970970(0x1a7)](_0x328167[_0x970970(0x2ee)])[_0x970970(0x2f3)][_0x970970(0x367)](_0x328167[_0x970970(0x2e8)]);}function submitQuiz(){const _0x4b2535=_0xa90e1a,_0x236687={'EKkDY':function(_0x501510,_0x76122b){return _0x501510!==_0x76122b;},'cVwYB':function(_0x3fc37a,_0xbb4833){return _0x3fc37a===_0xbb4833;},'TcXVD':_0x4b2535(0x3e4),'czQRA':_0x4b2535(0x1db),'scRTo':function(_0x9871d6,_0x2ad2fe){return _0x9871d6(_0x2ad2fe);},'IcRwJ':_0x4b2535(0x243),'Madgf':function(_0x25017b,_0x160917){return _0x25017b-_0x160917;},'qEnhX':function(_0x3457c8,_0x4fcd8c){return _0x3457c8+_0x4fcd8c;},'Jbcko':function(_0x4017e0,_0x4db671,_0x154720,_0x31b76f,_0x5add09){return _0x4017e0(_0x4db671,_0x154720,_0x31b76f,_0x5add09);}};if(timer)_0x236687[_0x4b2535(0x21c)](clearInterval,timer);if(!_0x236687[_0x4b2535(0x21c)](confirm,_0x236687[_0x4b2535(0x2d3)]))return;isQuizCompleted=!![];let _0x1fa041=0x0,_0x9e19ea=0x0;const _0x2af38e=_0x236687['Madgf'](Date[_0x4b2535(0x1c8)](),quizStartTime);questionsData['forEach']((_0x4149f1,_0x917839)=>{const _0x24eb04=_0x4b2535,_0x460d35=questionStates[_0x917839];_0x236687[_0x24eb04(0x412)](_0x460d35[_0x24eb04(0x32c)],null)&&(_0x236687[_0x24eb04(0x3c1)](_0x4149f1[_0x24eb04(0x420)][_0x460d35[_0x24eb04(0x32c)]]['id'],_0x4149f1['correct_choice_id'])?(_0x1fa041++,_0x460d35['status']=_0x236687[_0x24eb04(0x272)]):(_0x9e19ea++,_0x460d35[_0x24eb04(0x3ac)]=_0x236687['czQRA']));});const _0x36bbe7=JSON['parse'](localStorage[_0x4b2535(0x38d)]('quizPerformanceData'))||[];_0x36bbe7[_0x4b2535(0x1f9)]({'quizName':quizName,'hierarchy':hierarchy,'timestamp':Date[_0x4b2535(0x1c8)](),'totalTime':_0x2af38e,'stats':{'correct':_0x1fa041,'incorrect':_0x9e19ea,'notAttempted':questionsData[_0x4b2535(0x33e)]-_0x236687[_0x4b2535(0x221)](_0x1fa041,_0x9e19ea)}}),localStorage['setItem'](_0x4b2535(0x1da),JSON[_0x4b2535(0x317)](_0x36bbe7)),stats[_0x4b2535(0x250)]=_0x1fa041,stats[_0x4b2535(0x1ed)]=_0x9e19ea,markQuizAsCompleted(),_0x236687['Jbcko'](showPerformanceAnalysis,_0x1fa041,_0x9e19ea,_0x236687[_0x4b2535(0x2aa)](questionsData['length'],_0x236687[_0x4b2535(0x221)](_0x1fa041,_0x9e19ea)),_0x2af38e);}function showPerformanceAnalysis(_0x36c88e,_0x44dac7,_0x37c91a,_0x1fb7a7){const _0xf99fe2=_0xa90e1a,_0x2dd6a1={'jlNxr':_0xf99fe2(0x33d),'CBfWE':function(_0x5e4f16,_0x5275ee){return _0x5e4f16>_0x5275ee;},'MSRVR':function(_0x12b510,_0x4dab3a){return _0x12b510+_0x4dab3a;},'TyPes':function(_0x14630f,_0x168f1f){return _0x14630f*_0x168f1f;},'dLYZi':function(_0x3c92a9,_0x32083a){return _0x3c92a9+_0x32083a;},'HkoPl':'scoreCircle','COTHx':function(_0x5443cf,_0x182954){return _0x5443cf-_0x182954;},'BAnjX':function(_0x598454,_0x18ea44){return _0x598454/_0x18ea44;},'vqsSC':'totalQuestionsResult','KszNN':_0xf99fe2(0x3f7),'irbvq':_0xf99fe2(0x423),'lGVNN':_0xf99fe2(0x332),'yVLLj':function(_0x12d0ea,_0x2c07bc){return _0x12d0ea/_0x2c07bc;},'SRdro':_0xf99fe2(0x224)},_0x343ae8=document[_0xf99fe2(0x1a7)](_0x2dd6a1[_0xf99fe2(0x383)]),_0x4bfa1a=_0x2dd6a1[_0xf99fe2(0x3fd)](_0x2dd6a1[_0xf99fe2(0x330)](_0x36c88e,_0x44dac7),0x0)?Math[_0xf99fe2(0x1c7)](_0x2dd6a1['TyPes'](_0x36c88e/_0x2dd6a1[_0xf99fe2(0x326)](_0x36c88e,_0x44dac7),0x64)):0x0,_0x4cd06c=_0x2dd6a1[_0xf99fe2(0x268)](_0x2dd6a1[_0xf99fe2(0x268)](0x2,Math['PI']),0x41),_0x35d3f9=document[_0xf99fe2(0x1a7)](_0x2dd6a1[_0xf99fe2(0x341)]);_0x35d3f9[_0xf99fe2(0x3e0)][_0xf99fe2(0x271)]=_0x4cd06c+'\x20'+_0x4cd06c,_0x35d3f9[_0xf99fe2(0x3e0)]['strokeDashoffset']=_0x2dd6a1[_0xf99fe2(0x38c)](_0x4cd06c,_0x2dd6a1[_0xf99fe2(0x2a0)](_0x4bfa1a,0x64)*_0x4cd06c),document['getElementById'](_0xf99fe2(0x44c))[_0xf99fe2(0x1cd)]=_0x4bfa1a+'%',document[_0xf99fe2(0x1a7)](_0x2dd6a1[_0xf99fe2(0x265)])[_0xf99fe2(0x1cd)]=questionsData[_0xf99fe2(0x33e)],document[_0xf99fe2(0x1a7)]('correctResult')[_0xf99fe2(0x1cd)]=_0x36c88e,document['getElementById'](_0x2dd6a1[_0xf99fe2(0x3d0)])[_0xf99fe2(0x1cd)]=_0x44dac7,document[_0xf99fe2(0x1a7)](_0x2dd6a1['irbvq'])[_0xf99fe2(0x1cd)]=_0x37c91a;const _0x5a8946=Math[_0xf99fe2(0x3a9)](_0x2dd6a1['BAnjX'](_0x1fb7a7,0xea60)),_0x1f5991=Math[_0xf99fe2(0x3a9)](_0x1fb7a7%0xea60/0x3e8);document[_0xf99fe2(0x1a7)](_0x2dd6a1[_0xf99fe2(0x365)])[_0xf99fe2(0x1cd)]=_0x5a8946+':'+_0x1f5991[_0xf99fe2(0x25b)]()[_0xf99fe2(0x457)](0x2,'0');const _0x14a9a1=_0x2dd6a1[_0xf99fe2(0x258)](_0x1fb7a7,questionsData[_0xf99fe2(0x33e)]),_0x5e6fdd=Math[_0xf99fe2(0x3a9)](_0x14a9a1/0xea60),_0x5c897b=Math[_0xf99fe2(0x3a9)](_0x14a9a1%0xea60/0x3e8);document[_0xf99fe2(0x1a7)](_0x2dd6a1[_0xf99fe2(0x263)])[_0xf99fe2(0x1cd)]=_0x5e6fdd+':'+_0x5c897b['toString']()[_0xf99fe2(0x457)](0x2,'0'),_0x343ae8[_0xf99fe2(0x2f3)][_0xf99fe2(0x367)](_0xf99fe2(0x1c9));}function closePerformanceModal(){const _0x362b18=_0xa90e1a,_0x2d8b71={'arxke':'hidden'};document[_0x362b18(0x1a7)]('performanceModal')['classList']['add'](_0x2d8b71[_0x362b18(0x313)]);}function _0x1ffe(){const _0x229f6e=['prevBtn','OQHpP','reload','data-option-index','zZnRx','red','lGVNN','\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20</div>','remove','resume','table','Which\x20of\x20the\x20following\x20drugs\x20used\x20in\x20the\x20treatment\x20of\x20diabetes\x20is\x20known\x20to\x20cause\x20urinary\x20tract\x20infections?','paGIe','parse','erudQ','tIdSg','SuRKq','fQfMl','fromCharCode','UENWk','dxQSi','rIijS','a-i,\x20b-ii,\x20c-iii,\x20d-iv','wuPDg','eJLEx','Lithium','a-ii,\x20b-iii,\x20c-i,\x20d-iv','progressBar','Obstructive\x20sleep\x20apnea','<p>Acute\x20oral\x20overdose\x20results\x20primarily\x20in\x20<strong>cerebellar</strong>\x20and\x20<strong>vestibular</strong>\x20symptoms\x20and\x20high\x20doses\x20have\x20been\x20associated\x20with\x20marked\x20<strong>cerebellar\x20atrophy.</strong></p>\x0a<p>Dose-related\x20toxicity\x20of\x20phenytoin\x20causes\x20ataxia,\x20vertigo,\x20diplopia,\x20and\x20nystagmus.</p>\x0a<p>Other\x20options:</p>\x0a<p>Option\x20B:\x20High\x20dose\x20causes\x20<strong>cardiotoxicity</strong>\x20in\x20both\x20old\x20and\x20young,\x20healthy\x20patients.\x20However,\x20cardiotoxicity\x20is\x20more\x20pronounced\x20and\x20frequent\x20in\x20older\x20patients\x20and\x20those\x20with\x20known\x20cardiac\x20diseases.</p>\x0a<p>Option\x20C:\x20These\x20complications\x20can\x20be\x20minimised\x20by\x20administering\x20<strong>fosphenytoin</strong>\x20at\x20a\x20rate\x20of\x20<strong>less\x20than\x20150\x20mg</strong>\x20of\x20phenytoin\x20sodium\x20equivalents\x20per\x20minute,\x20not\x20250\x20mg.</p>\x0a<p>Option\x20D:\x20Phenytoin\x20is\x20not\x20effective\x20in\x20generalised\x20absent\x20seizures.</p>','059\x20Pharmacology\x20Ini-Cet\x202024','AHEJp','LKMBY','BdGlh','timeSpent','WyBpX','jlNxr','explanation_video','aENFN','McCfS','NoVWj','custom_quiz.html','search','test','XHVUx','COTHx','getItem','zroEY','QwbMl','Fosamprenavir','Metformin','Which\x20of\x20the\x20following\x20antidiabetic\x20drugs\x20is\x20known\x20to\x20cause\x20unexplained\x20diarrhea?','ioOlD','HINNj','vaUOy','nXzZQ','TywGG','eeCfM','xTZtM','wzgRP','EpWWR','HPEWZ','VtLXd','RdXfX','tkCpL','video[data-src]','XWcpc','solutionText','VNWui','a-iv,\x20b-ii,\x20c-iii,\x20d-i','yLHiK','Sitagliptin','2368431JbUgrf','Djbbf','floor','totalAttempted','WGnap','status','review-question\x20','vkMTg','\x22\x20controls\x20class=\x22w-full\x22></audio></div>','title','quizSidebar','xNeWP','REaqy','Pramipexole','addEventListener','</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20</button>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20','bookmarked','Kvoiz','MaRjU','CmJBY','lWkYi','kpvaa','cwBBO','Acts\x20by\x20reactive\x20oxygen\x20species','drgeM','filter','cVwYB','notAttempted','NMYRp','hKvhM','console','LpKSG','598362xsGhGg','ZQVFB','disabled','Bookmarked','tKdNA','JsVxM','EcOvq','removeItem','cSGuI','KszNN','gradient-purple\x20px-6\x20py-3\x20text-white\x20transition-all\x20duration-300\x20flex\x20items-center','kYEhY','questionMedia','Topiramate','Oflaxacin','open','loadSource','SMGry','GxUTg','OnurI','KFLDi','Given\x20intravenously\x20and\x20gets\x20deposited\x20in\x20adipose\x20tissue\x20therefore\x20less\x20toxic','DSBuR','display','currentMode','style','Are\x20you\x20sure\x20you\x20want\x20to\x20retake\x20the\x20quiz?\x20This\x20will\x20reset\x20all\x20your\x20answers.','VZZEo','More\x20immunogenic\x20than\x20iron\x20dextran','correct','taksr','enush','Felbamate','-600\x20text-white\x22>','fjppL','No\x20questions\x20available\x20for\x20this\x20quiz.','question_audio','PpOsB','faluC','YPqaF','customQuizData','PKDUo','SdjSi','CuWAc','MiPED','Glimepiride','buPFZ','RkhpB','incorrectResult','5DzSTmU','kmClu','return\x20(function()\x20','target','includes','CBfWE','<p>The\x20given\x20clinical\x20scenario\x20suggests\x20<strong>chronic\x20kidney\x20disease</strong>\x20secondary\x20to\x20diabetes,\x20and\x20<strong>hydrochlorothiazide</strong>\x20is\x20not\x20useful\x20in\x20preventing\x20the\x20<strong>progression</strong>\x20of\x20<strong>renal\x20damage.</strong></p>\x0a<p><strong>Chronic\x20kidney\x20disease</strong>\x20(CKD)\x20is\x20defined\x20as\x20abnormalities\x20of\x20kidney\x20structure\x20or\x20function,\x20present\x20for\x20a\x20<strong>minimum\x20of\x203\x20months</strong>,\x20with\x20implications\x20for\x20health.\x20CKD\x20is\x20classified\x20based\x20on\x20cause,\x20glomerular\x20filtration\x20rate\x20(GFR)\x20category\x20(G1–G5),\x20and\x20albuminuria\x20category\x20(A1–A3).\x20Some\x20of\x20the\x20leading\x20causes\x20of\u00a0\x20CKD\x20are\x20<strong>diabetes</strong>,\x20<strong>hypertension</strong>,\x20glomerulonephritis\x20and\x20polycystic\x20kidney\x20disease.</p>\x0a<p>In\x20patients\x20with\x20diabetes\x20mellitus,\x20often\x20there\x20exists\x20a\x20state\x20of\x20<strong>glomerular\x20hyperfiltration</strong>\x20due\x20to\x20decreased\x20vascular\x20resistance\x20of\x20afferent\x20arterioles\x20and\x20increased\x20vascular\x20resistance\x20of\x20efferent\x20arterioles\x20resulting\x20in\x20increased\x20glomerular\x20hydrostatic\x20pressure.\x20This\x20contributes\x20to\x20the\x20progression\x20of\x20the\x20CKD.</p>\x0a<p>The\x20following\x20drugs\x20have\x20been\x20approved\x20in\x20the\x20management\x20of\x20CKD\x20:</p>\x0a<ul>\x0a<li><strong>Angiotensin-converting\x20enzyme\x20inhibitors\x20/\x20Angiotensin\x20receptor\x20blockers</strong>\x20-\x20These\x20medications\x20appear\x20to\x20slow\x20the\x20rate\x20of\x20decline\x20of\x20kidney\x20function\x20in\x20a\x20manner\x20that\x20extends\x20beyond\x20the\x20reduction\x20of\x20systemic\x20arterial\x20pressure\x20and\x20that\x20involves\x20a\x20reduction\x20in\x20the\x20intraglomerular\x20hyperfiltration\x20and\x20hypertension.\u00a0</li>\x0a<li><strong>Finerenone</strong>\x20-\x20It\x20is\x20a<strong>\x20non\x20steroidal\x20mineralocorticoid\x20receptor\x20antagonist</strong>\x20which\x20decreases\x20proteinuria.\x20It\x20has\x20been\x20approved\x20to\x20reduce\x20the\x20risk\x20of\x20end-stage\x20kidney\x20disease,\x20cardiovascular\x20death,\x20and\x20heart\x20failure\x20in\x20diabetic\x20patients\x20with\x20CKD.</li>\x0a<li><strong>SGLT-2\x20inhibitors\x20</strong>-\x20These\x20drugs\x20inhibit\x20sodium-glucose\x20cotransporter\x20type\x202\x20in\x20the\x20proximal\x20convoluted\x20tubule.\x20By\x20increasing\x20NaCl\x20delivery\x20to\x20the\x20thick\x20ascending\x20limb,\x20gliflozins\x20trigger\x20tubuloglomerular\x20feedback\x20and\x20thereby\x20increase\x20preglomerular\x20vascular\x20resistance\x20and\x20decrease\x20glomerular\x20hypertension.\x20<span\x20style=\x22font-family:\x20-apple-system,\x20BlinkMacSystemFont,\x20\x27Segoe\x20UI\x27,\x20Roboto,\x20Oxygen,\x20Ubuntu,\x20Cantarell,\x20\x27Open\x20Sans\x27,\x20\x27Helvetica\x20Neue\x27,\x20sans-serif;\x22>This\x20contributes\x20to\x20the\x20effectiveness\x20of\x20gliflozins\x20to\x20prevent\x20diabetic\x20kid</span>ney\x20disease.\u00a0</li>\x0a</ul>','Rucaparib','questionNav','Jpmbh','QAESX','aZogk','markReviewBtn','studyModeLegend','gmBkE','FDPwu','nav-btn-bookmarked','navBtn_','MMEne','ZKdaK','Given\x20in\x20all\x20patients\x20with\x20seizures\x20regardless\x20of\x20cardiac\x20arrhythmias,\x20hypotension\x20and/or\x20CNS\x20depression','VMFpn','PbzyS','Wvijt','rGIcQ','jErJt','EKkDY','canPlayType','TNBuQ','Mkvgy','<div\x20class=\x22mt-2\x22><p\x20class=\x22text-sm\x20text-white\x20text-opacity-70\x20mb-1\x22>English:</p><audio\x20src=\x22','</span><span>','CpgNa','MOtHU','EpiOK','sfHjE','dRkec','bind','naqCQ','gray','choices','1,\x202\x20and\x204','WwCrT','notAttemptedResult','woFwx','WJTAT','dQghB','For\x20resistant\x20cases\x20of\x20malaria','evZeF','IUATR','Hydrochlorothiazide','1,2,3','RjEcS','yKJqT','constructor','MbWqX','explanationVideoPlayer','src','split','\x22\x20class=\x22w-full\x20rounded-lg\x22\x20controls></video></div>','nFjkd','<p><strong>Rucaparib</strong>\x20is\x20an\x20inhibitor\x20of\x20<strong>Poly\x20ADP\x20ribose\x20polymerase\x20(PARP)</strong>\x20used\x20for\x20<strong>BRCA-positive\x20breast\x20cancers</strong>.\u00a0</p>\x0a<p>Rucaparib\x20is\x20a\x20poly\x20ADP-ribose\x20polymerase/\x20PARP\x20inhibitor\x20approved\x20for\x20the\x20treatment\x20of\x20breast\x20and\x20advanced\x20ovarian\x20cancer.</p>\x0a<p>PARP\x20is\x20a\x20nuclear\x20protein\x20that\x20transfers\x20ADP-ribose\x20from\x20NAD+\x20to\x20target\x20proteins\x20and\x20this\x20plays\x20an\x20important\x20role\x20in\x20the\x20DNA\x20damage\x20response.\x20Rucaparib\x20and\x20olaparib\x20are\x20PARP\x20inhibitors.</p>\x0a<p>Inhibitors\x20of\x20<strong>PARP\x20(Poly\x20ADP\x20Ribosyl\x20Polymerase)</strong>\x20approved\x20for\x20breast\x20cancer:</p>\x0a<ul>\x0a<li>Olaparib</li>\x0a<li>Rucaparib</li>\x0a<li>Talazoparib</li>\x0a</ul>\x0a<p>Other\x20options:</p>\x0a<p>Option\x20A:\x20<strong>Palbociclib</strong>\x20is\x20a\x20selective\x20inhibitor\x20of\x20the\x20cyclin-dependent\x20kinases\x20CDK4\x20and\x20CDK6.\x20It\x20is\x20used\x20in\x20the\x20treatment\x20of\x20metastatic\x20breast\x20cancer.\u00a0</p>\x0a<p>Option\x20C:\x20<strong>Regorafenib</strong>\x20is\x20an\x20angiogenesis\x20inhibitor\x20that\x20is\x20indicated\x20as\x20a\x20second-line\x20treatment\x20for\x20unresectable\x20hepatocellular\x20carcinoma.\x20(The\x20first\x20line\x20is\x20Sorafenib).</p>\x0a<p>Option\x20D:\x20<strong>Vandetanib</strong>\x20is\x20an\x20oral\x20tyrosine\x20kinase\x20inhibitor\x20recently\x20FDA-approved\x20for\x20unresectable\x20locally\x20advanced\x20or\x20metastatic\x20medullary\x20thyroid\x20carcinoma.</p>','Not\x20Attempted','TZjJt','UqYYY','findIndex','eybGa','bookmarkText','(((.+)+)+)+$','forEach','TGTQw','timed_exam','Which\x20of\x20the\x20following\x20is\x20a\x20true\x20statement\x20regarding\x20Pretomanid?','\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<button\x20type=\x22button\x22\x20class=\x22option-button\x20','QhXED','NtCkR','explanation_audio_hin','gcfaD','not_attempted','submitSection','ZdjJT','https://dhmbxeygs57ff.cloudfront.net/uploads/3d80b15bec8745fa8ca1a9774dbcf000x1280x361.JPEG','EElks','JQbpa','accuracyScore','1,3\x20and\x204','question_video','kbYhU','glass-light\x20px-6\x20py-3\x20text-white\x20hover:bg-purple-500\x20hover:bg-opacity-20\x20transition-all\x20duration-300\x20flex\x20items-center','Aiftu','PCILX','log','Coagulation\x20profile\x20monitoring\x20is\x20required\x20for\x20which\x20of\x20the\x20following\x20drugs?','<p><strong>Dapagliflozin</strong>\x20is\x20known\x20to\x20cause\x20<strong>urinary\x20tract\x20infections</strong>.</p>\x0a<p>Dapagliflozin\x20is\x20a\x20sodium-glucose\x20transporter\x202\x20(<strong>SGLT-2</strong>)\x20inhibitor.\x20It\x20acts\x20by\x20inhibiting\x20the\x20SGLT-2\x20transporter\x20which\x20is\x20present\x20on\x20the\x20proximal\x20segment\x20of\x20the\x20renal\x20tubule\x20and\x20is\x20responsible\x20for\x20the\x20reabsorption\x20of\x2080-90%\x20of\x20filtered\x20glucose.\x20This\x20results\x20in\x20<strong>glycosuria</strong>.\x20Other\x20SGLT-2\x20inhibitors\x20include\x20canagliflozin\x20and\x20empagliflozin.</p>\x0a<p>Apart\x20from\x20their\x20effect\x20on\x20lowering\x20blood\x20glucose\x20levels,\x20SGLT2\x20inhibitors\x20can\x20cause\x20mild\x20weight\x20loss\x20and\x20reduction\x20in\x20blood\x20pressure.\x20They\x20have\x20also\x20been\x20shown\x20to\x20reduce\x20the\x20risk\x20of\x20hospitalization\x20in\x20patients\x20with\x20<strong>heart\x20failure</strong>.</p>\x0a<p>The\x20common\x20side\x20effects\x20include\x20<strong>urinary\x20tract\x20infections</strong>\x20and\x20<strong>genital\x20mycotic\x20infections</strong>\x20due\x20to\x20the\x20high\x20glucose\x20content\x20of\x20the\x20urine.\x20There\x20is\x20a\x20risk\x20of\x20the\x20development\x20of\x20<strong>diabetic\x20ketoacidosis</strong>.</p>\x0a<p>Other\x20options\x20:</p>\x0a<p>Option\x20B\x20-\x20<strong>Sitagliptin</strong>\x20is\x20a\x20dipeptidyl\x20peptidase-4\x20inhibitor.\x20Its\x20use\x20is\x20associated\x20with\x20an\x20increased\x20risk\x20of\x20heart\x20failure.</p>\x0a<p>Option\x20C\x20-\x20<strong>Pioglitazone</strong>\x20is\x20an\x20activator\x20of\x20the\x20peroxisome\x20proliferator-activated\x20receptor\x20γ\x20(PPARγ),\x20which\x20is\x20involved\x20in\x20the\x20regulation\x20of\x20genes\x20related\x20to\x20glucose\x20and\x20lipid\x20metabolism.\x20Its\x20adverse\x20effects\x20include\x20increased\x20incidence\x20of\x20<strong>heart\x20failure</strong>,\x20<strong>peripheral\x20edema</strong>,\x20weight\x20gain,\x20<strong>macular\x20edema</strong>,\x20and\x20<strong>osteoporosis</strong>.</p>\x0a<p>Option\x20D\x20-\x20<strong>Glimepiride</strong>\u00a0belongs\x20to\x20the\x20class\x20of\x20sulfonylureas.\x20It\x20stimulates\x20insulin\x20release\x20by\x20inhibiting\x20the\x20activity\x20of\x20the\x20β\x20cell\x20KATP\x20channel\x20complex.\x20Its\x20side\x20effects\x20include\x20<strong>hypoglycemia</strong>\x20and\x20<strong>weight\x20gain</strong>.</p>','JboJw','padStart','EYLMV','LTUZO','Pablociclib','RWluK','gtYkj','answered','iWYlM','dXcPa','getElementById','uIDkn','6871554JCgcKo','lJIHV','Fdsbe','apply','testModeLegend','ncODv','questionText','bMYlq','JnThn','pWLNS','Chlorpromazine','BynXh','<p><strong>Clofazimine</strong>\x20is\x20a\x20<strong>dye</strong>\x20with\x20leprostatic\x20and\x20antiinflammatory\x20properties.The\x20mechanism\x20of\x20antimicrobial\x20activity\x20of\x20clofazimine\x20against\x20mycobacteria\x20appears\x20to\x20be\x20multifactorial\x20and\x20includes\x20<strong>membrane\x20disruption</strong>,\x20inhibition\x20of\x20mycobacterial\x20phospholipase\x20A2,\x20inhibition\x20of\x20microbial\x20K+\x20transport,\x20generation\x20of\x20hydrogen\x20peroxide,\x20interference\x20with\x20the\x20bacterial\x20electron\x20transport\x20chain,\x20and\x20efflux\x20pump\x20inhibition.</p>\x0a<p>Clofazimine\x20is\x20orally\x20active.\x20It\x20<strong>accumulates\x20in\x20macrophages</strong>\x20and\x20gets\x20deposited\x20as\x20<strong>needle-shaped\x20crystals</strong>\x20in\x20many\x20tissues\x20including\x20subcutaneous\x20fat.\u00a0</p>\x0a<p>Clofazimine\x20is\x20used\x20as\x20a\x20component\x20of\x20multidrug\x20therapy\x20(MDT)\x20for\x20<strong>leprosy</strong>.\x20Because\x20of\x20its\x20<strong>anti-inflammatory</strong>\x20properties,\x20it\x20is\x20valuable\x20in\x20<strong>lepra\x20reactions</strong>.\u00a0Occasionally,\x20it\x20is\x20used\x20as\x20a\x20component\x20of\x20a\x20combination\x20regimen\x20for\x20extensive\x20drug\x20resistant\x20TB\x20(<strong>XDR-TB</strong>).\u00a0</p>\x0a<p>Adverse\x20effects\x20-\u00a0</p>\x0a<ul>\x0a<li><strong>Skin</strong>\x20-\x20The\x20major\x20disadvantage\x20is\x20<strong>reddish-black\x20discoloration</strong>\x20of\x20skin,\x20especially\x20on\x20exposed\x20parts.\x20Discoloration\x20of\x20hair\x20and\x20<strong>body\x20secretions\x20</strong>may\x20also\x20occur.\x20Dryness\x20of\x20the\x20skin,\x20itching\x20and\x20scaling\x20are\x20often\x20troublesome.\x20Acneform\x20eruptions\x20and\x20phototoxicity\x20have\x20been\x20noted.\x20<strong>Conjunctival\x20pigmentation</strong>\x20may\x20create\x20cosmetic\x20problems.\u00a0</li>\x0a<li><strong>GI\x20symptoms</strong>\x20-\x20Nausea,\x20anorexia,\x20abdominal\x20pain,\x20weight\x20loss\x20and\x20enteritis\x20with\x20intermittent\x20loose\x20stools\x20can\x20occur,\x20particularly\x20when\x20higher\x20doses\x20are\x20used\x20to\x20control\x20lepra\x20reaction.\x20Deposition\x20of\x20clofazimine\x20crystals\x20in\x20the\x20<strong>intestinal\x20submucosa</strong>\x20may\x20produce\x20gastrointestinal\x20symptoms.\u00a0</li>\x0a</ul>\x0a<p>Clofazimine\x20is\x20to\x20be\x20avoided\x20during\x20early\x20pregnancy\x20and\x20in\x20patients\x20with\x20liver\x20or\x20kidney\x20damage.\u00a0</p>\x0a<p>Other\x20options\x20:</p>\x0a<p>Option\x20A-\x20<strong>Ofloxacin</strong>\x20is\x20a\x20fluroquinolone.\x20As\x20a\x20component\x20of\x20MDT,\x20it\x20has\x20been\x20found\x20to\x20hasten\x20the\x20bacteriological\x20and\x20clinical\x20response,\x20where\x20it\x20is\x20cidal\x20to\x20<em>M.leprae</em>.\x20Its\x20side\x20effects\x20include\x20<strong>nausea</strong>,\x20vomiting,\x20and\x20abdominal\x20discomfort.\x20<strong>CNS\x20side\x20effects</strong>\x20like\x20dizziness,\x20anxiety\x20and\x20insomnia\x20are\x20also\x20seen.\x20<strong>Tendinitis</strong>\x20is\x20another\x20adverse\x20effect\x20seen\x20with\x20the\x20use\x20of\x20fluoroquinolones.</p>\x0a<p>Option\x20B-\x20<strong>Dapsone\x20</strong>exerts\x20its\x20antimicrobial\x20effect\x20by\x20the\x20inhibition\x20of\x20PABA\x20incorporation\x20into\x20folic\x20acid\x20by\x20<strong>folate\x20synthase</strong>.\x20Apart\x20from\x20being\x20used\x20in\x20leprosy,\x20dapsone\x20is\x20also\x20used\x20for\x20the\x20prophylaxis\x20of\x20<em>T.\x20gondii.\x20</em>The\x20anti-inflammatory\x20effects\x20are\x20the\x20basis\x20for\x20therapy\x20of\x20<strong>dermatitis\x20herpetiformis</strong>,\x20linear\x20immunoglobulin\x20A\x20bullous\x20disease,\x20and\x20relapsing\x20chondritis.\x20Mild\x20<strong>hemolytic\x20anemia</strong>\x20is\x20common,\x20especially\x20in\x20those\x20with\x20<strong>G-6-PD\x20deficiency</strong>.\x20Isolated\x20instances\x20of\x20reversible\x20<strong>peripheral\x20neuropathy</strong>,\x20<strong>drug\x20fever</strong>,\x20hematuria,\x20<strong>pruritus</strong>,\x20psychosis,\x20and\x20a\x20variety\x20of\x20skin\x20rashes\x20have\x20been\x20reported.</p>\x0a<p>Option\x20D\x20-\x20<strong>Rifampicin</strong>\x20interrupts\x20RNA\x20synthesis\x20by\x20binding\x20to\x20a\x20subunit\x20of\x20mycobacterial\x20DNA-dependent\x20RNA\x20polymerase.\x20Apart\x20from\x20being\x20used\x20to\x20treat\x20leprosy,\x20it\x20is\x20used\x20in\x20the\x20management\x20of\x20<strong>tuberculosis</strong>,\x20<strong>brucellosis</strong>,\x20and\x20prophylaxis\x20of\x20<em>Meningococcal</em>\x20meningitis.\x20<strong>Hepatitis</strong>\x20is\x20a\x20major\x20adverse\x20effect.\x20Other\x20side\x20effects\x20include\u00a0pruritus\x20with\x20rash,\u00a0<strong>redness\x20</strong>and\u00a0watering\x20of\x20eyes,<br\x20/><strong>flu-like</strong>\x20symptoms\x20and\x20abdominal\x20cramps.\x20<strong>Urine</strong>\x20and\x20secretions\x20may\x20become\x20<strong>orange-red</strong>.</p>','questionReviewSection','cQCXf','BbLFs','Todwi','toLowerCase','<p>Other\x20options:</p>\x0a<p>Option\x20B:\x20<strong>Ganaxolone</strong>\x20is\x20a\x20recently\x20approved\x20drug\x20for\x20the\x20treatment\x20of\x20seizures\x20associated\x20with\x20CDKL5\x20deficiency.\x20The\x20exact\x20mechanism\x20of\x20action\x20of\x20Ganaxolone\x20is\x20unknown,\x20but\x20its\x20anticonvulsant\x20effects\x20are\x20thought\x20to\x20result\x20from\x20positive\x20allosteric\x20modulation\x20of\x20the\x20GABA-A\x20receptor\x20in\x20the\x20CNS.\x20It\x20can\x20be\x20used\x20in\x20adults\x20as\x20well\x20as\x20children\x20older\x20than\x202\x20years\x20of\x20age.\x20The\x20most\x20common\x20adverse\x20reactions\x20associated\x20with\x20the\x20drug\x20are\x20somnolence,\x20pyrexia,\x20salivary\x20hypersecretion\x20and\x20seasonal\x20allergy.\u00a0</p>\x0a<p>Option\x20C:\x20<strong>Felbamate</strong>\x20is\x20the\x20NMDA\x20receptor\x20antagonist\x20prescribed\x20to\x20this\x20patient.\x20It\x20also\x20potentiates\x20GABA\x20action.\x20It\x20is\x20indicated\x20in\x20refractory\x20primary\x20or\x20secondary\x20generalised\x20seizures\x20and\x20Lennox-Gastaut\x20syndrome.\x20Felbamate\x20is\x20associated\x20with\x20aplastic\x20anemia\x20and\x20liver\x20failure.</p>\x0a<p>Option\x20D:\x20<strong>Stiripentol</strong>\x20is\x20a\x20GABA\x20A\x20receptor\x20modulator\x20with\x20GABA-enhancing\x20activity.\x20It\x20is\x20clinically\x20used\x20in\x20conjunction\x20with\x20valproate\x20and\x20clobazam\x20for\x20refractory\x20generalized\x20tonic-clonic\x20seizures\x20with\x20severe\x20myoclonic\x20epilepsy\x20in\x20infants\x20(Dravet\x20syndrome).</p>','A\x2060-year-old\x20patient\x20who\x20is\x20a\x20known\x20case\x20of\x20hypertension\x20and\x20diabetes\x20underwent\x20PCI\x20stent\x20placement\x20for\x20NSTEMI\x20last\x20year.\x20He\x20is\x20currently\x20on\x20aspirin,\x20metoprolol\x20and\x20atorvastatin.\x20He\x20comes\x20for\x20a\x20follow-up,\x20and\x20his\x20lipid\x20profile\x20is\x20as\x20follows-\x20Total\x20cholesterol\x20252mg/dl\x20LDL:\x20156mg/dl,\x20triglyceride\x20158mg/dl\x20and\x20HDL-\x2040\x20mg/dl.\x20Which\x20drugs\x20can\x20be\x20added\x20based\x20on\x20his\x20lipid\x20profile?','WkTho','userHistory','Which\x20of\x20the\x20following\x20medications\x20used\x20in\x20treating\x20leprosy\x20causes\x20skin\x20pigmentation?','3,4','<div\x20class=\x22glass-light\x20p-4\x20mb-4\x22><img\x20src=\x22','innerHTML','lQpLh','lJBAp','getAttribute','markReviewText','round','now','hidden','Inhibitors\x20of\x20Poly\x20ADP\x20ribose\x20polymerase\x20(PARP)\x20are\x20approved\x20for\x20BRCA-positive\x20breast\x20cancers.\x20Which\x20among\x20the\x20following\x20drugs\x20is\x20used?','Uhdub','quizFile','textContent','Inhaled\x20nitric\x20oxide\x20(iNO)\x20is\x20used\x20for?','<p>Coagulation\x20profile\x20monitoring\x20is\x20required\x20while\x20using\x20<strong>lepirudin</strong>.</p>\x0a<p><strong>Lepirudin</strong>\x20is\x20a<strong>\x20parenteral\x20direct\x20thrombin\x20inhibitor</strong>,\x20which\x20is\x20a\x20recombinant\x20form\x20of\x20hirudin\x20extracted\x20from\x20the\x20saliva\x20of\x20leech.\x20Its\x20action\x20is\x20independent\x20of\x20anti-thrombin,\x20which\x20means\x20it\x20can\x20reach\x20and\x20inactivate\x20fibrin-bound\x20thrombin\x20in\x20thrombi.\u00a0It\x20is\x20excreted\x20by\x20the\x20<strong>kidney</strong>\x20and\x20should\x20be\x20used\x20with\x20great\x20caution\x20in\x20patients\x20with\x20renal\x20insufficiency\x20as\x20no\x20antidote\x20exists.\u00a0</p>\x0a<p>Like\x20heparin,\x20lepirudin\x20must\x20be\x20administered\x20parenterally\x20and\x20is\x20monitored\x20by\x20<strong>aPTT</strong>.\x20Lepirudin\x20was\x20approved\x20for\x20use\x20in\x20patients\x20with\x20thrombosis\x20related\x20to\x20heparin-induced\x20thrombocytopenia\x20(HIT).\x20Its\x20production\x20was\x20discontinued\x20by\x20the\x20manufacturer\x20in\x202012.</p>\x0a<p>Other\x20options\x20:</p>\x0a<p>Option\x20B\x20-\x20<strong>Enoxaparin</strong>\x20is\x20a\x20low\x20molecular\x20weight\x20heparin\x20(LMWH)\x20that\x20inhibits\x20activated\x20factor\x20X\x20with\x20less\x20effect\x20on\x20thrombin.\x20Hence,\x20it\x20has\x20a\x20smaller\x20effect\x20on\x20the\x20coagulation\x20profile\x20and\x20<strong>does\x20not\x20need\x20monitoring</strong>.\u00a0</p>\x0a<p>Option\x20C\x20-\x20<strong>Fondaparinux</strong>\x20avidly\x20binds\x20antithrombin,\x20resulting\x20in\x20efficient\x20inactivation\x20of\x20factor\x20Xa.\x20It\x20is\x20effective\x20in\x20the\x20prevention\x20and\x20treatment\x20of\x20venous\x20thromboembolism\x20and\x20does\x20not\x20appear\x20to\x20cross-react\x20with\x20pathologic\x20HIT\x20antibodies\x20in\x20most\x20individuals.\x20Like\x20LMWH,\x20it\x20<strong>does\x20not\x20require\x20monitoring</strong>\x20of\x20the\x20coagulation\x20profile.</p>\x0a<p>Option\x20D\x20-\x20<strong>Dabigatran</strong>\x20is\x20an\x20oral\x20direct\x20thrombin\x20inhibitor\x20approved\x20for\x20the\x20reduction\x20in\x20risk\x20of\x20stroke\x20and\x20systemic\x20embolism\x20with\x20nonvalvular\x20atrial\x20fibrillation,\x20treatment\x20of\x20venous\x20thromboembolism\x20(VTE)\x20and\x20VTE\x20prophylaxis\x20following\x20hip\x20or\x20knee\x20replacement\x20surgery.\x20It\x20<strong>does\x20not\x20require\x20monitoring</strong>\x20of\x20coagulation\x20profile.</p>','yDYRh','NeTrN','Which\x20of\x20the\x20following\x20acts\x20by\x20suicide\x20inhibition?','setItem','tJbFq','<p>The\x20correct\x20set\x20of\x20matching\x20is<strong>\u00a0a-ii,\x20b-iii,\x20c-i,\x20d-iv.</strong></p>\x0a<table\x20style=\x22border-collapse:\x20collapse;\x20width:\x2034.3013%;\x20height:\x2089.5936px;\x22\x20border=\x221\x22>\x0a<tbody>\x0a<tr\x20style=\x22height:\x2022.3984px;\x22>\x0a<td\x20style=\x22width:\x2039.0285%;\x20height:\x2022.3984px;\x22>a.\x20Naloxone</td>\x0a<td\x20style=\x22width:\x2060.9715%;\x20height:\x2022.3984px;\x22>ii.\x20Opioid\x20overdose</td>\x0a</tr>\x0a<tr\x20style=\x22height:\x2022.3984px;\x22>\x0a<td\x20style=\x22width:\x2039.0285%;\x20height:\x2022.3984px;\x22>b.\x20Oxazepam</td>\x0a<td\x20style=\x22width:\x2060.9715%;\x20height:\x2022.3984px;\x22>iii.\x20Delirium\x20tremens</td>\x0a</tr>\x0a<tr\x20style=\x22height:\x2022.3984px;\x22>\x0a<td\x20style=\x22width:\x2039.0285%;\x20height:\x2022.3984px;\x22>c.\x20Varenicline</td>\x0a<td\x20style=\x22width:\x2060.9715%;\x20height:\x2022.3984px;\x22>i.\x20Smoking\x20cessation</td>\x0a</tr>\x0a<tr\x20style=\x22height:\x2022.3984px;\x22>\x0a<td\x20style=\x22width:\x2039.0285%;\x20height:\x2022.3984px;\x22>d.\x20Acamprosate</td>\x0a<td\x20style=\x22width:\x2060.9715%;\x20height:\x2022.3984px;\x22>iv.\x20Treatment\x20of\x20alcoholism</td>\x0a</tr>\x0a</tbody>\x0a</table>\x0a<p><strong><br\x20/>Naloxone</strong>\x20is\x20an\x20<strong>opioid\x20antagonist\x20</strong>used\x20to\x20reverse\x20the\x20effects\x20of\x20<strong>opioid\x20overdose</strong>,\x20such\x20as\x20respiratory\x20depression.</p>\x0a<p><strong>Oxazepam</strong>\x20is\x20a\x20<strong>benzodiazepine</strong>\x20used\x20for\x20the\x20management\x20of\x20<strong>delirium\x20tremens</strong>,\x20a\x20severe\x20alcohol\x20withdrawal\x20syndrome.</p>\x0a<p><strong>Varenicline</strong>\x20is\x20a\x20<strong>partial\x20agonist\x20</strong>at\x20the\x20<strong>nicotinic\x20acetylcholine\x20receptors,</strong>\x20used\x20for\x20<strong>smoking\x20cessation</strong>\x20by\x20reducing\x20withdrawal\x20symptoms\x20and\x20cravings.</p>\x0a<p><strong>Acamprosate</strong>\x20is\x20a\x20<strong>modulator\x20</strong>of\x20<strong>glutamate</strong>\x20and\x20<strong>GABA\x20neurotransmission</strong>,\x20used\x20for\x20the\x20treatment\x20of\x20<strong>alcoholism</strong>\x20by\x20reducing\x20cravings\x20and\x20the\x20risk\x20of\x20relapse\x20in\x20alcohol\x20abstinence.</p>','1,3,4','</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22option-text\x22>','.option-button','Furosemide','quizPerformanceData','incorrect','Match\x20the\x20treatment\x20with\x20its\x20respective\x20condition.','none','CvvZr','CWkgw','replace','MDaiK','<table\x20style=\x22border-collapse:\x20collapse;\x20width:\x2046.851%;\x20height:\x20134.39px;\x22\x20border=\x221\x22>\x0a<tbody>\x0a<tr\x20style=\x22height:\x2022.3984px;\x22>\x0a<td\x20style=\x22width:\x2041.8628%;\x20height:\x2022.3984px;\x22>Antiepileptic\x20Drugs</td>\x0a<td\x20style=\x22width:\x2058.1372%;\x20height:\x2022.3984px;\x22>Mechanism\x20of\x20Action</td>\x0a</tr>\x0a<tr\x20style=\x22height:\x2022.3984px;\x22>\x0a<td\x20style=\x22width:\x2041.8628%;\x20height:\x2022.3984px;\x22>\x0a<p><strong>Phenytoin\x20(Option\x20A)</strong></p>\x0a<p>Carbamazepine</p>\x0a<p><strong>Lamotrigine\x20(Option\x20B)</strong></p>\x0a</td>\x0a<td\x20style=\x22width:\x2058.1372%;\x20height:\x2022.3984px;\x22>Inhibit\x20Na\x20channels</td>\x0a</tr>\x0a<tr\x20style=\x22height:\x2022.3984px;\x22>\x0a<td\x20style=\x22width:\x2041.8628%;\x20height:\x2022.3984px;\x22>\x0a<p>Phenobarbital</p>\x0a<p>Vigabatrin</p>\x0a<p>Tiagabine</p>\x0a</td>\x0a<td\x20style=\x22width:\x2058.1372%;\x20height:\x2022.3984px;\x22>\x0a<p>Enhance\x20GABA\x20inhibition</p>\x0a<p>Vigabatrin\x20–\x20block\x20GABA\x20aminotransferase\x20irreversibly</p>\x0a<p>Tiagabine\x20–\x20block\x20GABA\x20reuptake</p>\x0a</td>\x0a</tr>\x0a<tr\x20style=\x22height:\x2022.3984px;\x22>\x0a<td\x20style=\x22width:\x2041.8628%;\x20height:\x2022.3984px;\x22>\x0a<p>Ethosuximide</p>\x0a<p>Zonisamide</p>\x0a<p>Gabapentin</p>\x0a<p>Pregabalin</p>\x0a</td>\x0a<td\x20style=\x22width:\x2058.1372%;\x20height:\x2022.3984px;\x22>\x0a<p>Block\x20Ca\x20channels</p>\x0a<p>Ethosuximide,\x20Zonisamide\x20–block\x20T-type\x20Ca\x20channels</p>\x0a<p>Gabapentin,\x20Pregabalin\x20–block\x20voltage\x20sensitive\x20Ca\x20channels</p>\x0a</td>\x0a</tr>\x0a<tr\x20style=\x22height:\x2022.3984px;\x22>\x0a<td\x20style=\x22width:\x2041.8628%;\x20height:\x2022.3984px;\x22>Levetiracetam</td>\x0a<td\x20style=\x22width:\x2058.1372%;\x20height:\x2022.3984px;\x22>Binds\x20synaptic\x20vesicle\x20protein\x202A</td>\x0a</tr>\x0a<tr\x20style=\x22height:\x2022.3984px;\x22>\x0a<td\x20style=\x22width:\x2041.8628%;\x20height:\x2022.3984px;\x22>Valproate</td>\x0a<td\x20style=\x22width:\x2058.1372%;\x20height:\x2022.3984px;\x22>\x0a<p>\u00a0Multiple\x20MOA:</p>\x0a<p>GABA\x20related\x20action</p>\x0a<p>NMDA\x20receptor\x20antagonist</p>\x0a<p>Histone\x20deacetylase\x20inhibitor</p>\x0a</td>\x0a</tr>\x0a<tr>\x0a<td\x20style=\x22width:\x2041.8628%;\x22><strong>Topiramate\x20(Option\x20D)</strong></td>\x0a<td\x20style=\x22width:\x2058.1372%;\x22>\x0a<p>Multiple\x20MOA:</p>\x0a<p>GABAergic\x20action</p>\x0a<p>AMPA\x20receptor\x20antagonist</p>\x0a<p>Acts\x20on\x20Na,\x20Ca\x20and\x20K\x20channels</p>\x0a</td>\x0a</tr>\x0a<tr>\x0a<td\x20style=\x22width:\x2041.8628%;\x22>Drugs\x20acting\x20on\x20glutamate\x20receptors</td>\x0a<td\x20style=\x22width:\x2058.1372%;\x22>\x0a<p>NMDA-type\x20glutamate\x20receptors:</p>\x0a<p>Valproate,\x20Felbamate</p>\x0a<p>AMPA-type\x20glutamate\x20receptors:</p>\x0a<p>Topiramate,\x20Perampanel</p>\x0a</td>\x0a</tr>\x0a<tr>\x0a<td\x20style=\x22width:\x2041.8628%;\x22>\x0a<p>Newer\x20drugs:Rufinamide\u00a0</p>\x0a<p>Lacosamide\x20\u00a0\x20\u00a0</p>\x0a<p>Ezogabine\x20\u00a0</p>\x0a<p>Perampanel</p>\x0a</td>\x0a<td\x20style=\x22width:\x2058.1372%;\x22>\x0a<p>Prolongs\x20inactivation\x20of\x20voltage-gated\x20Na\x20channels\x20\u00a0\x20Enhances\x20inactivation\x20of\x20voltage-gated\x20Na\x20channels\x20Inhibits\x20collapsin\x20response\x20mediator\x20protein\x202\x20\u00a0</p>\x0a<p>Potassium\x20channel\x20opener\x20\u00a0</p>\x0a<p>AMPA-type\x20glutamate\x20receptor\x20antagonist</p>\x0a</td>\x0a</tr>\x0a</tbody>\x0a</table>\x0a<p>\u00a0</p>','toggle','WuRAG','\x20-\x20Brain\x20And\x20Scalpel','Ibalizumab','toISOString','glass-light\x20px-6\x20py-3\x20text-white\x20hover:bg-yellow-500\x20hover:bg-opacity-20\x20transition-all\x20duration-300\x20flex\x20items-center','tCipZ','hSBpm','Mark\x20for\x20Review','qHbCd','incorrectAnswers','EMKkg','jWApt','OTTBI','wDXaY','867408ATUCLZ','68h','Dabigatran','DuDVP','Pioglitazone','GdjaJ','exception','push','gradient-yellow\x20px-6\x20py-3\x20text-white\x20transition-all\x20duration-300\x20flex\x20items-center','qpQMo','nav-btn-current','quizHierarchy','XZCPJ','appendChild','Dapsone','bookmarkedQuestions','MrRwD','\x22>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22option-letter\x22>','YwsKK','bPxRp','<div\x20class=\x22glass-light\x20p-4\x20mb-4\x22><video\x20src=\x22','questions','JWPXU','tjukd','mfPxY','AhQCW','zxxSa','Bibzq','TfdRN','totalTime','nzQVG','SxSyz','RAfRL','pop','<div\x20class=\x22mt-2\x22><p\x20class=\x22text-sm\x20text-white\x20text-opacity-70\x20mb-1\x22>English\x20Explanation:</p><audio\x20src=\x22','nzZoM','solutionAudio','BpYdi','fYSZF','Evolocumab','mRJcm','LMhZW','scRTo','currentQuestionIndex','RDdwq','block','WKPyc','qEnhX','BHbZe','vGkgr','avgTimeResult','<p>The\x20drug\x20that\x20binds\x20to\x20CD4\x20and\x20has\x20an\x20action\x20on\x20both\x20CCR5\x20and\x20CXCR4\x20in\x20tropic\x20HIV\x20infections\x20is<strong>\x20Ibalizumab.</strong></p>\x0a<p><strong>Ibalizumab</strong>\x20is\x20an\x20anti-CD4\x20monoclonal\x20antibody\x20approved\x20for\x20use\x20in\x20the\x20treatment\x20of\x20<strong>multidrug-resistant\x20HIV-1</strong>.\x20It\x20has\x20action\x20on\x20both\x20<strong>CCR5\x20and\x20CXCR4</strong>\x20in\x20tropic\x20HIV\x20infections\x20and\x20is\x20administered\x20intravenously.\u00a0</p>\x0a<p>It\x20acts\x20as\x20an\x20entry\x20inhibitor.\x20It\x20blocks\x20HIV-1\x20from\x20infecting\x20CD4+\x20T\x20cells\x20by\x20binding\x20to\x20domain\x202\x20of\x20CD4\x20cells.\x20It\x20also\x20interferes\x20with\x20post-attachment\x20steps\x20required\x20for\x20the\x20entry\x20of\x20HIV-1\x20virus\x20particles\x20into\x20host\x20cells\x20and\x20thus\x20prevents\x20the\x20viral\x20transmission\x20that\x20occurs\x20via\x20cell-cell\x20fusion.\u00a0</p>\x0a<p>Other\x20options:</p>\x0a<p>Option\x20A:\x20<strong>Maraviroc</strong>\x20binds\x20to\x20the\x20host\x20cell\x20CCR5\x20receptor\x20to\x20block\x20the\x20binding\x20of\x20viral\x20gp120.\x20It\x20prevents\x20the\x20entry\x20of\x20the\x20viral\x20particles.\x20It\x20does\x20not\x20bind\x20to\x20CD4.</p>\x0a<p>Option\x20C:\x20<strong>Elvitegravir</strong>\x20is\x20an\x20integrase\x20inhibitor\x20that\x20inhibits\x20HIV\x201\x20viral\x20integrase\x20enzyme\x20and\x20prevents\x20proviral\x20DNA\x20integration\x20into\x20host\x20cells.</p>\x0a<p>Option\x20D:\x20<strong>Fosamprenavir</strong>\x20is\x20a\x20protease\x20inhibitor\x20that\x20blocks\x20the\x20viral\x20protease\x20enzyme\x20necessary\x20to\x20produce\x20mature\x20virions\x20upon\x20budding\x20from\x20the\x20host\x20membrane.</p>','HvhEd','High\x20dose\x20causes\x20cardiotoxicity\x20in\x20old\x20and\x20nephrotoxicity\x20in\x20young\x20patients','YJWOp','solutionContainer','YcNtZ','Bromhexine\x20as\x20it\x20liquifies\x20sputum','qvLjn','NOcic','Persistent\x20pulmonary\x20hypertension\x20of\x20newborn','Subtrochanteric\x20fractures','study','__proto__','KNYeX','gzpSy','cnmBU','wPOVq','<p><strong>1,2\x20and\x204</strong>\x20can\x20be\x20added\x20based\x20on\x20his\x20lipid\x20profile.</p>\x0a<p>A\x20patient\x20with\x20hypertension\x20and\x20diabetes\x20who\x20underwent\x20PCI\x20stent\x20placement\x20for\x20NSTEMI\x20has\x20<strong>atherosclerotic\x20cardiovascular\x20disease\x20(ASCVD)</strong>.\x20The\x20treatment\x20goal\x20in\x20patients\x20with\x20ASCVD\x20is\x20to\x20<strong>decrease\x20LDL\x20levels</strong>.</p>\x0a<p>Ezetemibe,\x20Evolocumab,\x20Bemepedoic\x20acid\x20decrease\x20LDL.\x20<strong>Gemfibrozil</strong>\x20mainly\x20decreases\x20<strong>triglycerides</strong>\x20and\x20not\x20LDL.</p>\x0a<p>1.\x20<strong>Evolocumab</strong>\x20is\x20a\x20monoclonal\x20antibody\x20that\x20inhibits\x20PCSK-9\x20(proprotein\x20convertase\x20subtilisin/kexin).\x20Inhibition\x20of\x20PCSK-9\x20prevents\x20the\x20degradation\x20of\x20LDL\x20receptors\x20and\x20thus\x20increases\x20LDL-cholesterol\x20clearance\x20by\x20the\x20liver.\x20They\x20are\x20used\x20in\x20patients\x20with\x20atherosclerotic\x20cardiovascular\x20disease\x20(ASCVD)\x20to\x20decrease\x20LDL\x20levels.</p>\x0a<p>2.\x20<strong>Ezetimibe</strong>\x20inhibits\x20cholesterol\x20absorption\x20by\x20enterocytes\x20in\x20the\x20small\x20intestine.\x20It\x20lowers\x20the\x20total\x20and\x20LDL-C\x20levels.</p>\x0a<p>3.\x20<strong>Gemfibrozil\x20</strong>belongs\x20to\x20the\x20fibrate\x20group\x20of\x20drugs\x20that\x20binds\x20to\x20peroxisome\x20proliferator-activated\x20receptors\x20(PPARα),\x20which\x20stimulate\x20fatty\x20acid\x20oxidation\x20and\x20thereby\x20reduce\x20triglyceride\x20levels\x20mainly.</p>\x0a<p>4.\x20<strong>Bempedoic\x20acid</strong>\x20inhibits\x20adenosine\x20triphosphate-citrate\x20lyase\x20(ACL)\x20and\x20results\x20in\x20decreased\x20LDL\x20in\x20patients\x20not\x20responding\x20to\x20statin\x20therapy.</p>\x0a<p>Note\x20-\x20Ezetimibe,\x20colestipol,\x20bempedoic\x20acid\x20and\x20PCSK-9\x20inhibitors\x20like\x20alirocumab\x20have\x20been\x20proven\x20to\x20reduce\x20atherosclerosis\x20risk\x20when\x20added\x20to\x20statins,\x20whereas\x20the\x20fibrate\x20group\x20of\x20drugs\x20and\x20niacin\x20show\x20no\x20significant\x20effect\x20in\x20addition\x20to\x20statins.</p>','bGsvm','111406nfUzxE','<div\x20class=\x22p-3\x20rounded-lg\x20border\x20','Elvitregravir','HDGuz','A\x20G2P1\x20delivered\x20a\x20preterm\x20baby\x20at\x2036\x20weeks.\x20The\x20baby\x20was\x20admitted\x20in\x20the\x20NICU\x20for\x20a\x20week\x20and\x20was\x20given\x20expressed\x20breast\x20milk.\x20Unfortunately\x20the\x20baby\x20did\x20not\x20survive.\x20Which\x20of\x20the\x20following\x20drugs\x20can\x20be\x20used\x20to\x20reduce\x20the\x20engorgement\x20and\x20pain\x20of\x20the\x20lactating\x20breasts?','YFJNy','You\x20have\x20completed\x20all\x20questions.\x20Would\x20you\x20like\x20to\x20review\x20from\x20the\x20beginning?','You\x20have\x20reached\x20the\x20end\x20of\x20the\x20quiz.\x20Would\x20you\x20like\x20to\x20submit\x20your\x20answers\x20now?','YkqTz','xQJRJ','completed','Are\x20you\x20sure\x20you\x20want\x20to\x20submit\x20the\x20quiz?','Vandetinib','HvdxJ','HlVuY','</span></div>','isSupported','gcThA','dQBYa','Which\x20of\x20the\x20following\x20causes\x20a\x20decrease\x20in\x20serum\x20parathyroid\x20hormone?','gqgqb','ngxsD','incomplete','fCsKZ','correctAnswers','DPqMf','<div\x20class=\x22mt-4\x22><video\x20id=\x22review-video-','add','5739604BbtrsZ','rlcga','modeModal','RbCBZ','yVLLj','ugClU','svtBI','toString','info','gtSof','<div\x20class=\x22mt-2\x22><p\x20class=\x22text-sm\x20text-white\x20text-opacity-70\x20mb-1\x22>Hinglish\x20Explanation:</p><audio\x20src=\x22','totalQuestions','UJAyK','pLJxH','\x22><span\x20class=\x22font-bold\x20mr-3\x22>','SRdro','teSbK','vqsSC','3|1|0|2|4|5','iWtVC','TyPes','pwMsW','\x20>\x20','href','</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22bg-green-900\x20bg-opacity-20\x20p-4\x20rounded-lg\x20border\x20border-green-700\x22>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<h5\x20class=\x22text-green-400\x20font-bold\x20mb-2\x22>Explanation:</h5>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22text-white\x20text-opacity-90\x22>','get','oQAWj','Acute\x20oral\x20overdose\x20results\x20primarily\x20in\x20cerebellar\x20and\x20vestibular\x20symptoms\x20and\x20high\x20doses\x20have\x20been\x20associated\x20with\x20marked\x20cerebellar\x20atrophy','pMcDr','strokeDasharray','TcXVD','BIKmU','HgHIg','button','GQrjw','Rifampicin','BWWKr','Option\x20','correct_choice_id','amPPw','Dextromethorphan\x20alone\x20as\x20it\x20does\x20not\x20have\x20addictive\x20potential\x20like\x20codeine','auZMk','1,2,4','nndaD','vzmoU','yfZFO','sLcim','A\x20patient\x20known\x20case\x20of\x20diabetes,\x20shows\x20microalbuminuria\x20on\x20urine\x20analysis,\x20done\x20twice\x20at\x20an\x20interval\x20of\x206\x20months.\x20Renal\x20function\x20tests\x20are\x20normal.\x20Which\x20of\x20the\x20following\x20drugs\x20is\x20not\x20useful\x20in\x20preventing\x20the\x20progression\x20of\x20renal\x20damage?','<p>The\x20osmotic\x20diuretics\x20act\x20at\x20the\x20proximal\x20convoluted\x20tubule\x20and\x20the\x20potassium-sparing\x20diuretics\x20act\x20on\x20the\x20collecting\x20tubule.\x20Hence\x20C\x20and\x20D\x20are\x20the\x20right\x20statements.</p>\x0a<p>A\x20-\x20<strong>Osmotic\x20diuretics</strong>,\x20like\x20<strong>mannitol</strong>,\x20retain\x20water\x20isoosmotically\x20in\x20the\x20<strong>proximal\x20convoluted\x20tubule\x20</strong>(PCT)\x20and\x20descending\x20loop\x20of\x20Henle\x20which\x20are\x20freely\x20permeable\x20to\x20water.\x20Luminal\x20fluid\x20is\x20diluted\x20and\x20opposes\x20NaCl\x20reabsorption.\x20They\x20are\x20indicated\x20in\x20<strong>raised\x20intracranial</strong>\x20<strong>tension\x20</strong>and\x20in\x20<strong>dialysis\x20disequilibrium</strong>.</p>\x0a<p>B\x20-\x20<strong>Thiazides</strong>\x20act\x20on\x20the\x20<strong>distal\x20convoluted\x20tubule</strong>\x20(DCT).\x20They\x20block\x20the\x20<strong>Na+/Cl-\x20co-transporter</strong>\x20in\x20the\x20DCT.\x20This\x20results\x20in\x20the\x20loss\x20of\x20sodium,\x20chloride,\x20and\x20water\x20contributing\x20to\x20the\x20diuretic\x20effect.\x20Some\x20of\x20the\x20examples\x20are\x20hydrochlorothiazide,\x20chlorthalidone\x20and\x20metolazone.\x20Their\x20indications\x20include\x20<strong>hypertension</strong>,\x20edema,\x20<strong>diabetes\x20insipidus</strong>\x20and\x20<strong>hypercalciuria</strong>.</p>\x0a<p>C\x20-\x20<strong>Carbonic\x20anhydrase\x20inhibitors</strong>\x20act\x20on\x20the\x20<strong>proximal\x20convoluted\x20tubule</strong>\x20(PCT).\u00a0By\x20inhibiting\x20carbonic\x20anhydrase,\x20HCO3-\x20reabsorption\x20is\x20blocked\x20and\x20diuresis\x20occurs.\x20Examples\x20are\x20acetazolamide,\x20methazolamide,\x20dichlorphenamide,\x20and\x20dorzolamide.\x20They\x20are\x20used\x20in\x20the\x20treatment\x20of\x20<strong>glaucoma</strong>,\x20urinary\x20alkalinization\x20in\x20<strong>cystinuria</strong>,\x20management\x20of\x20<strong>metabolic\x20alkalosis</strong>,\x20and\x20<strong>acute\x20mountain\x20sickness</strong>.\u00a0</p>\x0a<p>D\x20-\x20<strong>Potassium-sparing\x20diuretics</strong>\x20include\x20<strong>aldosterone\x20antagonists\x20</strong>(spironolactone,\x20eplerenone)\x20and\x20<strong>inhibitors\x20of\x20renal\x20epithelial\x20Na+</strong>\x20<strong>channel\x20</strong>(triamterene,\x20amiloride).\x20They\x20act\x20on\x20the<strong>\x20late\x20distal\x20tubule</strong>\x20and\x20the\x20<strong>collecting\x20duct</strong>.\x20Aldosterone\x20antagonists\x20are\x20used\x20in\x20the\x20treatment\x20of\x20<strong>edema</strong>,\x20<strong>hypertension</strong>,\x20<strong>heart\x20failure</strong>\x20and\x20<strong>Conn\x27s\x20syndrome</strong>.\x20Amiloride\x20has\x20a\x20role\x20in<strong>\x20lithium-induced\x20diabetes\x20insipidus</strong>.</p>','uivqO','EVJIx','cRoew','KkAiG','VCUID','mwlYN','vrJmc','btMeT','bIQLF','hoggN','xWxYc','Phenytoin','fill','Panitumumab','True\x20statement\x20about\x20Iron\x20Isomaltoside\x201000\x20is','lTOWb','luWHH','RZrwG','BlMbG','Correct','TGINB','10393434GvcIZM','VFJZK','querySelectorAll','The\x20drug\x20that\x20binds\x20to\x20CD4\x20and\x20has\x20action\x20on\x20both\x20CCR5\x20and\x20CXCR4\x20in\x20tropic\x20HIV\x20infections\x20is','isArray','LsxCr','BAnjX','Bookmark','cTBoa','wIOfz','error','Enoxaparin','optionsContainer','FIEUy','flex','border-red-500','Madgf','div','Which\x20drug\x20acts\x20on\x20the\x20marked\x20receptor?','click','DeMtP','<p>In\x20the\x20given\x20scenario,\x20the\x20woman\x20requires\x20<strong>suppression\x20of\x20lactation</strong>,\x20for\x20which\x20<strong>cabergoline</strong>\x20is\x20indicated.</p>\x0a<p>In\x20the\x20postpartum\x20period,\x20prolactin\x20promotes\x20lactation.\x20<strong>Dopamine</strong>(DA)\x20is\x20the\x20primary\x20regulator\x20of\x20prolactin\x20secretion\x20from\x20the\x20pituitary\x20gland.\x20DA\x20released\x20from\x20the\x20hypothalamus\x20into\x20the\x20hypophyseal\x20portal\x20blood\x20supply\x20acts\x20on\x20lactotroph\x20<strong>D2\x20receptors</strong>\x20to\x20<strong>decrease\x20prolactin</strong>\x20secretion.\x20The\x20DA\x20agonists\x20like\x20bromocriptine\x20and\x20cabergoline\x20are\x20used\x20in\x20conditions\x20requiring\x20suppression\x20of\x20prolactin.</p>\x0a<p><strong>Cabergoline</strong>\x20is\x20an\x20<strong>ergot\x20derivative</strong>\x20with\x20a\x20longer\x20t1/2\x20(~65\x20h),\x20higher\x20affinity,\x20and\x20greater\x20selectivity\x20for\x20the\x20DA\x20D2\x20receptor\x20compared\x20to\x20bromocriptine.\x20Cabergoline\x20is\x20the\x20preferred\x20drug\x20for\x20the\x20treatment\x20of\x20<strong>hyperprolactinemia\x20</strong>because\x20of\x20greater\x20efficacy\x20and\x20lower\x20adverse\x20effects.\x20Therapy\x20is\x20initiated\x20at\x20a\x20dose\x20of\x200.25\x20mg\x20twice\x20a\x20week\x20or\x200.5\x20mg\x20once\x20a\x20week.\x20Cabergoline\x20induces\x20remission\x20in\x20a\x20significant\x20number\x20of\x20patients\x20with\x20<strong>prolactinomas</strong>.\x20At\x20higher\x20doses,\x20cabergoline\x20is\x20used\x20in\x20some\x20patients\x20with\x20acromegaly\x20alone\x20or\x20in\x20conjunction\x20with\x20somatostatin\x20analogs.</p>\x0a<p>Adverse\x20Effects\x20-\u00a0</p>\x0a<p>Compared\x20to\x20bromocriptine,\x20cabergoline\x20has\x20a\x20much\x20lower\x20tendency\x20to\x20induce\x20nausea,\x20although\x20it\x20still\x20may\x20cause\x20hypotension\x20and\x20dizziness.\x20Cabergoline\x20has\x20been\x20linked\x20to\x20<strong>valvular\x20heart\x20disease</strong>,\x20an\x20effect\x20proposed\x20to\x20reflect\x20agonist\x20activity\x20at\x20the\x20serotonin\x205HT2B\x20receptor.\u00a0However,\x20this\x20effect\x20is\x20seen\x20primarily\x20at\x20the\x20high\x20doses\x20used\x20in\x20patients\x20being\x20treated\x20for\x20Parkinson\x27s\x20disease\x20and\x20is\x20not\x20seen\x20in\x20the\x20conventionally\x20used\x20doses\x20(≤2\x20mg/week)\x20for\x20patients\x20with\x20prolactinomas.</p>\x0a<p>Other\x20options:\u00a0</p>\x0a<p>Option\x20B\x20-\x20<strong>Sumatriptan</strong>\x20is\x20a\x20<strong>5HT1B/1D\x20receptor\x20agonist</strong>\x20used\x20in\x20the\x20treatment\x20of\x20acute\x20attacks\x20of\x20<strong>migraine</strong>.</p>\x0a<p>Option\x20C\x20-\x20<strong>Chlorpromazine</strong>\x20is\x20a\x20<strong>typical\x20antipsychotic</strong>,\x20which\x20has\x20<strong>D2\x20antagonistic</strong>\x20activity.\x20It\x20is\x20used\x20in\x20the\x20treatment\x20of\x20<strong>schizophrenia</strong>,\x20<strong>acute\x20mania</strong>,\x20and\x20refractory\x20<strong>nausea\x20and\x20vomiting</strong>.\x20<strong>Hyperprolactinemia</strong>\x20is\x20an\x20<strong>adverse\x20effect</strong>\x20associated\x20with\x20its\x20use.</p>\x0a<p>Option\x20D\x20-\x20<strong>Pramipexole</strong>\x20is\x20a\x20<strong>non-ergot\x20alkaloid</strong>\x20with\x20a\x20broader\x20DA\x20receptor\x20agonist\x20activity,\x20with\x20the\x20highest\x20affinity\x20to\x20<strong>D3</strong>\x20receptors.\x20It\x20is\x20used\x20in\x20the\x20treatment\x20of\x20<strong>Parkinson\x27s\x20disease</strong>\x20and\x20<strong>restless\x20leg\x20syndrome</strong>.\x20It\x20is\x20not\x20indicated\x20for\x20the\x20treatment\x20of\x20breast\x20engorgement.</p>','IWtYS','LKGBO','Ezetemibe','kMvmN','JxHmH','KgtNh','Finerenone','explanation_audio_eng','Ganaxolone','timerContainer','explanation_images','ImYot','Tiagabine','\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22mb-4\x22>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22flex\x20justify-between\x20items-center\x20mb-3\x22>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<h4\x20class=\x22text-lg\x20font-bold\x20text-white\x22>Question\x20','Ygjyf','className','WnUnz','A\x20young\x20female\x20weighing\x2046\x20kg\x20is\x20on\x20digoxin\x20with\x20vd-6\x20L/kg\x20and\x20clearance\x204.6\x20L/h.\x20Calculate\x20the\x20half-life\x20of\x20digoxin.','bookmarkBtn','QnKuv','Cetuximab','warn','OMedh','a-iii,\x20b-i,\x20c-iv,\x20d-ii','PTJVm','WTPBO','Bromhexine\x20and\x20Dextromethorphan\x20syrup\x20as\x20they\x20liquify\x20sputum\x20and\x20reduce\x20cough\x20due\x20to\x20antitussive\x20effect','Cannot\x20be\x20given\x20with\x20erythropoietin','tnPEk','rWwtg','uBFJu','iWjHY','\x22\x20data-option-index=\x22','Cedon','riiTV','IcRwJ','\x22\x20alt=\x22Explanation\x20Image\x22\x20class=\x22w-full\x20rounded-lg\x22></div>','nbwSN','YTWBz','<p>Contraindicated\x20in\x20patients\x20on\x20enzyme\x20inducer\x20drugs\x20is\x20the\x20true\x20statement\x20regarding\x20<strong>Pretomanid</strong>.</p>\x0a<p><strong>Pretomanid</strong>\x20is\x20metabolized\x20in\x20part\x20by\x20CYP3A.\x20So\x20co-administration\x20with\x20strong\x20or\x20moderate\x20CYP3A\x20inducers\x20should\x20be\x20avoided.\x20Hence,\x20it\x20is\x20<strong>contraindicated</strong>\x20in\x20patients\x20on\x20<strong>enzyme-inducer</strong>\x20drugs.</p>\x0a<p>Pretomanid\x20is\x20a\x20bicyclic\x20<strong>nitroimidazole</strong>\u00a0that\x20acts\x20by\x20inhibiting\x20mycolic\x20acid\x20(a\x20component\x20of\x20the\x20mycobacterial\x20cell\x20wall)\x20and\x20protein\x20synthesis\x20in\x20the\x20mycobacteria.</p>\x0a<p>Pretomanid\x20in\x20combination\x20with\x20Bedaquiline\x20and\x20Linezolid,\x20was\x20approved\x20by\x20the\x20FDA\x20in\x202019\x20for\x20the\x20treatment\x20of\x20adult\x20patients\x20with\x20<strong>Pre\x20(XDR)\x20TB\x20</strong>(resistant\x20to\x20rifampicin\x20and\x20any\x20fluoroquinolones)\x20and\x20for\x20patients\x20who\x20are\x20treatment-intolerant\x20or\x20nonresponsive\x20to\x20multidrug-resistant\x20pulmonary\x20<strong>(MDR)\x20TB\x20</strong>treatment.</p>\x0a<p>Other\x20options:</p>\x0a<p>Option\x20A:\x20Pretomanid\x20is\x20given\x20for\x20<strong>Pre\x20-XDR\x20TB\x20(not\x20XDR\x20TB)\x20</strong>in\x20combination\x20with\x20Bedaquiline\x20and\x20Linezolid\x20(<strong>BPaL\x20regimen</strong>).\x20Pre-XDR\x20TB\x20is\x20resistant\x20to\x20rifampicin\x20and\x20any\x20fluoroquinolone,\x20and\x20therefore,\x20BPaL\x20is\x20given\x20to\x20such\x20patients.\u00a0</p>\x0a<p>Option\x20C:\x20Pretomanid\x20acts\x20by\x20<strong>reactive\x20nitrogen\x20species</strong>\x20like\x20NO\x20and\x20not\x20by\x20reactive\x20oxygen\x20species.</p>\x0a<p>Option\x20D:\x20Pretomanid\x20is\x20not\x20used\x20for\x20resistant\x20cases\x20of\x20malaria.</p>\x0a<p>*Note:\x20For\x20people\x20with\x20MDR/RR-TB,\x20the\x20regimen\x20comprises\x20<strong>bedaquiline\x20(B),\x20pretomanid\x20(Pa),\x20linezolid\x20(L)\x20and\x20moxifloxacin\x20(M)</strong>,\x20and\x20is\x20referred\x20to\x20as\x20<strong>BPaLM.</strong>\x20For\x20people\x20who\x20have\x20pre-XDR-TB,\x20the\x20regimen\x20can\x20be\x20used\x20without\x20moxifloxacin\x20(BPaL).</p>','ZMLBw','SzJYa','border-green-500','Given\x20in\x20XDR\x20TB\x20with\x20Bedaquiline\x20and\x20Linezolid','RkGAo','referrer','.m3u8','w-8\x20h-8\x20text-sm\x20font-medium\x20rounded\x20transition-all\x20duration-200','ZExUo','lDGMJ','Pharmacology','RYNBD','brhTA','correctCount','TLGyK','UflZW','tIuee','DfEkk','LCqsw','location','hhnfW','pathname','BfVpX','attachMedia','KRlXI','059-pharmacology-ini-cet-2024-e9585930.html','name','classList','questionStates','Xzjhi','Sumatriptan','<p>The\x20use\x20of\x20<strong>teriparatide</strong>\x20predisposes\x20an\x20individual\x20to\x20the\x20development\x20of\x20<strong>osteosarcoma</strong>.</p>\x0a<p><strong>Teriparatide</strong>\x20is\x20a\x20<strong>parathormone\x20analog</strong>,\x20which\x20is\x20given\x20as\x20<strong>subcutaneous</strong>\x20injections.\x20Pharmacokinetics\x20and\x20systemic\x20actions\x20of\x20teriparatide\x20on\x20mineral\x20metabolism\x20are\x20the\x20same\x20as\x20for\x20PTH.\x20Its\x20main\x20target\x20of\x20action\x20are\x20the\x20osteoblasts.\u00a0</p>\x0a<p>Teriparatide\x20is\x20administered\x20by\x20<strong>once-daily</strong>\x20subcutaneous\x20injection\x20of\x2020\x20μg\x20into\x20the\x20thigh\x20or\x20abdomen.\x20The\x20site\x20of\x20administration\x20should\x20be\x20rotated,\x20but\x20the\x20time\x20at\x20which\x20the\x20injection\x20is\x20made\x20should\x20be\x20the\x20same\x20each\x20day.</p>\x0a<p>Teriparatide\x20and\x20abaloparatide\x20(PTHrP\x20analog)\x20are\x20the\x20only\x20<strong>anabolic</strong>\x20agents\x20currently\x20available\x20that\x20<strong>increase\x20new\x20bone\x20formation\x20</strong>(option\x20C).\x20Candidates\x20for\x20treatment\x20include\x20<strong>women\x20who\x20have\x20a\x20history\x20of\x20osteoporotic\x20fracture</strong>,\x20who\x20have\x20multiple\x20risk\x20factors\x20for\x20fracture,\x20or\x20who\x20failed\x20or\x20are\x20intolerant\x20of\x20previous\x20osteoporosis\x20therapy.\x20<strong>Men\x20with\x20primary\x20or\x20hypogonadal\x20osteoporosis</strong>\x20are\x20also\x20candidates\x20for\x20treatment\x20with\x20these\x20agents.\u00a0</p>\x0a<p>Adverse\x20effects\x20include\x20<strong>hypercalcemia</strong>,\x20exacerbation\x20of\x20<strong>nephrolithiasis</strong>,\x20and\x20elevation\x20of\x20serum\x20uric\x20acid\x20levels.\x20The\x20development\x20of\x20<strong>osteosarcoma</strong>\x20has\x20been\x20a\x20serious\x20concern\x20in\x20patients\x20treated\x20with\x20teriparatide.\x20It\x20comes\x20with\x20a\x20<strong>black-box\x20warning</strong>,\x20and\x20use\x20should\x20be\x20limited\x20to\x20<strong>no\x20more\x20than\x202\x20years</strong>\x20and\x20avoided\x20in\x20patients\x20who\x20are\x20at\x20increased\x20baseline\x20risk\x20for\x20osteosarcoma\x20(including\x20those\x20with\x20Paget\x20disease\x20of\x20bone,\x20unexplained\x20elevations\x20of\x20alkaline\x20phosphatase,\x20open\x20epiphyses,\x20or\x20prior\x20radiation\x20therapy\x20involving\x20the\x20skeleton).</p>\x0a<p>Other\x20options\x20:</p>\x0a<p>Options\x20A\x20and\x20B\x20-\x20<strong>Osteonecrosis\x20of\x20the\x20jaw\x20bone</strong>\x20and\x20<strong>subtrochanteric\x20fractures</strong>\x20are\x20the\x20adverse\x20effects\x20of\x20<strong>bisphosphonates</strong>.</p>','createElement','fphcy','selected','testModeReviewLegend','5|2|1|0|4|3','Which\x20of\x20the\x20following\x20drugs\x20acts\x20as\x20an\x20inhibitor\x20of\x20PCSK-9?','tJEYl','ArrowLeft','gQlhZ','Contraindicated\x20in\x20patients\x20on\x20enzyme\x20inducer\x20drugs','Bempedoic\x20acid','key','GtrDm','Ydygz','wXOid','solution','Marrow','fIPiu','LxTEw','stats','map','<div\x20class=\x22mt-4\x22><img\x20src=\x22','trace','text','nav-btn-incorrect','AyjMK','Codeine\x20as\x20it\x20is\x20a\x20potent\x20drug\x20and\x20quickly\x20relieves\x20symptoms.','arxke','KaRML','Incorrect','dOtcA','stringify','EjJzS','</span>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22text-white\x20mb-4\x22>','Pertuzumab','currentQuestion','timed_study','Previous\x20progress\x20cleared.','PGyzE','bTRTg','hBOpK','<div\x20class=\x22mt-2\x22><p\x20class=\x22text-sm\x20text-white\x20text-opacity-70\x20mb-1\x22>Hinglish:</p><audio\x20src=\x22','No\x20solution\x20provided','solutionImages','dataset','\x22\x20data-src=\x22','dLYZi','Fondaparinux','cEtUw','RXdbU','bVvAP','markedForReview','selectedAnswer','ClWrN','Stiripentol','qvkUE','MSRVR','DOjGg','totalTimeResult','JeoAB','Clofazamine','questionIndex','No\x20solution\x20available.','endsWith','UnncD','VuvJd','mIqyI','UDEQk','uEiLK','performanceModal','length','bqHGv','FNXpr','HkoPl','hlRsR','<p>The\x20active\x20form\x20of\x20vitamin\x20D,\x20<strong>1,25-dihydroxyvitamin\x20D\x20(calcitriol)</strong>,\x20directly<strong>\x20suppresses\x20PTH\x20gene\x20expression</strong></p>\x0a<p><strong>Calcitriol</strong>\x20is\x20the\x20active\x20form\x20of\x20<strong>vitamin</strong>\x20<strong>D</strong>.\x20It\x20increases\x20<strong>calcium\x20absorption</strong>\x20from\x20the\x20<strong>intestines</strong>\x20and\x20helps\x20maintain\x20<strong>adequate\x20serum\x20calcium\x20levels.</strong>\x20When\x20calcium\x20levels\x20rise,\x20this\x20triggers\x20a\x20<strong>negative\x20feedback\x20mechanism</strong>\x20on\x20the\x20parathyroid\x20glands,\x20leading\x20to\x20<strong>decreased\x20secretion</strong>\x20of\x20<strong>parathyroid\x20hormone</strong>\x20(PTH).\x20PTH\x27s\x20primary\x20role\x20is\x20to\x20raise\x20<strong>blood\x20calcium</strong>\x20levels,\x20so\x20when\x20<strong>calcium</strong>\x20is\x20<strong>sufficient,</strong>\x20the\x20need\x20for\x20<strong>PTH\x20decreases,</strong>\x20resulting\x20in\x20<strong>lower\x20PTH</strong>\x20levels.</p>\x0a<p><strong>Vitamin</strong>\x20D\x20and\x20its\x20derivatives\x20are\x20the\x20primary\x20treatment\x20for\x20<strong>hypoparathyroidism.\x20Dihydrotachysterol</strong>\x20(DHT),\x20a\x20reduced\x20form\x20of\x20vitamin\x20D2,\x20has\x20a\x20<strong>quicker\x20onset,\x20shorter\x20duration,</strong>\x20and\x20<strong>stronger\x20impact</strong>\x20on\x20<strong>bone\x20mobilization</strong>\x20than\x20traditional\x20vitamin\x20D,\x20making\x20it\x20a\x20preferred\x20option.\x20While\x20most\x20<strong>hypoparathyroid\x20patients</strong>\x20respond\x20well\x20to\x20any\x20form\x20of\x20<strong>vitamin</strong>\x20<strong>D</strong>,\x20calcitriol\x20may\x20be\x20preferred\x20for\x20<strong>temporary\x20treatment</strong>\x20of\x20<strong>hypocalcemia</strong>\x20while\x20waiting\x20for\x20the\x20effects\x20of\x20a\x20<strong>slower-acting\x20vitamin</strong>\x20<strong>D</strong>\x20form.\x20Calcium\x20is\x20used\x20to\x20address\x20<strong>calcium\x20deficiency</strong>\x20and\x20as\x20a\x20<strong>dietary\x20supplement.\x20Vitamin</strong>\x20<strong>D</strong>\x20is\x20the\x20<strong>primary\x20treatment</strong>\x20for\x20<strong>hypoparathyroidism.</strong></p>\x0a<p><strong>Severe\x20hypermagnesemia</strong>\x20or\x20<strong>hypomagnesemia</strong>\x20can\x20also\x20inhibit\x20PTH\x20secretion.</p>\x0a<p>Other\x20options:\u00a0</p>\x0a<p>Option\x20B:\x20<strong>Risedronate</strong>\x20is\x20a\x20<strong>bisphosphonate</strong>\x20that\x20<strong>inhibits\x20bone\x20resorption,</strong>\x20but\x20it\x20doesn\x27t\x20directly\x20affect\x20PTH\x20secretion.</p>\x0a<p>Option\x20C:\x20<strong>Furosemide</strong>\x20is\x20a\x20<strong>diuretic</strong>\x20that\x20can\x20<strong>increase\x20calcium\x20excretion,</strong>\x20potentially\x20raising\x20PTH\x20as\x20the\x20body\x20tries\x20to\x20conserve\x20calcium.</p>\x0a<p>Option\x20D:\x20<strong>Lithium</strong>\x20can\x20actually\x20<strong>increase\x20PTH\x20secretion</strong>\x20by\x20affecting\x20<strong>calcium-sensing</strong>\x20receptors\x20in\x20the\x20parathyroid\x20glands.</p>','border-gray-600','HZVVS','not-attempted','contains','7VAwaoF','uojJq','\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20','nav-btn-not-attempted\x20hover:bg-white\x20hover:bg-opacity-20','hierarchy','w-8\x20h-8\x20text-sm\x20font-medium\x20rounded\x20','LCQIv','statsBar','MwPzx','Necitumumab','<p><strong>Iron\x20requirement</strong>\x20can\x20be\x20fulfilled\x20in\x20a\x20<strong>single\x20dose</strong>\x20is\x20true\x20regarding\x20<strong>Isomaltoside\x201000</strong>.</p>\x0a<p>Iron\x20isomaltose\x201000\x20is\x20a\x20new\x20IV\x20iron\x20formulation\x20that\x20can\x20supply\x20a\x20complete\x20replacement\x20dose\x20in\x20a\x20short,\x20single\x20visit.\x20It\x20is\x20used\x20in\x20adult\x20patients\x20with\x20an\x20intolerance\x20to\x20oral\x20iron\x20or\x20for\x20patients\x20with\x20CKD\x20not\x20requiring\x20hemodialysis.</p>\x0a<p>Other\x20options:</p>\x0a<p>Option\x20B:\x20\u00a0Isomaltoside\x201000\x20is\x20not\x20more\x20immunogenic\x20than\x20<strong>iron\x20dextran</strong>.</p>\x0a<p>Option\x20\u00a0C:\x20The\x20strength\x20of\x20iron\x20binding\x20causes\x20a\x20controlled\x20slow\x20release\x20of\x20bioavailable\x20iron,\x20decreasing\x20the\x20risk\x20of\x20toxicity\x20from\x20labile-free\x20iron.\x20Its\x20decreased\x20<strong>toxicity</strong>\x20cannot\x20be\x20attributed\x20to\x20deposition\x20in\x20adipose\x20tissue.</p>\x0a<p>Option\x20D:\x20Isomaltoside\x201000\x20can\x20be\x20given\x20with\x20<strong>erythropoietin</strong>.</p>','SGLT2\x20inhibitor','YMNVW','join','fDswT','Dapagliflozin','gZBpA','TvCEY','ysRWa','jKvWN','Lomitapide','BWpQZ','kviOB'];_0x1ffe=function(){return _0x229f6e;};return _0x1ffe();}function reviewQuestions(){const _0x2a39bf=_0xa90e1a,_0x2c1449={'ECsJs':_0x2a39bf(0x3b1),'LsxCr':'open','WyBpX':function(_0x446c6c,_0x2a0e20){return _0x446c6c===_0x2a0e20;},'SzJYa':'border-gray-600','SdjSi':_0x2a39bf(0x2da),'RWluK':_0x2a39bf(0x2a9),'Jpmbh':function(_0x1ead47,_0x315bd0){return _0x1ead47+_0x315bd0;},'pWLNS':_0x2a39bf(0x346),'cEtUw':_0x2a39bf(0x436),'VFJZK':function(_0x1faaa2,_0x467bfa){return _0x1faaa2===_0x467bfa;},'lJIHV':_0x2a39bf(0x3a8),'uivqO':function(_0x412d29,_0x90a42){return _0x412d29===_0x90a42;},'bVvAP':_0x2a39bf(0x298),'ImYot':_0x2a39bf(0x1db),'eJLEx':_0x2a39bf(0x315),'OnurI':_0x2a39bf(0x2ab),'enush':_0x2a39bf(0x3e4),'QhXED':function(_0x3389f0,_0x96a1b5){return _0x3389f0===_0x96a1b5;},'iWjHY':_0x2a39bf(0x364),'IUATR':_0x2a39bf(0x336),'tCipZ':_0x2a39bf(0x1b6),'nXzZQ':_0x2a39bf(0x1c9),'taksr':'reviewQuestionsContainer','YTWBz':function(_0x4337bc){return _0x4337bc();}};document[_0x2a39bf(0x1a7)](_0x2c1449[_0x2a39bf(0x1e9)])[_0x2a39bf(0x2f3)][_0x2a39bf(0x367)](_0x2c1449[_0x2a39bf(0x396)]);const _0xc26577=document['getElementById'](_0x2c1449[_0x2a39bf(0x3e5)]);_0xc26577['innerHTML']='',questionsData['forEach']((_0x4216ef,_0x2a43a5)=>{const _0x4ed387=_0x2a39bf,_0x16c354=questionStates[_0x2a43a5],_0x36ed07=_0x4216ef[_0x4ed387(0x27a)];let _0x18b2ae=_0x2c1449[_0x4ed387(0x1b2)],_0x386b9b=_0x2c1449[_0x4ed387(0x328)];if(_0x16c354[_0x4ed387(0x32c)]!==null){if(_0x2c1449[_0x4ed387(0x29b)](_0x2c1449[_0x4ed387(0x1aa)],_0x4ed387(0x35a)))_0x21a805[_0x4ed387(0x1a7)](_0x2c1449['ECsJs'])[_0x4ed387(0x2f3)]['toggle'](_0x2c1449[_0x4ed387(0x29f)]);else{const _0x339ca9=_0x4216ef[_0x4ed387(0x420)][_0x16c354['selectedAnswer']];_0x2c1449[_0x4ed387(0x285)](_0x339ca9['id'],_0x36ed07)?(_0x18b2ae=_0x4ed387(0x3e4),_0x386b9b=_0x2c1449[_0x4ed387(0x32a)]):(_0x18b2ae=_0x2c1449['ImYot'],_0x386b9b=_0x2c1449[_0x4ed387(0x377)]);}}const _0x52f052=document[_0x4ed387(0x2f8)](_0x2c1449[_0x4ed387(0x3da)]);_0x52f052[_0x4ed387(0x2bf)]=_0x4ed387(0x3ad)+_0x18b2ae;let _0x27c38d=(_0x4216ef[_0x4ed387(0x420)]||[])[_0x4ed387(0x30c)]((_0x209239,_0x2f1986)=>{const _0x4aa19f=_0x4ed387,_0x8f0899=_0x2c1449['WyBpX'](_0x16c354[_0x4aa19f(0x32c)],_0x2f1986),_0x20962b=_0x2c1449[_0x4aa19f(0x382)](_0x209239['id'],_0x36ed07);let _0x35d854=_0x2c1449[_0x4aa19f(0x2d9)];if(_0x20962b)_0x35d854=_0x2c1449[_0x4aa19f(0x3f1)];else{if(_0x8f0899)_0x35d854=_0x2c1449[_0x4aa19f(0x1a2)];}return _0x4aa19f(0x239)+_0x35d854+_0x4aa19f(0x262)+String[_0x4aa19f(0x371)](_0x2c1449[_0x4aa19f(0x401)](0x41,_0x2f1986))+_0x4aa19f(0x417)+_0x209239[_0x4aa19f(0x30f)]+_0x4aa19f(0x247);})[_0x4ed387(0x355)]('');const _0x30114a=_0x4216ef[_0x4ed387(0x384)]?_0x4ed387(0x252)+_0x2a43a5+_0x4ed387(0x325)+_0x4216ef[_0x4ed387(0x384)]+_0x4ed387(0x433):'';let _0x15919a='';if(_0x4216ef[_0x4ed387(0x2b7)])_0x15919a+=_0x4ed387(0x416)+_0x4216ef[_0x4ed387(0x2b7)]+'\x22\x20controls\x20class=\x22w-full\x22></audio></div>';if(_0x4216ef[_0x4ed387(0x444)])_0x15919a+=_0x4ed387(0x321)+_0x4216ef[_0x4ed387(0x444)]+_0x4ed387(0x3af);let _0x4cf8f7=(_0x4216ef[_0x4ed387(0x2ba)]||[])['map'](_0x2a8b03=>_0x2a8b03?_0x4ed387(0x30d)+_0x2a8b03+_0x4ed387(0x2d4):'')[_0x4ed387(0x355)]('');_0x52f052[_0x4ed387(0x1c2)]=_0x4ed387(0x2bd)+_0x2c1449[_0x4ed387(0x401)](_0x2a43a5,0x1)+'</h4>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<span\x20class=\x22text-sm\x20px-3\x20py-1\x20rounded-full\x20bg-'+(_0x18b2ae===_0x2c1449[_0x4ed387(0x3e6)]?'green':_0x2c1449[_0x4ed387(0x442)](_0x18b2ae,_0x2c1449[_0x4ed387(0x2bb)])?_0x2c1449[_0x4ed387(0x2cf)]:_0x4ed387(0x41f))+_0x4ed387(0x3e8)+_0x386b9b+_0x4ed387(0x319)+_0x4216ef[_0x4ed387(0x30f)]+'</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22space-y-2\x20mb-4\x22>'+_0x27c38d+_0x4ed387(0x26c)+(_0x4216ef[_0x4ed387(0x307)]||_0x2c1449[_0x4ed387(0x429)])+'</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20'+_0x30114a+_0x4ed387(0x34a)+_0x15919a+_0x4ed387(0x34a)+_0x4cf8f7+_0x4ed387(0x366),_0xc26577[_0x4ed387(0x1ff)](_0x52f052);}),_0x2c1449[_0x2a39bf(0x2d6)](initializeReviewVideos);}function initializeReviewVideos(){const _0x4cfb64=_0xa90e1a,_0x5c47a6={'nndaD':function(_0x208b19){return _0x208b19();},'gcfaD':function(_0x2da33e,_0x23a7c1){return _0x2da33e(_0x23a7c1);},'woFwx':_0x4cfb64(0x43f),'wDXaY':function(_0x58cdd8){return _0x58cdd8();},'HZVVS':function(_0x1add49,_0x5f43a0){return _0x1add49===_0x5f43a0;},'mRJcm':_0x4cfb64(0x24d),'dkEgQ':_0x4cfb64(0x2de),'IWtYS':'TuqeY','RdXfX':function(_0x59c4a6,_0x3783b6,_0x58d29b){return _0x59c4a6(_0x3783b6,_0x58d29b);}};document[_0x4cfb64(0x29c)](_0x4cfb64(0x3a0))[_0x4cfb64(0x43d)](_0x54fee6=>{const _0xc7691e=_0x4cfb64,_0x15ccc5={'gZBpA':function(_0xa3d1e2){const _0x354689=_0x2977;return _0x5c47a6[_0x354689(0x1f1)](_0xa3d1e2);}};if(_0x5c47a6[_0xc7691e(0x345)](_0x5c47a6[_0xc7691e(0x21a)],_0x5c47a6[_0xc7691e(0x21a)])){const _0x32a76e=_0x54fee6[_0xc7691e(0x324)][_0xc7691e(0x431)];if(_0x32a76e&&_0x32a76e[_0xc7691e(0x3fc)](_0x5c47a6['dkEgQ']))_0x5c47a6[_0xc7691e(0x345)](_0xc7691e(0x278),_0x5c47a6[_0xc7691e(0x2b0)])?(_0x50dcc0--,_0x5c47a6[_0xc7691e(0x27f)](_0x3f45cd),_0x1c734a<=0x0&&(_0x5c47a6[_0xc7691e(0x445)](_0x404b91,_0x2e8fa6),_0x35f588===_0x5c47a6[_0xc7691e(0x424)]?_0x5c47a6[_0xc7691e(0x27f)](_0x5dbcbb):_0x5c47a6[_0xc7691e(0x1f1)](_0x201c16))):_0x5c47a6[_0xc7691e(0x39e)](setupVideo,_0x54fee6,_0x32a76e);else _0x32a76e&&(_0x54fee6[_0xc7691e(0x431)]=_0x32a76e);}else _0x15ccc5[_0xc7691e(0x358)](_0x6ed7fc);});}function retakeQuiz(){const _0x326b80=_0xa90e1a,_0x4e5bc7={'ZKdaK':function(_0x2e52e5,_0x20eb7f){return _0x2e52e5(_0x20eb7f);},'dGqgA':function(_0x17487c,_0x57c630){return _0x17487c===_0x57c630;},'sLcim':_0x326b80(0x20b),'MOtHU':_0x326b80(0x3ef),'caIaG':function(_0x2dadb5){return _0x2dadb5();}};_0x4e5bc7[_0x326b80(0x40b)](confirm,_0x326b80(0x3e1))&&(window[_0x326b80(0x2eb)]['pathname'][_0x326b80(0x337)](_0x326b80(0x388))&&(_0x4e5bc7['dGqgA'](_0x4e5bc7[_0x326b80(0x282)],_0x4e5bc7[_0x326b80(0x282)])?localStorage[_0x326b80(0x3ce)](_0x4e5bc7[_0x326b80(0x419)]):_0x37ca0a[_0x326b80(0x431)]=_0x553786),_0x4e5bc7['caIaG'](clearProgress),location[_0x326b80(0x361)]());}function loadBookmarkedQuestions(){const _0x5ba2a3=_0xa90e1a,_0xa37db={'vkMTg':'bookmarkedQuestions'},_0x22b73b=JSON[_0x5ba2a3(0x36c)](localStorage[_0x5ba2a3(0x38d)](_0xa37db[_0x5ba2a3(0x3ae)]))||[];_0x22b73b[_0x5ba2a3(0x43d)](_0x4e67f2=>{const _0x1062d2=_0x5ba2a3;_0x4e67f2[_0x1062d2(0x1cc)][_0x1062d2(0x3fc)](quizName[_0x1062d2(0x1ba)]()[_0x1062d2(0x1e0)](/ /g,'-'))&&(_0x4e67f2[_0x1062d2(0x335)]<questionsData['length']&&(questionStates[_0x4e67f2[_0x1062d2(0x335)]][_0x1062d2(0x3b7)]=!![]));});}function toggleBookmark(){const _0x51099b=_0xa90e1a,_0x3b03ae={'kviOB':_0x51099b(0x400),'LpKSG':'button','vrJmc':function(_0x540cf4,_0x25579e){return _0x540cf4+_0x25579e;},'LxTEw':function(_0x200cdf){return _0x200cdf();},'PCILX':'modeModal','VZZEo':_0x51099b(0x1dd),'mwlYN':function(_0x2ee106){return _0x2ee106();},'drgeM':function(_0x5cce5b,_0x2328ac){return _0x5cce5b!==_0x2328ac;},'yfZFO':_0x51099b(0x393),'VNWui':_0x51099b(0x1ee),'nDLUz':_0x51099b(0x354),'rIijS':function(_0x13a9bd){return _0x13a9bd();},'Zmizl':function(_0x59c531){return _0x59c531();}},_0x5c883c=!questionStates[currentQuestionIndex]['bookmarked'];questionStates[currentQuestionIndex][_0x51099b(0x3b7)]=_0x5c883c;let _0x4d528e=JSON[_0x51099b(0x36c)](localStorage[_0x51099b(0x38d)](_0x51099b(0x201)))||[];if(_0x5c883c){if(_0x3b03ae['drgeM'](_0x3b03ae[_0x51099b(0x281)],_0x3b03ae[_0x51099b(0x3a3)])){const _0x156e5c={'quizName':quizName,'quizFile':window['location']['pathname'][_0x51099b(0x432)]('/')['pop'](),'questionIndex':currentQuestionIndex,'question':questionsData[currentQuestionIndex],'hierarchy':hierarchy,'timestamp':Date['now']()};_0x4d528e[_0x51099b(0x1f9)](_0x156e5c);}else{const _0x15dfba=_0xb1d9e6[_0x51099b(0x1a7)](_0x3b03ae[_0x51099b(0x35e)]);_0x15dfba['innerHTML']='';for(let _0x3f61fc=0x0;_0x3f61fc<_0x95cf7c[_0x51099b(0x33e)];_0x3f61fc++){const _0x20dec9=_0x440acc['createElement'](_0x3b03ae[_0x51099b(0x3c6)]);_0x20dec9[_0x51099b(0x1cd)]=_0x3b03ae[_0x51099b(0x28b)](_0x3f61fc,0x1),_0x20dec9[_0x51099b(0x2bf)]='w-8\x20h-8\x20text-sm\x20font-medium\x20rounded\x20transition-all\x20duration-200',_0x20dec9['onclick']=()=>_0x300805(_0x3f61fc),_0x20dec9['id']='navBtn_'+_0x3f61fc,_0x15dfba[_0x51099b(0x1ff)](_0x20dec9);}_0x3b03ae[_0x51099b(0x30a)](_0x2dd137);}}else _0x3b03ae[_0x51099b(0x3bf)](_0x3b03ae['nDLUz'],_0x3b03ae['nDLUz'])?(_0x52490e=_0x432e0a,_0x246e50[_0x51099b(0x1a7)](_0x3b03ae[_0x51099b(0x452)])['style'][_0x51099b(0x3de)]=_0x3b03ae[_0x51099b(0x3e2)],_0x3b03ae[_0x51099b(0x28a)](_0x49c4b9)):_0x4d528e=_0x4d528e[_0x51099b(0x3c0)](_0x16600d=>!(_0x16600d['quizFile'][_0x51099b(0x3fc)](quizName[_0x51099b(0x1ba)]()[_0x51099b(0x1e0)](/ /g,'-'))&&_0x16600d[_0x51099b(0x335)]===currentQuestionIndex));localStorage['setItem'](_0x51099b(0x201),JSON[_0x51099b(0x317)](_0x4d528e)),_0x3b03ae[_0x51099b(0x374)](updateBookmarkButton),_0x3b03ae['Zmizl'](updateQuestionNav);}function updateBookmarkButton(){const _0x245ca9=_0xa90e1a,_0x36f489={'xQJRJ':'bookmarkBtn','vGkgr':_0x245ca9(0x43b),'NOcic':_0x245ca9(0x1fa),'HgHIg':_0x245ca9(0x1e8),'RffFn':_0x245ca9(0x3ca)},_0x9f1d9e=document[_0x245ca9(0x1a7)](_0x36f489[_0x245ca9(0x241)]),_0x59bd0f=document[_0x245ca9(0x1a7)](_0x36f489[_0x245ca9(0x223)]),_0x2fe5fd=questionStates[currentQuestionIndex]['bookmarked'];_0x9f1d9e[_0x245ca9(0x2bf)]=_0x2fe5fd?_0x36f489[_0x245ca9(0x22d)]:_0x36f489[_0x245ca9(0x274)],_0x59bd0f[_0x245ca9(0x1cd)]=_0x2fe5fd?_0x36f489['RffFn']:_0x245ca9(0x2a1);}function toggleMarkForReview(){const _0x140466=_0xa90e1a,_0x503222={'WTPBO':function(_0x513990){return _0x513990();}};questionStates[currentQuestionIndex]['markedForReview']=!questionStates[currentQuestionIndex][_0x140466(0x32b)],_0x503222[_0x140466(0x2c9)](updateMarkReviewButton),_0x503222[_0x140466(0x2c9)](updateQuestionNav);}function updateMarkReviewButton(){const _0x55522a=_0xa90e1a,_0x51e9b3={'eeCfM':'markReviewBtn','YcNtZ':_0x55522a(0x1c6),'LKMBY':_0x55522a(0x3d1),'tIdSg':_0x55522a(0x450),'YkqTz':'Marked','TfdRN':_0x55522a(0x1eb)},_0xd941ac=document[_0x55522a(0x1a7)](_0x51e9b3[_0x55522a(0x398)]),_0x550f4e=document[_0x55522a(0x1a7)](_0x51e9b3[_0x55522a(0x22a)]),_0x42f0c5=questionStates[currentQuestionIndex][_0x55522a(0x32b)];_0xd941ac[_0x55522a(0x2bf)]=_0x42f0c5?_0x51e9b3[_0x55522a(0x37f)]:_0x51e9b3[_0x55522a(0x36e)],_0x550f4e[_0x55522a(0x1cd)]=_0x42f0c5?_0x51e9b3[_0x55522a(0x240)]:_0x51e9b3[_0x55522a(0x20e)];}function previousQuestion(){const _0x3fbe55=_0xa90e1a,_0x1732d7={'AQexf':function(_0x4fcbe8,_0x4a7d29){return _0x4fcbe8-_0x4a7d29;},'JboJw':function(_0x37d2a1){return _0x37d2a1();}};currentQuestionIndex>0x0&&(questionStartTime&&(questionStates[currentQuestionIndex][_0x3fbe55(0x381)]+=_0x1732d7['AQexf'](Date[_0x3fbe55(0x1c8)](),questionStartTime)),currentQuestionIndex--,displayQuestion(),_0x1732d7[_0x3fbe55(0x456)](saveProgress));}function nextQuestion(){const _0x3b7e38=_0xa90e1a,_0x42f724={'cRoew':function(_0x121a2a,_0x1d9c32){return _0x121a2a-_0x1d9c32;},'CvvZr':function(_0x1879ac){return _0x1879ac();},'rGIcQ':_0x3b7e38(0x38a),'rRIHB':function(_0x1d485a,_0x4bd8ba){return _0x1d485a===_0x4bd8ba;},'HlVuY':function(_0x26c0c5,_0x3c207d){return _0x26c0c5(_0x3c207d);},'bGomI':'You\x20have\x20reached\x20the\x20end\x20of\x20the\x20quiz.\x20Would\x20you\x20like\x20to\x20submit\x20your\x20answers\x20now?','fIPiu':_0x3b7e38(0x23e),'YPqaF':function(_0x87f5c2){return _0x87f5c2();}};questionStartTime&&(questionStates[currentQuestionIndex][_0x3b7e38(0x381)]+=_0x42f724[_0x3b7e38(0x287)](Date['now'](),questionStartTime)),currentQuestionIndex<questionsData['length']-0x1?(currentQuestionIndex++,_0x42f724[_0x3b7e38(0x1de)](displayQuestion),saveProgress()):currentMode===_0x42f724[_0x3b7e38(0x410)]||_0x42f724['rRIHB'](currentMode,'timed_exam')?_0x42f724[_0x3b7e38(0x246)](confirm,_0x42f724['bGomI'])&&_0x42f724['CvvZr'](submitQuiz):_0x42f724['HlVuY'](confirm,_0x42f724[_0x3b7e38(0x309)])&&(currentQuestionIndex=0x0,displayQuestion(),_0x42f724[_0x3b7e38(0x3ee)](saveProgress));}function startTimer(){const _0x18f29e=_0xa90e1a,_0x332854={'Todwi':function(_0x243f14,_0x4631df){return _0x243f14!==_0x4631df;},'aTBOy':function(_0x3fbeb2){return _0x3fbeb2();},'nmNSc':function(_0x4b4bfd,_0x45ad2a){return _0x4b4bfd<=_0x45ad2a;},'HvdxJ':function(_0x327876,_0x49a33b){return _0x327876(_0x49a33b);},'qvLjn':function(_0x1ffa34,_0x12071b){return _0x1ffa34===_0x12071b;},'RYNBD':'timed_exam','TGINB':function(_0x2238da){return _0x2238da();},'RZrwG':function(_0x3b6d7e,_0x2cccc1){return _0x3b6d7e(_0x2cccc1);},'tDubJ':function(_0x5833fd){return _0x5833fd();},'tnPEk':function(_0x4e1f34,_0xf6992d,_0x195141){return _0x4e1f34(_0xf6992d,_0x195141);}};if(timer)_0x332854[_0x18f29e(0x296)](clearInterval,timer);timeRemaining=0x78,_0x332854['tDubJ'](updateTimerDisplay),timer=_0x332854[_0x18f29e(0x2cc)](setInterval,()=>{const _0x1d34dd=_0x18f29e;_0x332854[_0x1d34dd(0x1b9)](_0x1d34dd(0x3d2),_0x1d34dd(0x2c3))?(timeRemaining--,_0x332854['aTBOy'](updateTimerDisplay),_0x332854['nmNSc'](timeRemaining,0x0)&&(_0x332854[_0x1d34dd(0x245)](clearInterval,timer),_0x332854[_0x1d34dd(0x22c)](currentMode,_0x332854[_0x1d34dd(0x2e3)])?_0x332854[_0x1d34dd(0x299)](submitQuiz):nextQuestion())):_0x5669e8[_0x1d34dd(0x431)]=_0x459c14;},0x3e8);}function updateTimerDisplay(){const _0x4fb273=_0xa90e1a,_0x300a97={'GwlNo':function(_0x20e966,_0x108ece){return _0x20e966/_0x108ece;},'cTBoa':function(_0x571bd0,_0x3ab691){return _0x571bd0%_0x3ab691;},'gtYkj':'timeDisplay','PTJVm':function(_0xb0517d,_0x4c3e45){return _0xb0517d+_0x4c3e45;}},_0x5f5317=Math[_0x4fb273(0x3a9)](_0x300a97['GwlNo'](timeRemaining,0x3c)),_0x26ef21=_0x300a97[_0x4fb273(0x2a2)](timeRemaining,0x3c);document[_0x4fb273(0x1a7)](_0x300a97[_0x4fb273(0x1a3)])['textContent']=_0x300a97[_0x4fb273(0x2c8)](_0x5f5317+':',_0x26ef21[_0x4fb273(0x25b)]()[_0x4fb273(0x457)](0x2,'0'));}function toggleSidebar(){const _0x5c2c68=_0xa90e1a,_0x17d733={'DeMtP':_0x5c2c68(0x3b1),'EZrLR':_0x5c2c68(0x3d6)};document[_0x5c2c68(0x1a7)](_0x17d733[_0x5c2c68(0x2ae)])[_0x5c2c68(0x2f3)]['toggle'](_0x17d733['EZrLR']);}document['addEventListener']('DOMContentLoaded',()=>{const _0x27d21e=_0xa90e1a,_0x21e6c2={'mxWsM':'answered','WnUnz':function(_0x203e0b){return _0x203e0b();},'NRzfS':function(_0x2372aa,_0x31b8e0){return _0x2372aa!==_0x31b8e0;},'MUtAe':_0x27d21e(0x3f6),'LMhZW':_0x27d21e(0x256),'oQAWj':_0x27d21e(0x1dd),'Ydygz':function(_0x6ce126){return _0x6ce126();},'ogWDR':function(_0x5b21e1){return _0x5b21e1();},'YwsKK':'flex','PpOsB':function(_0x34734a,_0x550d42){return _0x34734a===_0x550d42;},'GHVWe':'qvkUE'};if(resume)_0x21e6c2['WnUnz'](loadProgress)?_0x21e6c2['NRzfS'](_0x27d21e(0x3f6),_0x21e6c2['MUtAe'])?(_0x35b4f9[_0x333e75][_0x27d21e(0x3ac)]=_0x21e6c2['mxWsM'],_0x1dfff0[_0x27d21e(0x3aa)]++,_0x8dead6[_0x27d21e(0x3c2)]--):(document[_0x27d21e(0x1a7)](_0x21e6c2[_0x27d21e(0x21b)])['style'][_0x27d21e(0x3de)]=_0x21e6c2[_0x27d21e(0x26e)],_0x21e6c2[_0x27d21e(0x305)](initializeQuiz)):(_0x21e6c2['ogWDR'](clearProgress),document[_0x27d21e(0x1a7)](_0x21e6c2['LMhZW'])[_0x27d21e(0x3e0)][_0x27d21e(0x3de)]=_0x21e6c2[_0x27d21e(0x204)]);else{if(!window[_0x27d21e(0x2eb)][_0x27d21e(0x2ed)][_0x27d21e(0x337)]('custom_quiz.html'))_0x21e6c2[_0x27d21e(0x2c0)](clearProgress),document[_0x27d21e(0x1a7)](_0x27d21e(0x256))[_0x27d21e(0x3e0)]['display']=_0x21e6c2[_0x27d21e(0x204)];else{if(_0x21e6c2[_0x27d21e(0x3ec)](_0x27d21e(0x32f),_0x21e6c2['GHVWe']))_0x21e6c2[_0x27d21e(0x2c0)](initializeQuiz);else{const _0x3832e9={'quizName':_0x2ac9d3,'quizFile':_0x92d55[_0x27d21e(0x2eb)]['pathname'][_0x27d21e(0x432)]('/')[_0x27d21e(0x213)](),'questionIndex':_0x2d1f73,'question':_0x58dd63[_0x5c6b29],'hierarchy':_0x13df46,'timestamp':_0x33e5ab['now']()};_0x42ca50[_0x27d21e(0x1f9)](_0x3832e9);}}}}),document[_0xa90e1a(0x3b5)]('keydown',function(_0x98521f){const _0x44999d=_0xa90e1a,_0x4f8ba3={'qHbCd':'none','BpYdi':function(_0x396d91,_0x2b14aa){return _0x396d91===_0x2b14aa;},'wuPDg':_0x44999d(0x1c9),'dNTal':function(_0x2cd0ca,_0x46bf93){return _0x2cd0ca>=_0x46bf93;},'SxSyz':function(_0x4f3c0e,_0x216d3c){return _0x4f3c0e<=_0x216d3c;},'omjvd':function(_0x510318,_0x5b293b){return _0x510318-_0x5b293b;},'wpYkV':function(_0x16388b,_0x3c59ab){return _0x16388b(_0x3c59ab);},'cvOfN':function(_0x988938,_0x22d766){return _0x988938(_0x22d766);},'hhnfW':_0x44999d(0x2ff),'gmBkE':function(_0x272839,_0x56891d){return _0x272839===_0x56891d;},'tKdNA':'hKvhM','fDswT':function(_0x282cb8){return _0x282cb8();},'VMFpn':'ArrowRight','lQpLh':function(_0x2bf3a1,_0x92e3b6){return _0x2bf3a1!==_0x92e3b6;},'MSlZr':_0x44999d(0x3db),'dXcPa':_0x44999d(0x370),'JQbpa':function(_0x2128af,_0x4ac44f){return _0x2128af===_0x4ac44f;},'CmJBY':_0x44999d(0x31c),'awgjQ':function(_0x31328b,_0xea0702){return _0x31328b===_0xea0702;},'mfPxY':_0x44999d(0x38a),'lTOWb':_0x44999d(0x43f),'ClWrN':function(_0x60758e,_0x439918){return _0x60758e===_0x439918;},'pMcDr':function(_0x365a33,_0x595a70){return _0x365a33===_0x595a70;}};if(document['getElementById'](_0x44999d(0x256))['style'][_0x44999d(0x3de)]!==_0x4f8ba3[_0x44999d(0x1ec)])return;if(_0x4f8ba3[_0x44999d(0x217)](document['getElementById']('performanceModal')[_0x44999d(0x2f3)][_0x44999d(0x347)](_0x4f8ba3[_0x44999d(0x376)]),![]))return;if(_0x4f8ba3['dNTal'](_0x98521f[_0x44999d(0x303)],'1')&&_0x4f8ba3[_0x44999d(0x211)](_0x98521f[_0x44999d(0x303)],'4')){const _0x20fea1=_0x4f8ba3['omjvd'](_0x4f8ba3['wpYkV'](parseInt,_0x98521f['key']),0x1),_0x5c78ea=document[_0x44999d(0x29c)](_0x44999d(0x1d8));if(_0x20fea1<_0x5c78ea[_0x44999d(0x33e)])_0x4f8ba3['cvOfN'](selectOption,_0x20fea1);}else{if(_0x98521f['key']===_0x4f8ba3[_0x44999d(0x2ec)]){if(_0x4f8ba3[_0x44999d(0x406)](_0x44999d(0x3c4),_0x4f8ba3[_0x44999d(0x3cb)]))_0x4f8ba3['fDswT'](previousQuestion);else{const _0x21230e=_0x448071[_0x44999d(0x36c)](_0x4be6f5[_0x44999d(0x38d)]('userHistory'))||{},_0x3b4c2f=_0x4f903f['length'],_0x2760cb=_0x59104a[_0x44999d(0x250)]||0x0;_0x21230e[_0x179a7f]={'score':_0x2760cb,'total':_0x3b4c2f,'status':_0x44999d(0x242),'completedOn':new _0x4e4589()['toISOString']()},_0x15c3da[_0x44999d(0x1d3)]('userHistory',_0x462cea['stringify'](_0x21230e));}}else{if(_0x4f8ba3['BpYdi'](_0x98521f['key'],_0x4f8ba3[_0x44999d(0x40d)])||_0x4f8ba3[_0x44999d(0x217)](_0x98521f[_0x44999d(0x303)],'\x20')){if(_0x4f8ba3[_0x44999d(0x1c3)](_0x4f8ba3['MSlZr'],_0x4f8ba3[_0x44999d(0x1a6)]))_0x98521f['preventDefault'](),nextQuestion();else{const _0x5b5e98=new _0x19f0b8();_0x5b5e98[_0x44999d(0x3d7)](_0x52f950),_0x5b5e98['attachMedia'](_0x4c0bf4);}}else{if(_0x4f8ba3[_0x44999d(0x44b)](_0x98521f[_0x44999d(0x303)][_0x44999d(0x1ba)](),'b')&&(_0x4f8ba3['JQbpa'](currentMode,'study')||_0x4f8ba3[_0x44999d(0x44b)](currentMode,_0x4f8ba3[_0x44999d(0x3ba)])))_0x4f8ba3[_0x44999d(0x356)](toggleBookmark);else{if(_0x98521f[_0x44999d(0x303)][_0x44999d(0x1ba)]()==='m'&&(_0x4f8ba3['awgjQ'](currentMode,_0x4f8ba3[_0x44999d(0x20a)])||_0x4f8ba3[_0x44999d(0x406)](currentMode,_0x4f8ba3[_0x44999d(0x294)])))toggleMarkForReview();else _0x98521f[_0x44999d(0x303)][_0x44999d(0x1ba)]()==='s'&&(_0x4f8ba3[_0x44999d(0x32d)](currentMode,'test')||_0x4f8ba3[_0x44999d(0x270)](currentMode,_0x4f8ba3['lTOWb']))&&_0x4f8ba3[_0x44999d(0x356)](submitQuiz);}}}}});</script>

</body></html>